Computerised interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT) by Brocklehurst, P. et al.
              
City, University of London Institutional Repository
Citation: Brocklehurst, P., Field, D., Greene, K., Juszczak, E., Kenyon, S., Linsell, L., 
Mabey, C., Newburn, M., Plachcinski, R. ORCID: 0000-0001-9908-0773, Quigley, M., Steer, 
P., Schroeder, L. and Rivero-Arias, O. (2018). Computerised interpretation of the fetal heart 
rate during labour: a randomised controlled trial (INFANT). Health Technology Assessment, 
22(9), doi: 10.3310/hta22090 
This is the published version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  https://openaccess.city.ac.uk/id/eprint/24434/
Link to published version: http://dx.doi.org/10.3310/hta22090
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 22 ISSUE 9 FEBRUARY 2018
ISSN 1366-5278
DOI 10.3310/hta22090
Computerised interpretation of the fetal heart rate 
during labour: a randomised controlled trial (INFANT)
Peter Brocklehurst, David Field, Keith Greene, Edmund Juszczak,  
Sara Kenyon, Louise Linsell, Chris Mabey, Mary Newburn,  
Rachel Plachcinski, Maria Quigley, Philip Steer,  
Liz Schroeder and Oliver Rivero-Arias

Computerised interpretation of the fetal
heart rate during labour: a randomised
controlled trial (INFANT)
Peter Brocklehurst,1* David Field,2 Keith Greene,3
Edmund Juszczak,4 Sara Kenyon,5 Louise Linsell,4
Chris Mabey,6 Mary Newburn,7 Rachel Plachcinski,8
Maria Quigley,4 Philip Steer,9 Liz Schroeder10
and Oliver Rivero-Arias4
1Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
2Department of Health Sciences, University of Leicester, Leicester, UK
3University College London, London, UK
4National Perinatal Epidemiology Unit Clinical Trials Unit (NPEU CTU),
Nuffield Department of Population Health, University of Oxford, Oxford, UK
5Institute of Applied Health Research, University of Birmingham,
Birmingham, UK
6K2 Medical Systems, Plymouth, UK
7Collaboration for Leadership in Applied Health Research and Care (CLAHRC)
South London, King’s College London, London, UK
8National Childbirth Trust, London, UK
9Imperial College London, London, UK
10Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW,
Australia
*Corresponding author
Declared competing interests of authors: Keith Greene is the founder and shareholder of K2 Medical
Systems (Plymouth, UK) and Clinical Director for the development of the INFANT system. Christopher
Mabey is employed by, and is a shareholder of, K2 Medical Systems, the technology provider for the study.
Edmund Juszczak reports grants from the National Institute for Health Research (NIHR) Health Technology
Assessment (HTA) and Efficacy and Mechanism Evaluation programmes during the conduct of the study,
and is a member of the NIHR HTA Commissioning Board. Peter Brocklehurst reports grants and personal
fees from the Medical Research Council and grants from the National Institute for Health and Care
Excellence, NIHR Health Services and Delivery Research, NIHR HTA and Wellcome Trust, outside the
submitted work, and is chairperson of the NIHR HTA Women and Children’s Health panel and is a member
of the HTA Prioritisation Group. Sara Kenyon is a member of the NIHR HTA Women and Children’s Health
panel and received NIHR funding to undertake the HOLDS (High Or Low Dose Syntocinon® for delay in
labour) trial, and was part funded by the NIHR Collaboration for Leadership in Applied Health Research
and Care West Midlands.
Published February 2018
DOI: 10.3310/hta22090

This report should be referenced as follows:
Brocklehurst P, Field D, Greene K, Juszczak E, Kenyon S, Linsell L, et al. Computerised
interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT). Health
Technol Assess 2018;22(9).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.236
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science
Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 06/38/01. The contractual start date
was in September 2009. The draft report began editorial review in September 2016 and was accepted for publication in June 2017. The
authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and
publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on
the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA
programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brocklehurst et al. under the terms of a
commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of
private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials
and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief
Health Technology Assessment 
NIHR Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK
NIHR Journals Library Editors
Editor-in-Chief
Professor Hywel Williams Director, HTA Programme, UK and Foundation Professor and Co-Director of the
Centre of Evidence-Based Dermatology, University of Nottingham, UK
Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, 
University of Exeter Medical School, UK
Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management 
and Marketing, University College Cork, Ireland
Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK
Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson  Director of the NIHR Dissemination Centre, University of Southampton, UK
Ms Tara Lamont  Scientific Advisor, NETSCC, UK
Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, 
University of York, UK 
Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK
Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK
Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK
Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School,
University of Warwick, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact:  journals.library@nihr.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Computerised interpretation of the fetal heart rate during
labour: a randomised controlled trial (INFANT)
Peter Brocklehurst,1* David Field,2 Keith Greene,3 Edmund Juszczak,4
Sara Kenyon,5 Louise Linsell,4 Chris Mabey,6 Mary Newburn,7
Rachel Plachcinski,8 Maria Quigley,4 Philip Steer,9 Liz Schroeder10
and Oliver Rivero-Arias4
1Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
2Department of Health Sciences, University of Leicester, Leicester, UK
3University College London, London, UK
4National Perinatal Epidemiology Unit Clinical Trials Unit (NPEU CTU), Nuffield Department of
Population Health, University of Oxford, Oxford, UK
5Institute of Applied Health Research, University of Birmingham, Birmingham, UK
6K2 Medical Systems, Plymouth, UK
7Collaboration for Leadership in Applied Health Research and Care (CLAHRC) South London,
King’s College London, London, UK
8National Childbirth Trust, London, UK
9Imperial College London, London, UK
10Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
*Corresponding author p.brocklehurst@Bham.ac.uk
Background: Continuous electronic fetal monitoring (EFM) in labour is widely used and computerised
interpretation has the potential to increase its utility.
Objectives: This trial aimed to find out whether or not the addition of decision support software to assist
in the interpretation of the cardiotocograph (CTG) reduced the number of poor neonatal outcomes, and
whether or not it was cost-effective.
Design: Two-arm individually randomised controlled trial. The allocations were computer generated using
stratified block randomisation employing variable block sizes. The trial was not masked.
Setting: Labour wards in England, Scotland and the Republic of Ireland.
Participants: Women in labour having EFM, with a singleton or twin pregnancy, at ≥ 35 weeks’ gestation.
Interventions: Decision support or no decision support.
Main outcome measures: The primary outcomes were (1) a composite of poor neonatal outcome
{intrapartum stillbirth or early neonatal death (excluding lethal congenital anomalies), or neonatal morbidity
[defined as neonatal encephalopathy (NNE)], or admission to a neonatal unit within 48 hours for ≥ 48 hours
(with evidence of feeding difficulties, respiratory illness or NNE when there was evidence of compromise at
birth)}; and (2) developmental assessment at the age of 2 years in a subset of surviving children.
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Results: Between 6 January 2010 and 31 August 2013, 47,062 women were randomised and 46,042
were included in the primary analysis (22,987 in the decision support group and 23,055 in the no decision
support group). The short-term primary outcome event rate was higher than anticipated. There was no
evidence of a difference in the incidence of poor neonatal outcome between the groups: 0.7% (n = 172)
of babies in the decision support group compared with 0.7% (n = 171) of babies in the no decision
support group [adjusted risk ratio 1.01, 95% confidence interval (CI) 0.82 to 1.25]. There was no evidence
of a difference in the long-term primary outcome of the Parent Report of Children’s Abilities-Revised with
a mean score of 98.0 points [standard deviation (SD) 33.8 points] in the decision support group and
97.2 points (SD 33.4 points) in the no decision support group (mean difference 0.63 points, 95% CI –0.98
to 2.25 points). No evidence of a difference was found for health resource use and total costs. There was
evidence that decision support did change practice (with increased fetal blood sampling and a lower rate
of repeated alerts).
Limitations: Staff in the control group may learn from exposure to the decision support arm of the trial,
resulting in improved outcomes in the control arm. This was identified in the planning stage and felt to be
unlikely to have a significant effect on the results. As this was a pragmatic trial, the response to CTG alerts
was left to the attending clinicians.
Conclusions: This trial does not support the hypothesis that the use of computerised interpretation of the
CTG in women who have EFM in labour improves the clinical outcomes for mothers or babies.
Future work: There continues to be an urgent need to improve knowledge and training about the
appropriate response to CTG abnormalities, including timely intervention.
Trial registration: Current Controlled Trials ISRCTN98680152.
Funding: This project was funded by the National Institute for Health Research (NIHR) HTA programme
and will be published in full in Health Technology Assessment; Vol. 22, No. 9. See the NIHR Journals
Library website for further project information. Sara Kenyon was part funded by the NIHR Collaboration for
Leadership in Applied Health Research and Care West Midlands.
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Plain English summary
The INFANT study aimed to find out if we can improve how we monitor babies during labour. In the UK,continuous monitoring is used if either the mother or the baby is considered likely to not cope well
with contractions during labour. For these labours, a cardiotocograph is used to continuously record the
baby’s heart rate. The midwives/doctors look at a graph of the heart rate to find out how the baby
is coping.
Interpreting the pattern made by the baby’s heart rate is complicated. The INFANT study looked at
whether or not a computer system that analyses the heart rate can help the midwives/doctors interpret
the recording more accurately. The study asked questions about babies’ health and well-being, medical
procedures experienced by women and whether one approach provided better value for money than the
other in terms of delivering high-quality care. Women who agreed to have continuous electronic fetal
monitoring were divided at random into two groups. One group had the computer decision support
software switched on and the other group had it switched off. This made it possible to assess the effect of
the new software fairly, as the groups of women and babies were otherwise almost identical in terms of
their health and chance of complications.
Between January 2010 and August 2013, 47,062 women took part in the study. After the different
interventions in their care, we found no difference in the chance of babies being unwell between the two
groups of women: 0.7% (n = 172) of babies were unwell in the decision support group, as were 0.7%
(n = 171) of babies in the no decision support group. We found no differences in other outcomes, such as
the risk of pregnant women requiring an emergency caesarean section.
In this study, decision support software did not improve the care for women in labour.
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Scientific summary
Background
Continuous electronic fetal monitoring (EFM) in labour is widely used and has the potential to improve
neonatal outcomes. The benefits of EFM have been limited so far. The reasons for this appear to be complex,
but include difficulties with interpreting the fetal heart rate trace correctly during labour. Computerised
interpretation of the fetal heart rate has the potential to objectively detect abnormalities of the fetal heart
rate pattern that are associated with asphyxia but not recognised as abnormal by the birth attendants,
bringing to their attention the need to act to prevent stillbirth or exposure to significant asphyxia.
The electronic information capture system used in both arms of the trial, Guardian® (version 2.050.038.001,
K2 Medical Systems, Plymouth, UK), is a system for managing information from labour monitoring. It
displays the cardiotocograph (CTG) on a computer screen alongside other clinical data (e.g. the partogram
and maternal vital signs) that are collected as part of routine clinical care. It can display CTG data obtained
from external ultrasound transducers or from fetal scalp electrodes. Guardian acts as an interface to collect
and display data at the bedside, centrally on the labour ward, in consultants’ offices or remotely. The
decision support software (INFANT®; version 2.050.035.001, K2 Medical Systems, Plymouth, UK) analyses
the quality of the fetal heart signals and, if adequate, displays baseline fetal heart rate, heart rate variability,
accelerations, type and timing of decelerations, the quality of the signal and the contraction pattern. It then
makes an assessment of the overall pattern, which can result in a colour-coded alert, depending on the
severity of any abnormality detected. The decision support software does not provide recommendations for
any action that should be taken in response to these abnormalities. This was left to the discretion of the
attending clinicians.
Objectives
Our hypotheses were that:
l A substantial proportion of substandard care results from a failure to correctly identify abnormal fetal
heart rate patterns.
l Improved recognition of abnormality would reduce substandard care and poor outcomes.
l Improved recognition of normality would reduce unnecessary intervention.
The aim of the INFANT trial was to determine whether or not the addition of computerised interpretation
of the intrapartum CTG to current clinical care could improve the management of labour for women who
were judged to require EFM, and also to determine whether or not the use of the decision support
software is cost-effective.
Methods
This was a two-arm pragmatic individually randomised controlled trial in labour wards in England, Scotland
and the Republic of Ireland.
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Eligibility
Eligible women were those:
1. who were judged to require EFM by the local clinical team based on their existing practice, and who
had consented to EFM
2. who were pregnant with a single fetus or twin fetuses
3. who were at ≥ 35 weeks’ gestation
4. had a fetus with no known major abnormality, including any known heart arrhythmia such as heart block
5. who were aged ≥ 16 years
6. who were able to give consent to participate as judged by the attending clinicians.
Randomisation
Women were allocated, in the ratio of 1 : 1, to (1) CTG monitoring with decision support or (2) CTG
monitoring with no decision support. The allocations were computer-generated using stratified block
randomisation employing variable block sizes to balance between the two trial arms by singleton or twin
pregnancy, and within each participating centre. The trial was not masked.
Primary outcome measures
Primary short-term outcome
A composite of poor neonatal outcome including deaths [intrapartum stillbirths plus neonatal deaths
(i.e. deaths up to 28 days after birth) except deaths as a result of congenital anomalies], significant
morbidity [moderate or severe neonatal encephalopathy (NNE), defined as the use of whole-body cooling]
and admissions to a neonatal unit within 48 hours of birth for ≥ 48 hours (with evidence of feeding
difficulties or respiratory illness and when there was evidence of compromise at birth suggesting that the
condition was the result of mild asphyxia and/or mild NNE).
Primary long-term outcome
Developmental progress as measured by the Parent Report of Children’s Abilities-Revised (PARCA-R)
composite score at the age of 2 years for a subset of children.
Secondary outcome measures
Secondary short-term outcomes
Neonatal
l Intrapartum stillbirth (excluding deaths as a result of congenital anomalies).
l Neonatal deaths up to 28 days after birth (excluding deaths as a result of congenital anomalies).
l Moderate or severe NNE.
l Admission to neonatal unit within 48 hours of birth for ≥ 48 hours with evidence of feeding difficulties,
respiratory illness or NNE (when there was evidence of compromise at birth).
l Admission to a higher level of care.
l An Apgar score of < 4 at 5 minutes after birth.
l The distribution of cord blood gas data for cord artery pH.
l Metabolic acidosis (defined as a cord artery pH of < 7.05 and a base deficit in extracellular fluid of
≥ 12 mmol/l).
l Resuscitation interventions.
l Seizures.
l Destination immediately after birth.
l Length of hospital stay.
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Maternal
l Mode of delivery.
l Operative intervention (caesarean section or instrumental delivery) for:
¢ fetal indication or
¢ failure to progress or
¢ a combination of fetal distress and failure to progress or
¢ other reason.
l Grade of caesarean section.
l Episiotomy.
l Any episode of fetal blood sampling.
l Length of:
¢ first stage of labour from trial entry
¢ second stage of labour from trial entry
¢ labour from trial entry (total).
l Destination immediately after birth.
l Admission to a higher level of care.
Secondary long-term outcomes (infant)
Health and development outcomes at 24 months
l Non-verbal cognition scale (PARCA-R).
l Vocabulary subscale (PARCA-R).
l Sentence complexity subscale (PARCA-R).
l Late deaths up to 24 months (after the neonatal period).
Diagnosed with cerebral palsy:
l Non-major disability.
l Major disability.
l Breastfeeding (collected at 12 and 24 months).
Quality-of-care outcomes
In the case of any adverse infant outcomes potentially associated with intrapartum asphyxia (trial primary
outcome based on the baby’s condition after birth, plus a cord artery pH of < 7.05 with a base deficit of
≥ 12 mmol/l) and all neonatal deaths and intrapartum stillbirths, care during labour was assessed by a panel
comprising a senior obstetrician, neonatologist and midwife, to determine if it could be considered to be
suboptimal (possible or likely that different management would have prevented the adverse outcome).
Process outcomes
l Total number of CTG abnormalities (blue, yellow and red levels of concern) detected by the decision
support software.
l Number of blue levels of concern on the decision support software, indicating a mild abnormality on
the CTG.
l Number of yellow levels of concern on the decision support software, indicating a moderate
abnormality on the CTG.
l Number of red levels of concern on the decision support software, indicating a severe abnormality on
the CTG.
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l Number of women with at least one yellow level of concern on the decision support software,
indicating an abnormality on the CTG.
l Number of women with at least one red level of concern on the decision support software, indicating a
severe abnormality on the CTG.
l Time from first red level of concern to birth.
Data collection schedule
Labour data and immediate outcomes were stored on the Guardian system and sent electronically to the
co-ordinating centre. Data were extracted from the notes of babies admitted to the neonatal unit and for
all neonatal deaths. All surviving children who were discharged were ‘flagged’ at the NHS Information
Centre (England) and NHS Greater Glasgow & Clyde Safe Haven (Scotland), allowing all deaths to be
identified. A sample of surviving children and mothers was followed up at 2 years by means of a parent-
completed questionnaire to assess the child’s health, development and (health service) resource use and to
assess the mother’s well-being and resource use.
Sample size and analysis
The required sample size was 46,000 births. We assumed an incidence rate of the primary outcome of
3 per 1000 births. This was calculated using reported rates of intrapartum stillbirth, neonatal death,
moderate and severe NNE in broadly similar populations, and mild NNE (reliable data on significant
asphyxial morbidity resulting in transfer to neonatal care were not available and so could only be
estimated). The effect size that could be detected with 46,000 women (23,000 in each group), assuming a
5% level of significance and 90% power, was a 50% reduction in the poor neonatal outcome rate from
3 to 1.5 per 1000 births.
A statistical analysis plan was developed and approved by the Trial Steering Committee prior to analysis.
Participants were analysed in the groups into which they were randomly allocated, regardless of allocation
received. All women and babies with available data were included, except women with a missing consent
form and women who withdrew consent to use their data. The number of babies with the composite
primary outcome was presented for each group, and the risk ratio (RR) plus 95% confidence interval (CI)
calculated. The mean [standard deviation (SD)] PARCA-R composite score was calculated and the mean
difference plus 95% CI was calculated and compared using linear regression. Hazard ratios were estimated
using a Cox proportional hazards model and rate ratios were estimated using Poisson regression. We
adjusted for the stratification factors used in the randomisation, and robust variance estimators were used
in all models to account for the correlation in outcomes between twins and siblings delivered in a
subsequent pregnancy during the trial period. The mean (SD) PARCA-R composite score was calculated
and the mean difference plus 95% CI was calculated and compared. For secondary outcomes including
the components of the primary outcome, a 1% level of statistical significance was employed.
The following prespecified subgroup analyses were undertaken, using the statistical test of interaction, for
all neonatal outcomes, instrumental vaginal deliveries and caesarean section:
1. singletons versus twins
2. suspected growth restriction at labour onset versus no growth restriction
3. centre
4. body mass index (BMI) group [underweight (i.e. a BMI of 12–18.5 kg/m2), normal (a BMI of
18.5–24.9 kg/m2), overweight (a BMI of 25–29.9 kg/m2), obese (a BMI of 30–70 kg/m2), unrecorded].
For the economic evaluation, health-care resource use was compared using RRs for binomial variables and
mean differences for continuous covariates. Parametric methods were used to estimate mean resource use,
cost and maternal health-related quality of life EuroQol-5 Dimensions, three-level version (EQ-5D-3L),
scores. Differences between treatment arms were adjusted using a random intercept binomial (for RRs) or
linear (for mean differences) model adjusting for the stratification factors at randomisation (centre and
twin birth) and clustering as a result of twins and multiple-birth episodes. A 95% significance level was
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used for all comparisons. A multiple imputation framework with a chained equation was used for
estimating resource use and EQ-5D-3L scores at 12 and 24 months.
The INFANT trial was registered with Current Controlled Trials ISRCTN98680152.
Results
Between 6 January 2010 and 31 August 2013, 47,062 women were randomised to the INFANT trial.
A total of 1020 women (2.2%) were excluded from the analysis of the primary outcome. Data at the time
of birth were available for 100% of women and babies eligible to be analysed. Follow-up data at 2 years
were available for 56% of those contacted, although data were sufficiently complete for the analysis for
6707 children (53%).
There was no evidence of a difference in the incidence of the primary outcome of poor neonatal outcome
between the groups, with a poor outcome being experienced by 0.7% of babies in both the decision
support group (n = 172) and the no decision support group (n = 171) [adjusted risk ratio (aRR) 1.01,
95% CI 0.82 to 1.25]. Similarly, there was no evidence of a difference in any component of the composite
primary outcome between the groups.
There was no evidence of any differences in any of the trial’s secondary outcomes for the baby, including
Apgar score, admission to a neonatal unit, metabolic acidosis of cord blood samples, the need for neonatal
resuscitation and duration of hospital stay.
Just over half of all births were spontaneous vaginal births and there was no statistically significant
difference in this outcome between the two groups. Half of the operative births were caesarean sections
and half were instrumental. The proportion of women who underwent fetal blood sampling was higher in
the decision support group (10.3%) than in the no decision support group (9.5%) (aRR 1.08, 99% CI 1.01
to 1.16). No other statistically significant differences in clinical outcomes were found between the two
groups from trial entry to birth.
The overall proportion of cases with poor outcome in which babies were judged to have suboptimal care
likely to have affected the outcome was 38% (21/71 cases).
There was evidence of a lower rate of yellow levels of concern in the decision support group (adjusted rate
ratio 0.87, 99% CI 0.84 to 0.89).
There was no evidence of a difference between the two groups for any of the 2-year outcomes,
including the long-term primary outcome of the PARCA-R, with a mean composite score of 98.0 points
(SD 33.8 points) in the decision support group and 97.2 points (SD 33.4 points) in the no decision
support group (mean difference 0.63, 95% CI –0.98 to 2.25).
There was no evidence that the decision support software produced different outcomes in any of the
prespecified subgroups.
No evidence of a difference was detected in any category of resource use assessed, in categories of costs,
or in total costs at 24 months for the infant (£104, 95% CI –£174 to £382) or for the mother (–£149,
95% CI –£314 to £16).
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Conclusions
There is no evidence of a difference in the risk of a poor neonatal outcome, or intervention in labour,
when using CTG interpretation software to support decision-making versus not using CTG interpretation in
46,000 women.
The strength of this study lies in its contemporaneous data collection and its size. Weaknesses include the
potential for staff to learn from exposure to the decision support arm of the trial, resulting in improved
outcomes in the control arm. This was identified when the trial was being planned. Part of our prior
hypothesis was that, although some poor CTG interpretation is because of a lack of training, some
clinicians may have a poor intrinsic pattern recognition ability that is not susceptible to improvement by
training. This would not be affected by training and the performance of such clinicians would be
particularly improved by assistance from automatic interpretation. There was some evidence that clinician
behaviour was changed in the decision support arm of the trial. It may be that different action was taken
in response to the alerts in the decision support arm of the trial, for example the clinicians might have
reduced the dose of an oxytocin infusion in women having their labour augmented or changed maternal
position if the CTG abnormality resulted from vena caval compression. Such actions could have prevented
further yellow alerts, leading to a decrease in the incidence of repeat yellow alerts in this group, but we do
not have any direct evidence that this was the case.
Detecting abnormalities in the fetal heart rate can improve outcome only if caregivers respond
appropriately to the alerts. An expert panel reviewed all severe adverse outcomes in the trial and found no
evidence that there were differences in levels of suboptimal care between the two groups. Therefore, we
conclude that our hypothesis, that substandard care is largely related to a failure to identify pathological
fetal heart rate patterns, is not supported.
There is currently no evidence to support the use of computerised interpretation of the CTG in women
who have EFM in labour to improve clinical outcomes for mothers or babies.
Trial registration
This trial is registered as ISRCTN98680152.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research (NIHR). Sara Kenyon was part funded by the NIHR Collaboration for
Leadership in Applied Health Research and Care West Midlands.
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Chapter 1 Introduction
The justification for the trial, the supporting literature and the methods of the trial were publishedas a trial protocol in BMC Pregnancy and Childbirth. Sections of this chapter are reproduced from
Brocklehurst.1 This is an Open Access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited. The text below includes minor additions and
formatting changes to the original text.
Continuous electronic fetal monitoring (EFM) in labour is widely used throughout the developed world.
However, its potential for improving fetal and neonatal outcomes has not been realised. The reasons for
this are probably complex, but are likely to include difficulty of interpreting the fetal heart rate trace
correctly during labour, when the birth attendant has many competing tasks. For intrapartum monitoring to
improve fetal and neonatal outcomes, the interpretation of the fetal heart rate has to be substantially and
consistently improved. This standard has to be sustained and be independent of any health professional’s
individual ability. Computerised interpretation of the fetal heart rate and intelligent decision support has the
potential to deliver this improvement in care. The aim of EFM is to detect abnormalities of the fetal heart
rate pattern during labour that are associated with asphyxia so that action can be taken to expedite delivery
and prevent stillbirth and the development of neonatal encephalopathy (NNE). Therefore, the potential
benefits of EFM are immense. Prevention of even a modest proportion of perinatal asphyxia will improve
the health and well-being of thousands of children and their families throughout the world each year. In
addition, the cost to the NHS Litigation Authority (NHSLA) for obstetrics is very large and rising. EFM could
contribute to a substantial reduction. Furthermore, if this technology can work in the complex process of
labour, it also has the potential to improve patient safety in a wide range of health-care settings.
The problem of perinatal asphyxia
Perinatal asphyxia, if severe, can result in intrapartum stillbirth. If less severe, it results in the development of
an encephalopathic state in the newborn. This is characterised by a decreased level of consciousness, altered
reflexes, abnormal tone and ultimately permanent damage to the brain. Moderate or severe NNE occurs in
approximately 2 out of 1000 births.2 With more severe asphyxial encephalopathy there is an increased risk of
death or neurodevelopmental abnormalities: 25% of infants who have moderate asphyxial encephalopathy
will develop cerebral palsy and around 80% of infants who have severe encephalopathy and survive will
develop cerebral palsy.3 Perinatal asphyxia may account for up to 30% of all cases of cerebral palsy4 and it is
a very significant health-care and financial burden on the NHS. A reduction in the number of babies born
with perinatal asphyxia would reduce the associated mortality and, among survivors, the burden of ill health
and incapacity. It could also result in substantial savings in litigation costs in the UK.
Efficacy of continuous electronic fetal monitoring
Continuous electronic fetal monitoring was invented in the 1960s.5,6 The recorder displays the fetal heart
rate and maternal uterine activity on a continuous line graph, called the cardiotocograph (CTG) tracing.
EFM was widely introduced in the 1970s7 and it became controversial in the 1980s when it was shown
to poorly predict Apgar scores and fetal acid–base status at delivery.8 The largest randomised controlled
trial (RCT) (the Dublin trial) showed no reduction in perinatal mortality or in cerebral palsy using EFM.9
However, systematic reviews and meta-analyses of all trials indicated some benefits of EFM: for example,
a 58% reduction in odds of deaths attributable to intrapartum hypoxia [95% confidence interval (CI) 2%
to 83%]10 (Table 1) and a 50% reduction in risk of neonatal seizures (95% CI 20% to 69%) (Figure 1).20
EFM is widely used on many women during labour in the UK. National Institute for Health and Care
Excellence (NICE) guidelines for fetal monitoring in the NHS detail explicit criteria for implementing EFM;
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as a result, EFM is carried out in capproximately 60% of all women in labour.21 EFM has been shown to be
associated with an increase in caesarean sections and instrumental vaginal births. In a review of 11 trials
involving a total of 18,961 women, there was a 63% increase in the odds of a caesarean section (95% CI
1.29 to 2.07), and in 10 trials involving a total of 18,615 women there was a 15% increase in the odds of
an instrumental vaginal birth (95% CI 1.01 to 1.33).20
Human error and systems failure
In the late 1980s it became apparent that a human element might be a factor in the failure of EFM to
deliver improved outcomes. In one case–control study, the intrapartum management of 38 babies severely
asphyxiated at birth was compared with that of 120 controls.22 Cardiotography was abnormal in 29% of
babies in the control group, but in only 9% was the abnormality severe. In contrast, 87% of the babies
asphyxiated at birth had an abnormal CTG and in 61% of cases the abnormality was severe. However,
the most striking finding was the length of time required for the staff to recognise the CTG abnormality.
With moderate abnormalities, the mean time until recognition was 91 minutes [standard deviation (SD)
61 minutes]; paradoxically, with severe abnormalities it was 128 minutes (SD 100 minutes). The authors
could give no plausible reason for the standard of CTG interpretation being so poor. However, it was clear
from this study that, if the quality of interpretation of the intrapartum CTG had been higher, the benefits
from EFM would almost certainly have been significantly and substantially enhanced.
TABLE 1 The effect of EFM vs. intermittent auscultation on the incidence of deaths attributable to intrapartum
hypoxia
Study and year
of publication
Patients in the (n) Perinatal deaths (n)
Perinatal deaths as a result
of fetal hypoxia (n)
EFM group IA group EFM IA EFM IA
Haverkamp
et al., 197611
242 241 2 (FD 0, ND 2) 1 (FD 0, ND 1) 0 0
Renou et al.,
197612
175 175 1 (FD 0, ND 1) 1 (FD 1, ND 0) 0 1 (FD)
Kelso et al.,
197813
253 251 0 1 (FD 0, ND 1) 0 1 (ND)
Haverkamp et al.,
197914
230
229
231 3 (FD 0, ND 3) 0 0 0
Wood et al.,
198115
445 482 1 (FD 0, ND 1) 0 0 0
MacDonald et al.,
19859
6474 6490 14 (FD 3, ND 11) 14 (FD 2, ND 12) 7 (FD 3, ND 4) 7 (FD 2, ND 5)
Neldam et al.,
198616
482 487 0 1 (FD 1, ND 0) 0 1 (FD)
Luthy et al.,
198717
122 124 17 (FD 1, ND 16) 18 (FD 1, ND 17) 0 1 (FD)
Vintzileos et al.,
199318
746 682 2 (FD 0, ND 2) 9 (FD 2, ND 7) 0 6 (FD 2, ND 4)
Total 9398 9163 40 (4.2/1000) 45 (4.9/1000) 7 (0.7/1000)a 17 (1.8/1000)a
IA, intermittent auscultation; FD, fetal (intrapartum) death; ND, neonatal death.
a Statistically significant difference; Mantel–Haenszel odds ratio 0.42 (95% CI 0.17 to 0.98).
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0.01 0.1 1 10 100
Favours CTG Favours IA
Study or subgroup
Continuous CTG
n/N
IA
n/N
Risk ratio
M-H, fixed, 95% CI
Risk ratio
M-H, fixed, 95% CIWeight (%)
5.2
6.0
4.0
5.3
53.7
9.0
13.8
3.0
100.0
2/682
0/493
3/7330
2/241
2/232
27/6554
4/175
7/124
1/251
16,082
0/746
0/485
1/7288
2/242
2/463
12/6530
0/175
7/122
0/253
16,304
Athens 199318
Copenhagen 198516
Dallas 198619
Denver 197611
Denver 197914
Dublin 19859
Melbourne 197612
Seattle 198717
Sheffield 197813
Total (95% CI)
Total events: 24 (Continuous CTG), 48 (IA)
Heterogeneity: χ2 = 4.10, df = 7 (p = 0.77); I 2 = 0.0%
Test for overall effect: z = 2.89 (p = 0.0039)
Test for subgroup differences: not applicable
0.18 (0.01 to 3.80)
Not estimable
0.34 (0.03 to 3.22)
1.00 (0.14 to 7.01)
0.50 (0.07 to 3.53)
0.45 (0.23 to 0.88)
0.11 (0.01 to 2.05)
1.02 (0.37 to 2.81)
0.33 (0.01 to 8.08)
0.50 (0.31 to 0.80)
FIGURE 1 The effect of EFM vs. intermittent auscultation on the incidence of neonatal seizures. Review: continuous cardiotocography as a form of EFM for fetal assessment
during labour; comparison: continuous cardiotocography vs. intermittent auscultation; outcome: 26 neonatal seizures. CTG, cardiotocography; df, degrees of freedom;
FBS, fetal blood sample; IA, intermittent auscultation; M-H, Mantel–Haenszel.
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3
In 1990, Ennis and Vincent published the results of their study of 64 cases of poor perinatal outcome
from the archives of the Medical Protection Society.23 In 11 cases, EFM was not performed, despite being
indicated, and in six cases the technical quality of the tracing was inadequate. In 19 cases the CTG trace
was missing, and in 14 cases a significant abnormality in the CTG trace either was unnoticed or did not
result in any action being taken; in only 14 cases was appropriate monitoring performed and action taken.
In only 16 cases was a consultant involved to aid in the interpretation of the CTG. In a further case–control
study based in Oxford, published in 1994, intrapartum care was assessed in 141 cases of cerebral palsy
and in 62 perinatal deaths with a probable intrapartum cause.24 The authors found that, compared with
control babies, abnormal fetal heart rate patterns were 2.3 times as common in babies who went on to
develop cerebral palsy and 6.7 times as common in fetuses that died in the perinatal period. In addition,
the authors found that clinicians failed to respond to these clear signs of abnormality in 26% of cerebral
palsy cases and 50% of perinatal deaths, compared with 7% of control cases. On the basis of these
figures, it can be estimated that approximately one case of cerebral palsy and one perinatal death can
possibly be prevented in every 4500 deliveries. If one assumes 700,000 births per annum in the UK, 174
cases of cerebral palsy and 158 perinatal deaths could be prevented each year. Stewart et al.25 reported
that perinatal mortality in the UK is twice as high at night as during the day, and twice as high in July and
August as in the rest of the year. They suggested that excess deaths may be because of over-reliance on
inexperienced staff at night and a shortage of staff during the peak summer holiday months; they also
suggested that the excess might be related to physical and mental fatigue of the caregivers. In 1999, the
Confidential Enquiry into Stillbirths and Deaths in Infancy (CESDI) studied the proportion of 567 cases for
which there was evidence of suboptimal care in labour. CESDI then looked at whether or not improved
care could possibly or probably have prevented the adverse outcome.26 Suboptimal care was identified in
71% of cases; a better outcome could possibly (in 28% of cases) or probably (in 22% of cases) have been
anticipated, if care had been adequate. The report authors noted that interpretation of the CTG remained
the most frequent problem identified as a cause of suboptimal care.
Does improving training solve the problem?
In a study of the efficacy of intrapartum intervention, Young et al.27 found evidence of substandard care in
labour in 74% of babies with low Apgar scores. Following the introduction of regular audit of low Apgar
scores, with intensive feedback to clinical staff, this proportion fell to 23%, but then increased to 32%
over the following year. However, following the introduction of compulsory training in CTG interpretation
for all staff, the proportion of low Apgar score cases associated with substandard care fell back once again
to only 9%. It is clear from this study that improved interpretation of CTGs during labour can bring about
a striking increase in the quality of care, with measurable impacts on neonatal condition. However,
intensive education is not sustainable in most clinical settings. With recent changes in the training of junior
medical and midwifery staff, it is clear that there is a need to develop other systems that are less reliant on
individual motivation and training. These systems need to work equally well, regardless of the time of day,
day of the week, month of the year, and the level of staffing on the labour ward.
Litigation and the costs to families and society
Maternity services are associated with far higher litigation costs than other services. This is reflected in
the various arrangements for the development of risk management standards across the UK (Clinical
Negligence Scheme for Trusts in England; Welsh Risk Pool; Clinical Negligence and Other Risks Indemnity
Schemes and NHS Quality Improvement Scotland in Scotland).
The total cost of claims reported to the NHSLA over the period 1996–2006 was £3.8B [Great British
pounds (GBP)]. The annual figures for the value of maternity claims paid out (Table 2) demonstrate an
increase of almost sixfold over the last 13 years and the rate of increase shows no signs of slowing. In
response to a parliamentary question on 29 January 2007, it was stated that the total NHS compensation
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payout in 2006 was £593M, with £68M resulting from just 10 cases, all of which were related to
pregnancy and childbirth. By 2015/16, the total payout had risen to £1.488B, with £578M being
attributable to maternity cases alone.28 In 2007, the BBC reported a settlement of £6M for a child with
cerebral palsy after doctors were alleged to have mismanaged the birth.29 By 2015, the cost of a single
case of cerebral palsy had risen to over £10M.30 Even successful defence can cost up to £0.5M. In 2016,
the NHSLA reported that the annual value of submitted claims related to pregnancy-related cerebral
palsy had risen from £354M in 2004/5 to £989.7M in 2015/16.28 In 2000, the British Medical Journal
highlighted the importance of ‘system errors’ in medical disasters31 and analogies were drawn with errors
in aviation. It suggested that some techniques used in this industry could be applied effectively to medical
care, such as safety drills, revalidation, ‘nearmiss’ reporting and a ‘no blame’ culture. The role of expert
systems and ‘intelligent alarms’ was highlighted.
The potential solution: development of the intelligent decision
support software
A group in Plymouth has been working on the problem of resolving human error in the management of
labour for many years [Medical Research Council (MRC) funded for 10 years] and has developed intelligent
computer systems as decision aids to support clinicians. The group was funded by the MRC for development
and clinical validation of a decision support tool for the management of labour using the CTG. It comprises
feature extraction of all relevant data from the CTG and clinical history which have been found to influence
clinicians’ decision-making, and then an analysis of these within a rule-based expert system. The specific piece
of decision support software to be evaluated in INFANT has been designed by K2 Medical Systems (Plymouth,
UK) (a spin-off company from the University of Plymouth) to run on the K2 Medical Systems data collection
system (Guardian®). Guardian is a system for managing information from labour monitoring.
TABLE 2 Litigation costs from maternity services
Year maternity claims paid out Total cost in millions (GBP)
2003/4 96
2004/5 121
2005/6 144
2006/7 171
2007/8 162
2008/9 222
2009/10 197
2010/11 234
2011/12 422
2012/13 508
2013/14 458
2014/15 501
2015/16 578
GBP, Great British pounds.
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The data collection system (Guardian)
The Guardian system consists of a medical-grade personal computer (PC) platform (Figure 2) that meets
the Medicines and Healthcare products Regulatory Agency standards for a class IIa device. The design has
been informed by user preference studies and ethnographic and audio-visual observations of clinical care
and decision-making.32,33 It has a touch-screen user interface (Figure 3) and is connected to a conventional
CTG recorder at the woman’s bedside.
The PC uses the Microsoft Windows® (Microsoft Corporation, Redmond, WA, USA) operating system
and runs the decision support software developed by the Plymouth group. The clinician enters clinical
information (antenatal risk factors, vaginal examination data, fetal blood sample results, etc.) via the
touch-screen. This information is displayed as a partogram (Figure 4). It displays the CTG on a computer
screen alongside other clinical data [e.g. the partogram, maternal vital signs (including Modified Early
Warnings Systems charts) and details of maternal anaesthesia and analgesia] that are collected as part of
routine clinical care. Guardian does not interpret any of the data being collected, but acts as an interface
to collect and display data at the bedside, centrally on the labour ward, in consultants’ offices or remotely.
The system requires little or no training to use and has been used for routine clinical care by a number of
FIGURE 2 Guardian system: example of hardware.
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hospitals throughout the UK.34 If CTG is performed by ultrasound or electrocardiography (ECG) clip, the PC
system automatically collects these data from the RS 232 digital data port of any CTG recorder. The system
displays the CTG data on the screen (Figure 5).
The decision support software
The decision support software is a specific piece of software that has been developed to run on
the Guardian system. It extracts the important features of baseline heart rate, heart rate variability,
accelerations, type and timing of decelerations, the quality of the signal and the contraction pattern from
the CTG. The decision support software then analyses these data along with the quality of the signals.
The system’s assessment of the CTG is presented as a series of colour-coded alerts depending on the
severity of the abnormality detected (Figures 6–8). The system can therefore be viewed as an intelligent
prompt, but by recording the chronology of events it also offers the opportunity to later audit the actual
clinical decision-making process in a similar way to an aircraft’s black box.
FIGURE 3 Guardian system: example of screen.
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FIGURE 5 Guardian system: example of decision support on screen.
FIGURE 4 Guardian system: example of partogram on screen.
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FIGURE 6 Example of a ‘blue level of concern’.
FIGURE 7 Example of a ‘yellow level of concern’.
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Studies using the intelligent support software
Three studies conducted by the Plymouth group35–37 demonstrated that the software, when used ‘offline’,
performed as well as expert obstetricians in interpreting the CTG and managing labour subsequently, and
that the system performed better than routine clinical practice. The system identified more cases that went
on to have a poor outcome and anticipated clinical decision-making. In one of these studies involving
labours that had resulted in a stillbirth, the system ‘intervened’ (i.e. recognised the abnormality which
would have prompted delivery) more than 6 hours earlier than happened in actual clinical practice and
more than 2 hours before the experts. If this translated into clinical practice, it would be reasonable to
expect that a number of such deaths might have been prevented if the software had been in use at the
time. In all other poor-outcome groups the system ‘intervened’ much earlier than had happened in routine
clinical practice and at a similar time as the experts. The system failed to predict one perinatal death,
whereas the experts in the ‘offline’ study, and those functioning in routine clinical practice, failed to
predict several deaths. These extensive ‘offline’ validation studies have shown that the system matches the
performance of an expert obstetrician in interpreting the CTG and performed considerably better than
routine clinical practice. Furthermore, the system is not overinterventional. From these data it seems
reasonable to hypothesise that the clinical use of this computer-based decision support software would
decrease the incidence of perinatal mortality and morbidity.
Current practice
Continuous electronic fetal monitoring is widely used for the majority of women during labour and birth in
the UK. NICE guidelines for fetal monitoring detail explicit criteria indicating which women should be
offered EFM during labour; approximately 60% of all women in labour meet these criteria.21 This study did
not aim to influence the number of women who received EFM.
FIGURE 8 Example of a ‘red level of concern’.
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Research objectives
Our hypotheses were that:
1. a substantial proportion of substandard care results from a failure to correctly identify abnormal fetal
heart rate patterns
2. improved recognition of abnormality would reduce substandard care and poor outcomes
3. improved recognition of normality would reduce unnecessary intervention.
These led to the objectives of the study, to:
1. determine whether or not intelligent decision support can improve interpretation of the intrapartum
CTG and, therefore, improve the management of labour for women who are judged to require EFM.
Specifically, will the system, compared with current clinical practice:
i. identify more clinically significant heart rate abnormalities?
ii. result in more prompts and timely action on clinically significant heart rate abnormalities?
iii. result in fewer poor neonatal outcomes?
iv. change the incidence of operative interventions?
2. assess whether or not the use of intelligent decision support improved the quality of routine care
received by women undergoing EFM during labour. This information was important for evaluating
whether or not the decision support software decreases the risk of suboptimal care in labour; it was
also useful to explore the effect that such an intervention may have on litigation costs for obstetrics
3. determine whether or not the use of the decision support software was cost-effective in terms of the
incremental cost per poor perinatal outcome prevented
4. determine whether or not use of the decision support software had any effect on the longer-term
neurodevelopment of children born to women participating in the INFANT study.
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Chapter 2 Methods
The INFANT study was an individually randomised controlled trial of 46,000 women who were judged torequire EFM in labour. Follow-up was completed at 2 years for a sample of 7000 surviving children
born to women participating in the INFANT study.
Trial eligibility and randomisation
Inclusion criteria
Women admitted to a participating labour ward who fulfilled all of the following criteria were eligible to
be recruited and randomised.
l Women were judged to require EFM by the local clinical team based on existing guidelines, and the
woman consented to have EFM, and EFM was possible.
¢ Note that EFM is defined as the active decision of the health-care professional and the woman to
initiate EFM for the purpose of fetal monitoring, usually because of perceived risk factor(s) that
increase the likelihood of fetal compromise occurring in labour.
¢ The decision to initiate EFM can occur at any time during labour. Some women with known factors
that place them at higher risk of fetal compromise during labour would already know that EFM
throughout labour was planned. Others started labour with intermittent monitoring and then were
judged to require EFM at some point during the labour. Women were eligible to participate at any
stage of labour.
l Women were pregnant with a single fetus or twins.
l Gestational stage was ≥ 35 weeks (≥ 245 days).
l There was no known gross fetal abnormality, including any known fetal heart arrhythmia such as
heart block.
l Women were aged ≥ 16 years.
l Women were able to give consent to participate in the trial as judged by the attending clinicians.
Exclusion criteria
l Triplet or higher-order pregnancy.
l Criteria for EFM not met, including elective caesarean section prior to the onset of labour.
Information for women and obtaining informed consent
Information about the trial was provided to women during the antenatal period (see Appendix 1), after
their booking appointment. This process was individualised for each participating centre depending on
their routine practices. For example, in some centres, women were provided with information about the
trial at their routine ultrasound scan appointment (18–22 weeks). All women had the opportunity to
ask questions.
When a woman presented in early labour to the labour ward in a participating centre, she was given a
copy of the participant information leaflet (see Appendix 2) and a verbal explanation of the INFANT trial.
She was then asked whether or not she would like to participate in the study and, if she agreed, she was
asked to sign an INFANT trial consent form. Then, if at any point EFM was commenced during labour, the
midwife responsible for the woman’s care checked her eligibility to participate in the trial and that she was
still happy to take part. This was documented, and then the woman was randomised by the Guardian
system to either the decision support (intervention) arm or the no decision support (control) arm.
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All women in labour admitted to the participating centres were expected to have their labour information
recorded in the Guardian system, in accordance with the current practice in each centre. This did not
change the way health professionals managed labour; it merely changed the way they managed the
information generated by the process of monitoring labour and how they recorded this information. It was
clearly stated that women were free to withdraw from the study at any time for any reason without
prejudice to future care, and with no obligation to give the reason for withdrawal.
Written informed consent was obtained by means of a dated signature from the woman and the signature
of the person who obtained informed consent (see Appendix 3); this would be the principal investigator
(or a qualified health-care professional with delegated authority). A copy of the signed informed consent
document was given to the woman. A further copy was retained in the woman’s medical notes, a copy
was retained by the principal investigator and a final copy was sent to the trial co-ordinating centre.
A senior investigator was available at all times to discuss concerns raised by women or clinicians during the
course of the trial.
Randomisation
The Guardian system prompted the health professional providing care to consider whether or not the
woman was eligible for the INFANT trial when EFM had been used for > 5 minutes. Intermittent use of
EFM for durations of up to 5 minutes could be employed for intermittent monitoring, but when used for
longer periods of time this would indicate that a decision had been made to initiate EFM, in which case
the woman may have been eligible to participate in the trial. If the health-care professional indicated that
the woman was not yet eligible because an active decision had not been made to initiate EFM, then the
Guardian system prompted the health-care professional again, if the CTG continued to be recorded for
longer than 5 minutes in that or any subsequent episode of monitoring.
When the health-care professional indicated that a woman was eligible to participate, the Guardian system
clarified that the necessary eligibility criteria for trial entry had been met (i.e. that the health professional
gave the required answers to a number of questions posed by the Guardian system, and then the
Guardian system randomly allocated the women in the ratio 1 : 1 to either ‘CTG with no decision support’
or ‘CTG with decision support’) (Figure 9). The allocations were computer generated in Stata® version 10
(StataCorp LP, College Station, TX, USA) using stratified block randomisation employing variable block
sizes to balance between the two trial arms by singleton or twin pregnancy, and within each participating
centre. The procedures for randomisation were fully documented, reviewed and signed off prior to the
start of the trial and monitored by the co-ordinating centre during the trial.
Planned interventions
The intervention was the use of decision support software. In order to accurately reflect any potential
impact of the decision support software in contemporary NHS practice, such as changes in midwifery
presence during labour consequent upon knowledge of the allocation, it was desirable that clinicians were
not masked to allocation.
Clinical management
The Guardian system was developed to be used with all women in labour in the participating centres.
It was only the decision support software that runs on this system that was being tested in this trial.
Clinicians in all participating centres were initially trained in the use of the decision support software by
staff from the trial co-ordinating centre (see Appendix 4). This process included developing a ‘training
team’ at each site which was responsible for cascading training among the local clinicians. The clinical
management of women in the trial was not altered by their participation; however, staff caring for women
in the decision support arm received a series of graded alerts or alarms when abnormalities of the CTG
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were detected by the system, which increased in urgency with the severity of the abnormality as judged by
the system. No additional training was provided to clinical staff in how to respond to fetal heart rate
abnormalities as part of their participation in the trial because, in the UK and Republic of Ireland, staff
supervising labour and delivery are expected to have had such training, for example by completing
computer-based training packages every 6–12 months, attending annual lectures and attending regular
CTG review meetings.
Primary outcome measures
Primary short-term outcome
The primary short-term outcome was a composite of poor neonatal outcome including deaths [intrapartum
stillbirths plus neonatal deaths (i.e. deaths up to 28 days after birth) except deaths as a result of congenital
anomalies], significant morbidity (moderate or severe NNE, defined as the use of whole-body cooling) and
admissions to a neonatal unit within 48 hours of birth for ≥ 48 hours (with evidence of feeding difficulties
or respiratory illness and when there was evidence of compromise at birth suggesting that the condition
was the result of mild asphyxia and/or mild encephalopathy).
Note: we recognised that the signs of mild encephalopathy can be subtle and hence a number of babies
identified as having this condition were likely to have a range of non-specific signs such as respiratory
difficulty and poor feeding rather than features more specifically associated with encephalopathy.38
Therefore, we included ‘admission to the neonatal unit within 48 hours of birth for ≥ 48 hours where
there is evidence of compromise at birth’. Since this was a mature group of babies (born ≥ 35 weeks),
any difference in the incidence of these admissions was felt likely to result from differences in perinatal
asphyxia.
Antenatal information supplied to
all participating labour ward
admissions
Women who met trial
eligibility criteria
Decision made to initiate continuous EFMIntermittent
auscultation
Continuous EFM
Randomisation
Control arm
CTG monitoring
with no decision
support
Intervention arm
CTG monitoring
with decision
support
FIGURE 9 Flow diagram.
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Primary long-term outcome
The primary long-term outcome was the Parent Report of Children’s Abilities-Revised (PARCA-R) composite
score39,40 at the age of 2 years for a subset of 7000 infants.
Note: neurodevelopmental delay and cerebral palsy are the most important long-term adverse outcomes
associated with perinatal asphyxia. However, the incidence of moderate or severe cerebral palsy is around
1.5–2.5 per 1000 live births, depending on the definition and the method of ascertainment. There is also
uncertainty about the proportion of these cases that results from intrapartum asphyxia in mature infants;
however, 30% appears to be a reasonable estimate.4 Therefore, given the rarity of this outcome, it was
unlikely that a clear difference could be demonstrated between the two groups in a trial of 46,000 births.
In order to have reassurance that any benefits of the intervention, with respect to short-term outcomes,
had not occurred at the expense of later neurodevelopmental delay, we measured neurodevelopment in a
proportion of the surviving children at the age of 2 years.
Secondary outcome measures
Secondary short-term outcomes
Neonatal
l Intrapartum stillbirth (excluding deaths as a result of congenital anomalies).
l Neonatal deaths up to 28 days after birth (excluding deaths as a result of congenital anomalies).
l Moderate or severe encephalopathy.
l Admission to neonatal unit within 48 hours of birth for ≥ 48 hours with evidence of feeding difficulties,
respiratory illness or encephalopathy (when there was evidence of compromise at birth).
l Admission to a higher level of care.
l An Apgar score of < 4 at 5 minutes after birth.
l The distribution of cord blood gas data for cord artery pH.
l Metabolic acidosis (defined as a cord artery pH of < 7.05 and a base deficit in extracellular fluid of
≥ 12 mmol/l).
l Resuscitation interventions.
l Seizures.
l Destination immediately after birth.
l Length of hospital stay.
Maternal
l Mode of delivery.
l Operative intervention (caesarean section or instrumental delivery) for:
¢ fetal indication or
¢ failure to progress or
¢ a combination of fetal distress and failure to progress or
¢ other reason.
l Grade of caesarean section.
l Episiotomy.
l Any episode of fetal blood sampling.
l Length of:
¢ first stage of labour from trial entry
¢ second stage of labour from trial entry
¢ labour from trial entry (total).
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l Destination immediately after birth.
l Admission to a higher level of care.
Secondary long-term outcomes (infant)
Health and development outcomes at 24 months
l Non-verbal cognition scale (PARCA-R).
l Vocabulary subscale (PARCA-R).
l Sentence complexity subscale (PARCA-R).
l Late deaths up to 24 months (after the neonatal period).
l Diagnosed with cerebral palsy.
l Non-major disability.
l Major disability.
l Breastfeeding (collected at 12 and 24 months).
Quality-of-care outcomes
l Adverse outcome (trial composite primary outcome plus metabolic acidosis) when it is judged that
suboptimal care has occurred in labour: levels 1 to 3 separately and combined.
l Level 1: suboptimal care, but different management would have made no difference to outcome.
l Level 2: suboptimal care, and different management might have made a difference to outcome.
l Level 3: suboptimal care, and different management would reasonably be expected to have made a
difference to the outcome.
Note: in all cases of adverse outcome (trial primary outcome plus a cord artery pH of < 7.05 with a base
deficit of ≥ 12 mmol/l) and all neonatal deaths and intrapartum stillbirths care in labour was assessed, to
determine if it was suboptimal, by panel review similar to that undertaken by the Confidential Enquiry into
Maternal and Child Health (CEMACH).26 Intrapartum notes were copied and anonymised, and all references
to trial allocation removed. The notes were then examined by a panel of an experienced obstetrician,
midwife and neonatologist to identify if there was suboptimal care, particularly in relation to interpretation
of the CTG and actions that flowed from any identification of CTG abnormalities.
Process outcomes (after trial entry)
l Total number of CTG abnormalities (blue, yellow and red levels of concern) detected by the decision
support software.
l Number of blue levels of concern on the decision support software, indicating a mild abnormality on
the CTG.
l Number of yellow levels of concern on the decision support software, indicating a moderate
abnormality on the CTG.
l Number of red levels of concern on the decision support software, indicating a severe abnormality on
the CTG.
l Number of women with at least one yellow level of concern on the decision support software,
indicating an abnormality on the CTG.
l Number of women with at least one red level of concern on the decision support software, indicating a
severe abnormality on the CTG.
l Time from first red level of concern to birth.
Note that it was important to collect and analyse process outcomes in the trial, as a failure to detect
differences in clinical or quality-of-care outcomes between the two randomised groups may be because of
poor adherence with the alerts of the system, rather than the system not correctly identifying abnormalities
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with the CTG. In addition, as the trial allocation was not masked, it was important to measure any change
that resulted from clinicians being aware of whether or not the decision support system was in operation.
l Number of thumb entries per hour from time of trial entry to first yellow level of concern or until fully
dilated (10 cm) if no abnormality detected or first yellow level of concern occurred prior to trial entry.
l Number of vaginal examinations.
l Epidural analgesia.
l Labour augmentation.
l Presence of meconium.
Note: some of these later process outcomes (e.g. the number of thumb entries per hour) were proxy
measures to determine the presence of a health professional in the delivery room during the labour, which
allowed us to quantify any differences between the groups with respect to support offered to women
during labour. Although unlikely, knowledge of the trial allocation could have resulted in less frequent
contact with the woman allocated decision support in labour. Less frequent contact would have resulted in
a lower number of these process measures.
Data collection
For all participating women and babies, labour variables and outcomes were stored automatically and
contemporaneously on the Guardian system. Data collected via the system were sent electronically to the
trial co-ordinating centre. Data were extracted from the notes of babies admitted to the neonatal unit and
for all neonatal deaths (see Appendices 5–7), as well as for mothers admitted for a higher level of care
(see Appendix 8). Not all data fields were collected at every centre. However, when an item was collected,
these data were sent to the clinical trials unit. The trial did not collect the reason why EFM was being used,
as this was not recorded. All children surviving to be discharged home from hospital following their birth
were ‘flagged’ at the NHS Information Centre for those born in England, and for those born in Scotland
comparable systems were used. All deaths occurring after discharge home from hospital were notified to
the trial co-ordinating centre. At 2 years after trial entry a sample of 7000 surviving children (3500 in each
group) were followed up. The family was sent a two-part parent-completed questionnaire to assess the
child’s health, development and well-being (see Appendix 9). The first part of the questionnaire comprised
the PARCA-R, which had been previously validated as a means of assessing neurodevelopment in a trial
setting.39,40 The second part focused on general health issues, and had also been used previously.
Calculation of proposed sample size
The proposed total sample size was 46,000 births.
The following data sources and assumptions were used in the calculation of the trial sample size.
Incidence of intrapartum stillbirth
This was estimated as 0.35 per 1000 births. This estimate was derived from the following incidence data:
0.51 per 1000 births for women of all gestation periods (England, Wales and Northern Ireland, 2004)41
and 0.27 per 1000 births for women at ≥ 37 weeks’ gestation (Trent Region, 2005).42 This trial restricted
eligibility to women at ≥ 35 weeks’ gestation; therefore, the incidence was expected to be lower than in
women at all gestational ages, which includes those who deliver preterm. However, it was also expected
to be higher than for all women at term. As the women being recruited were all judged to require EFM
and it was assumed that women in this ‘risk group’ would be at increased risk of adverse outcomes, the
incidence was likely to be higher. In addition, these estimates used a denominator of all modes of births
and so they included women having elective caesarean sections, who are not at risk of intrapartum
stillbirth as there is no intrapartum period. Approximately 7% of women have elective caesarean sections,
and removal of these women would increase the incidence further. Therefore, an estimate of an incidence
of 0.35 per 1000 births appeared reasonable.
METHODS
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Incidence of neonatal death
This was estimated as 0.7 per 1000 births. This estimate was derived from the following data: 3.4 per
1000 births for women of all gestation periods (England, Wales and Northern Ireland, 2004)41 and 0.89
per 1000 births in those women at ≥ 37 weeks’ gestation (Trent Region, 2005).42 This trial restricted
eligibility to women at ≥ 35 weeks’ gestation; therefore, the incidence would be expected to be lower
than among women of all gestational ages, which includes those who deliver preterm. However, it would
be higher than for all women at term. A reasonable estimate of neonatal death for babies at 35 weeks’
gestation or more was therefore considered to be 1.0 per 1000 births. Using data from the Trent Survey
200542, 30% of neonatal deaths were as a result of congenital anomalies. Therefore, this rate was reduced
to 0.7 per 1000 births. As the women being recruited were all judged to require EFM and it was assumed
that women in this ‘risk group’ would be at increased risk of adverse outcomes, the incidence may have
been higher. Therefore, an estimate of an incidence of 0.7 per 1000 births appeared reasonable.
Incidence of severe and moderate neonatal encephalopathy
The most appropriate estimate of the incidence of NNE in babies born at ≥ 35 weeks’ gestation was
1.3 per 1000 births (Trent & Northern Region, 2002).43 However, as above, women being recruited to this
trial were all judged to require EFM, which means that they may have been at increased risk of adverse
outcomes; therefore, the incidence may have been higher.
Combined outcomes
Data were available on some combined outcomes. For example, the incidence of intrapartum stillbirths
plus deaths on the labour ward assumed to be as a result of intrapartum asphyxia (the incidence of which
is much lower than neonatal mortality) plus severe and moderate NNE was 1.7 per 1000 births (95% CI
1.5 to 1.9; range 0.8–2.3) (18 hospitals, Trent, 2003–4) and 1.9 per 1000 births (95% CI 1.6 to 2.3;
range 0.6–2.3) (12 hospitals, Yorkshire Neonatal Network, 2004–5).43 These data are for babies born at
≥ 35 weeks’ gestation, with the incidence of these outcomes being higher in the larger hospitals, which
attract women with more complicated pregnancies.
Incidence of primary outcome for INFANT
We assumed an incidence of the primary outcome of 3 per 1000 births. This was calculated by summing
the rate of intrapartum stillbirth, neonatal death, and moderate and severe encephalopathy, which gave
an incidence of 2.35 per 1000 births. However, added to this figure was mild encephalopathy, which
was reported to occur in 1.25 per 1000 births, and other significant morbidity [other admissions to the
neonatal unit within 48 hours of birth for ≥ 48 hours (e.g. with feeding difficulties, respiratory symptoms
or seizures)], for which there were no good estimates of incidence. The estimate of 3 per 1000 births erred
on the side of caution and an increased incidence of this outcome in the trial would either (a) increase the
power of the trial to demonstrate the same effect size or (b) allow detection of a smaller effect size with
the same trial size or (c) necessitate a smaller trial if the postulated effect size (or larger) was detected.
Effect size
The effect size that can be detected with 46,000 women (23,000 in each group), assuming a 5% level
of significance and 90% power, was a 50% reduction in poor neonatal outcome rate from 3 to 1.5 per
1000 births. We approximated the number of women recruited with the number of infants born, even
though women with a twin pregnancy were eligible to join the trial. Approximately 1 in 80 pregnancies
are twin pregnancies; however, a proportion of these births will occur at < 35 weeks’ gestation and a
large proportion of the term births would be by elective caesarean section. Therefore, we estimated that
< 1% of all births in the study would be twins. In a study of 164 preterm infants,40 the mean PARCA-R
composite score at 2 years was 80 points (SD 33 points) and the mean Mental Development Index (Bayley
Scales of Infant Development II) score was approximately half a SD below the standardised mean of 100.
We assumed that a normal group of term-born infants would have a PARCA-R composite score half a
SD above this sample of preterm infants, so we estimated a mean 2-year score of 96 points (SD 33 points).
Based on this estimate, a follow-up sample of 7000 children (3500 per arm) in the INFANT study would
have over 90% power to detect a difference of 3 points in the PARCA-R composite score with a two-sided
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5% significance level. The incidence of severe metabolic acidosis (a cord artery pH of < 7.05) has been
reported as 10 per 1000 births.44–47 The proposed sample size was therefore able to detect a 28% relative
risk reduction in this incidence with > 80% power in those babies who had their cord artery pH measured.
Assumptions
Variations in some of the assumptions of incidence produced marked variations in the required sample size
as the anticipated overall incidence was so low. For example, Table 3 illustrates the impact on the required
sample size of varying the incidence of the primary outcome, assuming a 5% level of significance and
90% power for the same effect size (a 50% relative risk reduction).
Table 4 illustrates the variation on the effect size that could be detected with a sample size of approximately
46,000 women with variations in incidence.
Loss to follow-up
It was assumed that loss to follow-up for the short-term primary outcome would be negligible, as most of
this information would be collected before the woman left the delivery room in which she had been
recruited. For neonatal outcomes, a small number of babies were admitted to a neonatal unit separate
from where they were born or planned to be born, in which case data were collected from these sites
through the research midwives employed by the study in the participating centres. At the time of entry to
the study all women were asked for permission for their contact details to be downloaded to the trial
co-ordinating centre along with their clinical details from the Guardian system. The families selected for
follow-up at 2 years were contacted by post 8 weeks after birth and informed that they had been selected
for the follow-up study. Contact with families who agreed to take part was maintained during the period
between birth and the follow-up assessment by sending a birthday card each year along with a FREEPOST
change-of-address card to facilitate communication with University College London (UCL) Comprehensive
Clinical Trials Unit about updated contact details.
TABLE 3 Sample size assuming 5% level of significance, 90% power and 50% relative risk reduction
Incidence of primary outcome in (per 1000 births)
Relative risk Total sample size requiredNo decision support group Decision support group
3.0 1.5 0.5 46,000
4.0 2.0 0.5 34,000
5.0 2.5 0.5 27,000
6.0 3.0 0.5 22,000
TABLE 4 Effect size detectable assuming 5% level of significance and 90% power, with variation in incidence of
primary outcome in the no decision support group
Total sample size Relative risk
Incidence of primary outcome in (per 1000 births)
No decision support group Decision support group
46,000 0.50 3.00 1.50
46,000 0.56 4.00 2.25
46,000 0.61 5.00 3.05
46,000 0.64 6.00 3.85
METHODS
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Trial management
Research governance
The sponsor of the trial was initially the University of Oxford (January 2009 to May 2012), but changed to
UCL when the trial moved (May 2012 to June 2016). The trial was run on a day-to-day basis by the project
management group. This group reported to the Trial Steering Committee (TSC), which was responsible to
the research sponsor. At each participating centre, local principal investigators reported to the project
management group via the project-funded staff based at the UCL Comprehensive Clinical Trials Unit.
Insurance
NHS indemnity operated in respect of the clinical treatment being provided. In addition, the sponsor had
appropriate insurance-related arrangements in place.
Trial Steering Committee
The trial was supervised by an independent TSC. The precise terms of reference for the TSC were agreed
at its first meeting. A TSC charter similar to that used by the Data Monitoring Committee (DMC) (see Data
Monitoring Committee) was completed.
Data Monitoring Committee
An independent DMC was established for the trial. This was independent of the trial organisers. The terms
of reference for the DMC were agreed at the first meeting. A DMC charter was completed following the
recommendations of the DAMOCLES (DAta MOnitoring Committees: Lessons, Ethics, Statistics) study.48
During the period of recruitment to the trial, interim analyses were supplied, in strict confidence, to the
DMC, together with any other analyses the DMC requested. In the light of interim data, and other
evidence from relevant studies, the DMC would inform the TSC if, in its view, there was proof beyond
reasonable doubt that the data indicated that any part of the protocol under investigation was either
clearly indicated or contraindicated, either for all women or for a particular subgroup of trial participants.
A decision to inform the TSC would in part be based on statistical considerations. Appropriate criteria for
proof beyond reasonable doubt could not be specified precisely. A difference of at least three standard
errors (SEs) in the interim analysis of a major endpoint may have been needed to justify halting, or
modifying, the study prematurely. This criterion had the practical advantage that the exact number of
interim analyses would be of little importance, and so no fixed schedule was proposed.49 Unless
modification or cessation of the protocol was recommended by the DMC, the TSC, collaborators and
administrative staff (except those who supply the confidential information) would remain masked to the
results of the interim analysis. Collaborators and all others associated with the study were able to write,
through the trial office, to the DMC, to draw attention to any concerns they may have about the possibility
of harm arising from the treatment under study, or about any other matters that may have been relevant.
Publication policy
The chief investigator was responsible for co-ordinating the dissemination of data from this study. All
publications using data from the study to undertake original analyses were submitted to the TSC for
review before release. To safeguard the scientific integrity of the trial, it was agreed that data from
the study would not be presented in public before the main results were published, without the prior
consent of the TSC. The success of the trial depended on a large number of midwives and obstetricians.
For this reason, chief credit for the results would be given not to the committees or central organisers, but
to all who collaborated and participated in the study. It was agreed that authorship at the head of the
primary results paper would take the form ‘The INFANT Collaborative Group’, to avoid giving undue
prominence to any individual.
DOI: 10.3310/hta22090 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 9
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brocklehurst et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21

Chapter 3 Substudy of maternal anxiety in labour
during recruitment to the pilot phase of the INFANT
trial
During the process of application to the Research Ethics Committee (REC) for approval to undertake theINFANT trial, the committee was concerned that the use of the decision support technology during
labour may increase anxiety among the women taking part. The committee asked the trial team to provide
some reassurance that participating in the trial would not result in unacceptable anxiety for the women
taking part.
We developed the study described below to address this. Sections of this chapter have been reproduced with
permission from Barber et al.50 Copyright © 2013, MA Healthcare Limited. Quotations from participants in
this qualitative study have been reproduced verbatim from this publication with permission from the journal.
Introduction
Anxiety is common in pregnancy51 and EFM can lead to increased anxiety.52 A study in Australia reported
interviews with 100 women shortly after a straightforward birth and found that only 15% reported no
anxiety during labour and birth.53
Confidential enquiries into perinatal deaths have repeatedly demonstrated that most poor infant outcomes
arise during labour. EFM was introduced into clinical practice to try to prevent these poor outcomes;
however, we know that poor interpretation of fetal heart rate patterns occurs. Improvements in CTG
interpretation have to be sustainable and ideally be independent of clinicians’ abilities. Computerised
interpretation and decision support have the potential to improve care.
If women are aware of an effective method of interpreting their baby’s heart rate during labour, and
understand that this is safer than an individual clinician’s interpretation, this may result in reduced anxiety.
The INFANT decision support software assesses the CTG and provides a colour-coded ‘ladder of concern’,
which appears on the CTG screen (see Chapter 1 for more detail).
The aim of this study was to explore whether or not the use of EFM during labour increases or reduces
anxiety levels among women and whether or not the addition of the INFANT decision support software
has a positive or negative effect on these anxiety levels. We initially used a survey to measure anxiety in
women randomised to each arm of the INFANT trial. We then used qualitative interviews in a smaller
number of women to explore their feelings of anxiety associated with the use of monitoring in labour and
the decision support system.
Methods
Survey
From 5 January 2010 to 18 July 2010, 469 women were recruited to the pilot phase of the INFANT trial from
the Royal Blackburn Hospital. A total of 234 women were recruited to the CTG monitoring only (control)
group and 235 were recruited to the CTG monitoring plus decision support (intervention) group. The
eligibility criteria and process of recruitment are described in Chapter 2. In a subset of women approached to
participate in the INFANT trial, we measured anxiety in the latent phase of labour when cervical dilatation
was ≤ 3 cm with an effaced cervix. If the woman was recruited into the trial, we measured anxiety at a
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further two time points: during the active phase of labour when the cervical dilatation was 4–7 cm, and
within 48 hours post partum. At each time point, the midwife asked women to rate their anxiety using a
visual analogue scale – anxiety (VAS-A) from 1 (not at all) to 10 (very much so). Their responses were
recorded on the VAS-A study form (Figure 10).
Statistical analysis
The change in VAS-A scores in the two groups (control and intervention) (1) from the latent to the active
phase of labour and (2) from the latent phase to the postpartum period was analysed using repeated
measures analysis of covariance (ANCOVA). This enabled us to include all women in the analysis, even
those with data at only one time point. The correlation between scores between phases was calculated
using the Pearson correlation coefficient. Two-sided significance tests were used, taking a p-value of 0.05
as significant. The analysis was conducted using statistical software Stata version 11.1.
FIGURE 10 The INFANT study visual analogue scale form.
SUBSTUDY OF MATERNAL ANXIETY IN LABOUR DURING RECRUITMENT TO THE PILOT PHASE OF THE INFANT TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Qualitative study
Women from two of the study sites in the INFANT trial (Warrington Hospital and University Hospital of
North Staffordshire) were approached to be interviewed about their experiences of birth and fetal
monitoring by a single trained qualitative researcher. Women were approached after giving birth and
before hospital discharge. A purposive sampling approach was used to ensure that equal numbers of
women from the two arms of the trial were recruited, and that the number and severity of alerts was
wide-ranging and well balanced between the two groups. The trial’s statistician identified potential
women to be included and informed the qualitative researcher of their study number. The interviewer was
masked to the women’s trial allocation and pattern of alerts until after the interviews were complete.
The interviews collected views of the whole birth experience but included semistructured prompting to
explore women’s feelings about monitoring and their understanding of the INFANT trial. The interviewer
and another senior qualitative researcher undertook the analysis jointly. An initial thematic analysis was
undertaken using NVivo (QSR International, Warrington, UK) software to support the coding process. This
was followed by a framework analysis, summarising the experiences and attitudes of each woman and
mapping these against the woman’s characteristics (hospital of birth, study allocation, maternal age,
gestation at trial entry and number of yellow and red alerts).
Results
Quantitative study
The VAS-A score sheets were completed by 275 out of 469 (59%) women [CTG monitoring only: 142 out
of 234 (61%); CTG monitoring plus decision support: 133 out of 235 (57%)]. In the control group, data
were available for 128 (55%) women from the latent phase, 104 (44%) for the active phase and 81 (35%)
for the postpartum period. In the intervention group, data were available for 124 (53%) women for the
latent phase, 106 (45%) for the active phase and 81 (34%) for the postpartum period.
The VAS-A scores are shown in Table 5. The scores were approximately normally distributed. In each
group, anxiety levels increased from a score of around 5 points in the latent phase to around 6 points in
the active phase, then dropped below 5 points in the postpartum period. There was no difference
between groups in the change in anxiety from the latent to the active phase (p = 0.84) or from the latent
phase to the postpartum period (p = 0.88). The scores were positively correlated: 0.48 between latent and
active phase, 0.41 between the latent phase and the postpartum period, and 0.44 between the active
phase and the postpartum period.
Qualitative study
A total of 18 women were interviewed, including six with their birthing partner, who was either their
partner or mother. Table 6 provides a list of the women interviewed with details of their hospital of birth,
TABLE 5 Change in anxiety (VAS-A) scores between phases of labour by allocation group
Phase
VAS-A scores
Between-group
difference in mean
change (95% CI) p-value
CTG monitoring only
CTG monitoring plus
decision support
n Mean (SD) n Mean (SD)
Latent 128 5.0 (2.7) 124 4.8 (2.6)
Active 104 5.7 (2.7) 106 5.5 (2.9) –0.08 (–0.93 to 0.76) 0.84
Postpartum 81 4.5 (2.4) 81 4.4 (2.4) –0.06 (–0.84 to 0.71) 0.88
Reproduced with permission from Barber et al.50 Copyright © 2013, MA Healthcare Limited.
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trial group, age, gestation at trial entry and number of alerts. Four women had no alerts, seven had at
least one yellow but no red alerts and seven had at least one red alert. The number of red and yellow
alerts were evenly distributed across the trial groups.
Levels of understanding
Among participants, there was a patchy understanding of what the trial was about, beyond a general view
that it was seeking to understand people’s experiences in labour and improve care for other women in the
future. This is a finding that is widely reflected in the literature.54–56 Women were frequently unclear about
what is ‘normal’ monitoring of the baby in labour and what is part of the trial, and whether or not they
would have been monitored anyway:
It was nothing, you know, that was intervening with anything, so I hadn’t minded at all. I just hadn’t
been totally aware that I’d be hooked up to a machine the whole time. I just thought it was if you
needed to be on the machine, they’d then monitor it through the computer . . . I wasn’t sure whether
I had to be on the machine for the sake, you know, for the baby’s sake and whatnot or whether it
was because I was, because of the study. I wasn’t too sure what it was that I had to actually be on
it for.
Participant 02, control arm
TABLE 6 Details of participants in the qualitative study
Interview IDa Hospital Trial arm
Maternal
age (years)
Gestation at
randomisation
(weeks)
Number
of yellow
alerts
Number of
red alerts
01 Warrington Control 30 41 2 2
02 Warrington Control 23 39 3 0
08 Warrington Control 30 40 1 0
14 Warrington Control 23 26 4 1
21 Warrington Control 29 40 5 1
22 Warrington Control 36 38 twins 13 2
07 Warrington Decision support 49 41 5 0
15 Warrington Decision support 28 39 0 0
18 Warrington Decision support 26 41 1 0
19 Warrington Decision support 38 37 4 2
20 Warrington Decision support 36 38 3 0
04 North Staffs Control 37 39 0 0
05 North Staffs Control 31 37 0 0
11 North Staffs Control 39 42 3 0
03 North Staffs Decision support 27 40 0 0
09 North Staffs Decision support 28 41 8 2
10 North Staffs Decision support 21 41 6 1
16 North Staffs Decision support 31 38 4 0
Warrington, Warrington Hospital; North Staffs, University Hospital of North Staffordshire.
a Numbers 06, 12, 13 and 17 were originally contacted and then declined to take part.
Reproduced with permission from Barber et al.50 Copyright © 2013, MA Healthcare Limited.
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My understanding at the time of it was really just that it would be somebody maybe 1 or 2 years after
the birth would be following up with a questionnaire and maybe a phone call or something just to
see what my experience was . . . I don’t recall the monitoring being part of the study but a huge deal
wasn’t made of it anyway, but as I say it wouldn’t have been a problem if it was, but I was going to
be monitored anyway with being induced.
Participant 05, control arm
Participant 05 (control arm) also said, ‘I didn’t remember them saying which group I was in. Is there
different groups?’. Similarly, participant 14 (control group) said, ‘I don’t remember anything to do with
groups’. Furthermore, she did not clearly recall any monitoring at all. This participant had a vague
recollection of ‘bands’ being used for monitoring her baby’s heart, and that the baby’s heartbeat had
dropped at one stage, but said, ‘I definitely don’t remember anything being put round me’ other than
her transcutaneous electrical nerve stimulation machine. Similarly, a woman in the intervention arm
(participant 18) said, ‘Groups? They might have mentioned it but I don’t remember it’.
One couple (04, control arm) knew they had been allocated to a group but were unaware of how and
why they had been selected for participation. The male partner had spent quite a lot of time trying to
work out for himself what the monitor readings meant:
Female: It would be nice to know.
Male: You know, why your specific case was chosen. Was it just it was randomly chosen or was it
because they wanted to, to look at it for a certain reason?
Female: Or is it just that we were placed in this particular bracket, you know?
Male: Well, was it just random that our, you know, results were picked out? Or was it because, like
we think, [female] had a rapid delivery? Or, you know, or something come up on the results why
they decide?
However, other participants in both groups were aware that there were different arms and demonstrated
an awareness of which arm they were in as well as how they were allocated to a group:
Basically what they told us, well it says in the leaflet as well, that you might not be selected for the
trial on a computer. Basically she tapped in some information on the screen and then it come up
whether you’d be selected for it. And she typed it in and she said we weren’t selected for it.
Participant 01, control arm
It was frequently suggested by participants that being given information about the trial towards the end of
pregnancy rather than during the labour episode may improve understanding, as it was difficult for people
to absorb the information or give it any priority during labour. This approach of providing information
during pregnancy should have been happening in the centres, and a few women did recall discussing it
at antenatal appointments or seeing posters about it in previous visits, but others did not. Women also
mentioned feeling ‘vague’ or ‘confused’ about the information provided during labour because of the pain
relief medication they had taken.
There was little evidence that feeling underinformed had led women to regret taking part. This was because
EFM was commonly seen as routine care and not particularly invasive. Even women who disliked not being
able to mobilise because of the monitoring failed to express major concerns about the information and
consent process.
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One exception to this was a woman in the decision support arm who said that she felt ‘mithered’ by
having to answer all the questions needed to take part in the trial:
I didn’t want to be asked; I just wanted to be left alone to get on with going through the labour . . .
I just wanted to be left alone and that took like 15, 20 minutes to do all that so like she was asking
me questions and I was contracting as well . . . I signed it because I thought – and I said this to my
mum this morning – the only reason that I signed it was because I thought if the midwife thinks that
we’re co-operating with this then she’ll give us some drugs [laughter]. She’ll give me some more
drugs, that’s what I thought . . . It was something that was so shoved in my face and I didn’t really
have a choice basically . . . because I wanted to keep my midwife nice and sweet.
Participant 15, decision support arm
She complained that she ‘hated’ being monitored because it restricted her movements. It did not make
her feel more anxious, but she regretted taking part because she felt that it spoilt her otherwise good
experience of a spontaneous vaginal birth. She was so bothered by the restrictions on movement that she
requested that the monitoring be stopped. It is clear from her interview that she did not understand that
she would have had monitoring anyway and that it was not a consequence of taking part in the trial. She
said that monitoring should be used ‘only if it’s an emergency for the baby’ and did not understand that
the purpose of monitoring was to detect concerns before they become emergencies. When this was
discussed during the interview she commented:
So in that case it does change my views differently then, then yes, if I would have known it was
something to do with protecting the baby then yes I would have had it on in labour.
Participant 15, decision support arm
Monitoring and reassurance
Women in both groups of the trial reported finding monitoring reassuring. There was no difference in the
pattern of responses between the two groups, or between women with few alerts and those with many.
For example, one woman said:
That showed what the heartbeat was doing, you know, ranging from sort of whatever it was,
100 to 150. And there was a guide next to it to say what’s acceptable and what’s, you know, risky.
[um] So that was quite reassuring, wasn’t it?
Participant 04, control arm, no alerts
Oh, I thought it was brill, to be honest, because as I say a lot of the time I felt a little bit out of the
loop. From where I was sitting I could see all the screens and what was going on so I found that,
you know, sort of quite comforting.
Participant 03, decision support arm, no alerts
Being able to monitor what was happening with [baby 1] and sort of midway through what was
happening with [baby 2] with their heart rates and things made me very reassured.
Participant 22, control arm, 13 yellow and two red alerts
I did quite enjoy having the monitors on actually. . . . you can just see, see sort of their heartbeat and
how strong your contractions were, whereas normally you couldn’t, you haven’t got that.
Participant 09, decision support arm, eight yellow and two red alerts
Several women (or their partners) said that the monitor also helped reassure the partner. This generated a
sense of involvement because they could observe a contraction and support their partner appropriately.
Participant 19 (decision support arm) said that her partner ‘kept checking the paper. I think he was
fascinated by it’.
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Monitoring and restriction of movement
On those occasions when objections were raised about monitoring, this was most usually because of the
restrictions it placed on movement. Some women said that they did not find the monitor restrictive or
uncomfortable, including participant 19 (decision support arm). When asked if she could move around
she said:
Participant 19: Yes, I was on my side for most of it, they said that’s the most comfortable position for
me so I just stayed on my side.
Interviewer: Did you mind being monitored at all?
Participant 19: No, no anything that helps really.
Interviewer: When you say helps, in what way?
Participant 19: I mean, well like just in case there’s any complications, I’d rather be monitored and
have them spot them, so.
Interviewer: You found it sort of reassuring?
Participant 19: Yes, yes extra reassurance.
However, other women talked about wanting to alleviate pain by moving around or to be able to go to
the toilet. The monitor restricted this movement and some women felt that the monitor straps were
uncomfortable. Some women expressed a preference for a wireless monitor. One woman had heard that
this was available in other hospitals. Women who disliked being monitored expressed varying degrees
of resignation, assuming that they would have their movement restricted anyway (e.g. because of an
epidural) or that the disadvantages of limited movement had to be balanced against the benefits for the
baby and their own peace of mind:
The fact that it restricted me, that was a bit of a pain, but I don’t know whether I would have moved
round that much or, you know. Because I mean I could have sat on the ball, you know, the blow up
ball . . . rather than the chair, which is one of the things they recommend. But I didn’t want it. I just
wanted to sit on the chair . . . No, it’s reassuring, I think because you know you don’t want your
baby’s heart rate to go down. And it was quite good as well in that my husband could see when the
contractions were coming on . . . I think we, it made no difference to us taking part, you know, it
wasn’t detrimental, it wasn’t, I was going to be monitored anyway whether I took part in the trial
or not.
Participant 20, decision support arm, three yellow alerts
And the reason I agreed, why I thought it was brilliant, was because it’s extra checks, it’s extra checks
for him. And I think well he’s going to be monitored closely from now on which is amazing but, you
know, because I’d do anything for him, you know, healthy baby, and if it picks up on something,
fantastic, and it’s doing research for everything else, so yes . . . So it turned out that I was on this
monitor for this and my heart and everything so I couldn’t move off the bed for all them hours, they
wouldn’t let me move. So I couldn’t walk round, so my plan had gone way out the window. I wasn’t
walking round, I’d not had my bath at all, I’m stuck on this bed, I’ve been induced. . . . The birth plan
was just sit on the ball, stay upright and move as much as you can. That was basically it. And nothing
happened like that and I’m saying ‘Can I get off this bed?’ ‘No, you’re being monitored for this and
you’re being monitored for your heart, you’re being monitored, baby’s being monitored because of
the poo because that’s dangerous, no you can’t move off this bed’. I was like ‘Ohhhh’, so I just lay
down the whole day. Which was really nice and very boring.
Participant 11, control arm, three yellow alerts
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Monitoring and anxiety
Women did describe anxious moments during their labour; however, these did not seem to be associated
with monitoring, but were more related to the urgent comments and behaviour of staff as they responded
to the monitoring results or to other clinical concerns.
There was only one clear exception to this:
So it was quite good because obviously people could see what was going on . . . because the doctor
come in and said I’ve been watching you on the screen . . . Sometimes, I kept hearing her say when
the heartbeat, because they kept saying she’s being naughty, they just kept saying that, and it was
flashing messages up to them and I heard her say a couple of times ‘I think that heartbeat’s okay for
the minute’ but that was telling her it was, so . . . They did talk about it quite a bit, they used it as a
guide but said they would use their own judgement to make any decisions . . . In a way I don’t know
if it’s a good thing or a bad thing, though, because right towards the end because her heartbeat had
been playing up all day, we were all focused on it . . . Everyone was just focused on this monitor and
the heartbeat, so I think that got a little bit stressful, because I did end up telling him [partner] ‘Stop
telling me what’s happening or talking about it’ because it was making me panic . . . He says to me
afterwards that he was, it was the most scared he’d ever been in his life but at the time he seemed
really quite cool and took it all in his stride but obviously he was just putting a show on for me.
Participant 16, decision support arm, four yellow alerts
Nonetheless, participant 16 concluded: ‘The study didn’t really affect the birthing experience at all so that,
you know, I’d do it again, that’s fine’.
This woman’s interpretation was that the staff used the decision support to justify postponing any
intervention. She was glad not to have a caesarean section, but she felt that she could have had an
instrumental delivery earlier: ‘I do think that because her heartbeat had been playing up so long
throughout the day and things weren’t moving on for me that they should have looked at me a bit earlier
and made a decision a bit earlier’. The woman’s mother, who was present during the labour and birth,
and was interviewed with her, was even more convinced of the need for an early delivery:
It was about half nine and I can remember the midwife saying, ‘We’re going to leave you till eleven
and if nothing’s happened by eleven we’ll get the doctor and we’ll see about taking you to theatre.
But then when 11 o’clock came they had a look at you and you’d dilated quite a bit by then so they
said we’ll leave you another hour, that took you to 12.00 and then again we’ll leave you another
2 hours, and that annoyed me because that’s what they kept saying. Although, you know, she was
well into labour I think they should have took her for a C-section at about 11 o’clock, I do.
Mother of participant 16, decision support arm
This example suggests that CTG with decision support could lead to some cases of raised anxiety levels.
There were two examples in the control group in which monitoring without decision support also caused
some anxiety. Participant 08 reported that her mother had been worried at one point, although she herself
was relaxed and asleep:
My mum was watching where they was monitoring me and I think I fell asleep so as I had
diamorphine. And at one point, because they had one on me and one obviously for the baby’s
heartbeat, and the baby must have moved so it went to zero and my mum thought it was me. She
said she couldn’t see my chest rising or anything and thought I wasn’t breathing and she looked at
this monitor and seen zero and she was like, ‘She’s not breathing, she’s not breathing’ and I woke up
and I was like ‘What?’ [laughter].
Participant 08, control arm
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The partner of participant 21 (five yellow alerts and one red alert) recalled his own fears:
Partner: Yes it was helpful, but it was also, I think, in some respects that she couldn’t see it was as
well because there was quite a few scary moments.
Woman: You see, I couldn’t see that because it was . . .
Partner: Yes, I mean his heart, I could see his heartbeat going down and she couldn’t see it, so I was a
bit worried there.
Woman: But as soon as his heartbeat started going down they all, them sitting on their desk came in
to have a look.
They were both surprised at the amount of paperwork the monitoring generated for the midwife, and felt
that this detracted staff from providing reassurance and support:
You need somebody that’s talking to you, explaining things and actually maintaining the relationship
with you as opposed to just doing, writing down and checking the monitors and things like that
because otherwise you end up panicked and it’s not good.
Participant 21, control arm, 5 yellow alerts and 1 red alert
Discussion
We found no evidence from the quantitative analysis of anxiety, using VAS-A scores, that CTG monitoring
plus decision support is associated with a change in women’s anxiety levels compared with CTG
monitoring alone. Labour appears to be an anxious time for most women, and uncertainty about whether
or not their baby will be all right contributes to this anxiety. Alerts indicating abnormalities of the fetal
heart rate are very likely to lead to anxiety for parents and clinicians, but this anxiety is appropriate if the
alert also prompts a response that ensures that the baby is kept safe. If the decision support software
results in the number of false ‘abnormal’ heart rate patterns being reduced, and the true-positive rate is
optimised (i.e. abnormal CTGs are not overlooked), then any anxiety engendered by monitoring would be
minimised and would probably be acceptable to women.
Findings from the qualitative interview illustrate that EFM per se did lead to significant anxiety for the
women interviewed. Concerns about monitoring were commonly to do with discomfort and restriction of
movement. Some women reported finding the activity of monitoring reassuring. There is a possibility that
the use of monitoring itself leads to a belief that birth is a risky process, which therefore needs careful
monitoring. This in turn may lead people to report that they find monitoring reassuring. It has been argued
that women in labour ‘became very susceptible to the reassurance of the cultural props around them. The
symbolic messages of the hospital setting gave them something to cling onto’.57 Women’s feelings of control
during labour are an important predictor of a positive birth experience, and may help in decreasing anxiety.58
This paper also argued that information giving during labour and participation in decision-making were
crucial in helping women to achieve feelings of control. It is possible that the trial information, given out in
the booking appointment in early pregnancy, at the time of the 22-week anomaly scan and at the routine
34-week appointment, contributed to women achieving these feelings of control. In a trial examining
different approaches to the presentation of information about prenatal screening,59 the information provided
did not increase anxiety. Very detailed information has been shown to have the potential to reduce anxiety.59
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This small qualitative sample cannot be generalised to all of the women who participated in the trial.
However, when considered alongside the results of the survey, we feel confident that raised anxiety levels
resulting directly from EFM with decision support is uncommon. When women are anxious in labour,
it appears to be more to do with general feelings of anxiety about the baby’s health, which may be
exacerbated by staff behaviours. However, there was one woman in our sample whose anxiety seemed to
be directly linked to the use of decision support. This means that we need to be aware of the possibility of
this happening with other women and consider ways to provide reassurance and explanation. We also
found that CTG monitoring without decision support caused some anxiety and we need to consider how
further explanation and reassurance can help these women.
Details of ethics approval
The Northern and Yorkshire REC gave approval to the study. The reference number of the ethics approval
is 09/H0903/31.
SUBSTUDY OF MATERNAL ANXIETY IN LABOUR DURING RECRUITMENT TO THE PILOT PHASE OF THE INFANT TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
Chapter 4 Analysis plan for the trial
Primary analysis
An outline analysis plan was developed and agreed by the TSC and the DMC before any data were
collected, and a detailed plan was agreed before data were unmasked and analysed. Demographic factors
and clinical characteristics were summarised with counts (percentages) for categorical variables, means (SDs)
for normally distributed continuous variables or medians [interquartile ranges (IQRs) or entire ranges] for
other continuous variables. The primary analysis was a comparison of the management approaches assigned
at randomisation. Participants were analysed in the groups to which they were randomly assigned regardless
of deviation from the protocol or treatment received. Comparative statistical analysis entailed calculating the
risk ratio (RR) plus 95% CI for the primary outcome (99% CIs for all other dichotomous outcomes), the
mean difference (plus 99% CI) for normally distributed continuous outcomes or the median difference (plus
99% CI) for skewed continuous variables. Analyses were adjusted for the stratification factors used in the
randomisation procedure: centre and singleton/twin pregnancy. Analysis of secondary outcomes was clearly
delineated from the primary analysis in the statistical reports produced. For secondary outcomes, a 1% level
of statistical significance was employed to take account of the number of comparisons. The trial is reported
according to the principles of the Consolidated Standards of Reporting Trials (CONSORT) statement.
Prespecified subgroup analysis
The consistency of the effect of decision support on the babies of groups of women recruited to the trial was
explored to see whether or not decision support is of particular help to the babies of specific subgroups of
women using the statistical test of interaction. Therefore, the categories of prespecified subgroup analysis were:
1. singletons versus twins
2. suspected growth restriction at labour onset versus no growth restriction
3. centre
4. body mass index (BMI) group [underweight (12–18.4 kg/m2), normal (18.5–24.9 kg/m2), overweight
(25–29.9 kg/m2) and/or unrecorded obese (30–70 kg/m2)].
Data collection schedule
Information was to be collected at the following times:
l electronically during labour via the Guardian system
¢ all women
l Post Birth Data Collection (PBDC) Form M (Mother) (see Appendix 8)
¢ all women receiving a higher level of care, surgery or a procedure in theatre following delivery
l PBDC Form B (Baby) (see Appendix 5)
¢ all babies receiving a higher level of care or surgery following birth
l PBDC Chart B (Baby) Neonatal Encephalopathy Data (see Appendix 6)
¢ all babies receiving a higher level of care and classified as having NNE
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l Death of a baby in the INFANT study form (see Appendix 7)
¢ all intrapartum stillbirths and neonatal deaths up to 28 days after birth
l Parent’s Questionnaire at 24 months (health and development outcomes)
¢ a subset of 7000 participants consenting to follow-up
l Parent’s Questionnaire at 12 and 24 months (health economic items)
¢ a subset of 700 participants within the follow-up sample of 7000.
Derivation of variables
Primary outcomes
l Composite of poor neonatal outcomes, defined as any of:
¢ intrapartum stillbirths, except deaths as a result of congenital anomalies (Table 7)
¢ neonatal deaths up to 28 days after birth, except deaths as a result of congenital anomalies
(Table 8)
¢ moderate or severe NNE (Table 9)
¢ admission to neonatal unit within 48 hours of birth for ≥ 48 hours with evidence of feeding
difficulties, respiratory illness or NNE (Table 10).
l PARCA-R composite score at 24 months:
¢ Total sum of scores on the PARCA-R in section A, B and C of the Parent Questionnaire at
24 months (Appendix 9).
TABLE 7 Intrapartum stillbirths except deaths as a result of congenital anomalies
Baby outcome = ‘Stillbirth’ in Guardian
MINUS Any deaths as a result of congenital anomalies recorded on the death of a baby in the INFANT study form
TABLE 8 Neonatal deaths up to 28 days after birth except deaths as a result of congenital anomalies
Baby outcome = ‘Early neonatal death’ in Guardian and died within 28 days after birth
OR A ‘Yes’ response to Q14 on the PBDC Form B (Baby) and died within 28 days after birth
OR A completed death of a baby in the INFANT study form and died within 28 days after birth
OR Deaths notified by the NHS Information Centre (England) and the NHS Greater Glasgow & Clyde Safe Haven
(Scotland) up to 28 days after birth
MINUS Any deaths as a result of congenital anomalies recorded on the death of a baby in the INFANT study form
TABLE 9 Moderate or severe encephalopathy
A ‘Yes’ response to therapeutic hypothermia on the PBDC Chart B (Baby) Neonatal Encephalopathy Data
AND Confirmed by a masked review committee
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Neonatal secondary outcomes
l Intrapartum stillbirth except deaths as a result of congenital anomalies.
l Neonatal deaths up to 28 days after birth except deaths as a result of congenital anomalies.
l Moderate or severe NNE.
l Admission to neonatal unit within 48 hours of birth for ≥ 48 hours with evidence of feeding difficulties,
respiratory illness or NNE.
¢ (For the above, see definition in Primary outcomes.)
l Admission to a higher level of care within 48 hours of birth for ≥ 48 hours [A ‘Yes’ response to Q2 on
the PBDC Form B (Baby)].
l An Apgar score of < 4 (from the Guardian variable ‘Apgars 5 mins’).
l Distribution of cord blood gas data for cord artery pH (summarise the variable cord artery results
in Guardian).
l Metabolic acidosis.
¢ A cord artery pH of < 7.05 and a base excess of ≥ 12 mmol/l for the variable cord artery results
in Guardian.
l Resuscitation interventions.
¢ Count of the number of interventions (listed under ‘Resuscitation Type’ in Guardian).
l Seizures.
¢ A ‘Yes’ response to Q7 on the PBDC Form B (Baby).
l Destination immediately after birth.
¢ Summarise the Guardian variable ‘infant transfer dest’.
l Length of stay (Table 11).
TABLE 10 Admission to neonatal unit within 48 hours of birth for ≥ 48 hours with evidence of feeding difficulties,
respiratory illness or encephalopathy
A ‘Yes’ response to Q2 on the PBDC Form B (Baby)
AND A ‘Yes’ response to Q5 or Q6 on the PBDC Form B (Baby)
AND A ‘Yes’ response to Q8 on the PBDC Form B (Baby)
AND A ‘Yes’ response to Q9 on the PBDC Form B (Baby)
AND Confirmed as compromised at birth by a masked review committee (score of ≥ 3 on Primary Outcome Review
Scoring Sheet)
TABLE 11 Length of hospital stay (baby)
‘Infant Discharge Date’ in Guardian
OR Date of discharge recorded in Q12 of the PBDC Form B (Baby)
MINUS ‘Delivery Date Time’ in Guardian
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Maternal secondary outcomes
l Mode of delivery.
¢ Recorded in Guardian in field ‘Mode of Delivery’.
l Operative intervention (caesarean section and instrumental delivery) for:
¢ fetal distress or
¢ failure to progress or
¢ combination of fetal distress and failure to progress or
¢ other reason.
¢ Indications in Guardian recorded in the fields: ‘Forceps Indicators’, ‘Ventouse Indicators’ and
‘CS Indicators’ were coded into these four categories according the rules listed in Table 12.
When a woman had more than one indication recorded and at least one was fetal distress and
at least one was failure to progress, she was classified as category iii.
TABLE 12 Classification of indications for instrumental vaginal delivery and caesarean section
Indications for instrumental vaginal delivery and caesarean section
Fetal
distress
Failure to
progress Other
Abnormal CTG Yes
Abnormal FBS pH Yes
Abnormal presentation or lie Yes
APH Yes
Intrapartum haemorrhage Yes
Breech presentation Yes
Cephalopelvic disproportion Yes
Chorioamnionitis Yes
Cord prolapse or presentation Yes
Delay in first stage Yes
Delay in second stage Yes
Eclampsia Yes
Failed induction Yes
Failed forceps/ventouse Yes
Failed trial of forceps Yes
Failed trial of ventouse Yes
Failure to progress Yes
Fetal compromise – abnormal CTG Yes
Fetal compromise – meconium stained liquor Yes
Fetal compromise suspected or indicated Yes
Fetal reason Yes
HELLP Yes
Intrapartum haemorrhage Yes
ANALYSIS PLAN FOR THE TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
TABLE 12 Classification of indications for instrumental vaginal delivery and caesarean section (continued )
Indications for instrumental vaginal delivery and caesarean section
Fetal
distress
Failure to
progress Other
IUGR Yes
Low scalp pH Yes
Malpresentation Yes
Malpresentation/unstable lie Yes
Maternal condition Yes
Maternal distress/exhaustion Yes
Maternal effort contraindicated Yes
Maternal hypertension Yes
Maternal medical condition Yes
Maternal medical disease Yes
Maternal request Yes
Multiple pregnancy Yes
Non-reassuring CTG Yes
Non-reassuring FBS Yes
Obstructed twin/triplet Yes
Other Yes
Other (fetal) Yes
Other (maternal) Yes
Other maternal medical history Yes
Placenta abruption Yes
Placenta praevia Yes
Planned as elective Yes
Pre-eclampsia Yes
Presumed fetal compromise Yes
Previous caesarean section Yes
Previous infertility Yes
Previous lower-segment caesarean section Yes
Previous poor obstetric outcome Yes
Previous obstetric history Yes
Previous traumatic vaginal delivery Yes
Previous uterine surgery Yes
Prolonged second stage
Pyrexia in labour Yes
Ruptured uterus Yes
Slow progress in first stage Yes
Slow progress in second stage Yes
Suspected fetal distress Yes
Unstable lie Yes
FBS, fetal blood sample; APH, antepartum haemorrhage; HELLP, haemolysis, elevated liver enzymes, low platelet count.
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l Grade of caesarean section.
¢ Recorded in Guardian in field ‘CS Priority’.
l Episiotomy.
¢ Recorded in Guardian in field ‘Episiotomy’.
l Any episode of fetal blood sampling.
¢ Recorded in Guardian in field ‘No of FBS’.
l Length of first stage, second stage and total length of labour from trial entry.
¢ Recorded in Guardian, was calculated from fields ‘Labour start time’, ‘Second stage/fully dilated’
and ‘Delivery Date Time’.
l Destination immediately after birth.
¢ Recorded in Guardian in field ‘Mother transfer dest’.
Quality-of-care outcome
Adverse outcome and suboptimal care (Table 13).
Process outcomes
Process outcomes were derived for the control group in the same way as the intervention group; the
decision support software was running in the background even though it was not displayed, so it was
possible to review the pattern of alerts retrospectively across the trace.
l Number of CTG abnormalities (blue, yellow and red levels of concern) detected by the decision support
software, after trial entry.
¢ Recorded in Guardian in fields ‘Number of Blue after randomisation’, ‘Number of Yellow after
randomisation’ and ‘Number of Red after randomisation’.
l Number of blue levels of concern on the decision support software, indicating a mild abnormality on
the CTG, after trial entry.
¢ Recorded in Guardian in field ‘Number of Blue after randomisation’.
l Number of yellow levels of concern on the decision support software, indicating a moderate
abnormality on the CTG, after trial entry.
¢ Recorded in Guardian in field ‘Number of Yellow after randomisation’.
TABLE 13 Adverse outcome and suboptimal care
Composite primary outcome (see definition in Primary outcomes)
AND Metabolic acidosis (see definition in Neonatal secondary outcomes)
AND Judged to have experienced suboptimal care in labour by a panel of experienced clinicians masked to allocation
OR Stillbirth or neonatal death not as a result of a congenital anomaly
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l Number of red levels of concern on the decision support software, indicating a severe abnormality on
the CTG, after trial entry.
¢ Recorded in Guardian in field ‘Number of Red after randomisation’.
l Number of women with at least one yellow level of concern on the decision support software,
indicating an abnormality on the CTG, after trial entry.
¢ Recorded in Guardian in field ‘Number of Yellow after randomisation’.
l Number of women with at least one red level of concern on the decision support software, indicating a
severe abnormality on the CTG, after trial entry.
¢ Recorded in Guardian in field ‘Number of Red after randomisation’.
l Time from first red level of concern after trial entry to birth.
¢ Recorded in Guardian, calculated from fields ‘Date Time 1st Red after randomisation’ and ‘Delivery
Date Time’.
l Number of thumb entries per hour from time of trial entry to first yellow level of concern or until fully
dilated (10 cm) if no abnormality detected or first yellow level of concern occurred prior to trial entry.
¢ Recorded in Guardian in fields ‘Count of thumbprints between randomisation and first yellow’ and
‘Count of thumbprints between randomisation and fully dilated’. The rate will be calculated using
the fields ‘Date time 1st yellow after randomisation’, ‘Second stage/fully dilated’ and ‘Delivery
Date Time’.
l Number of vaginal examinations after trial entry.
¢ Recorded in Guardian in field ‘No of VEs after randomisation’.
l Epidural analgesia after trial entry.
¢ Recorded in Guardian in fields ‘PD did woman have an epidural’ and ‘PD did woman have an
epidural time’. Only count if first recorded after the time of trial entry.
l Labour augmentation after trial entry.
¢ Recorded in Guardian in fields, ‘Syntocinon in 1st or 2nd stage’ and ‘Syntocinon in 1st or 2nd
stage time’. Only counted if the first recording was after the time of trial entry.
l Presence of meconium after trial entry.
¢ Recorded in Guardian in field ‘PD any meconium recorded during labour’ and ‘PD any meconium
recorded during labour time’. Only counted if the first recording was after the time of trial entry.
Health and development outcomes at 24 months
l Components of the PARCA-R:
¢ Non-verbal cognition scale. (Sum of scores in Section A of the Parent Questionnaire at 24 months:
‘Your child at play’ Q1–33.)
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¢ Vocabulary subscale. (Sum of scores of the 100 items in Section B of the Parent Questionnaire at
24 months: ‘What your child can say’.)
¢ Sentence complexity subscale. (Sum of scores in Section C of the Parent Questionnaire at
24 months: ‘Your child’s understanding’ Q1–18.)
l Infant deaths at 24 months (Table 14).
l Disability status at age 2 years (Table 15).
l Cerebral palsy diagnosis.
¢ A ‘Yes’ response to Q9 in Section G of the Parent Questionnaire at 24 months.
l Health economic outcomes.
¢ Ever been given breast milk or put to the breast.
¢ A ‘Yes’ response in Section 1 of the Health Economic Parent Questionnaire at 24 months.
¢ Age when last breastfed or put to the breast (days).
¢ Convert response categories to days in Section 1 of the Health Economic Parent Questionnaire
at 24 months.
Missing data for any components of the disability classification questions meant that the overall
classification may result in several categories:
l Major.
¢ At least one component in sections A–G is classified as major.
l At least non-major.
¢ One component in sections A–G is classified as non-major, but one item is missing and therefore it
is not possible to conclude that the overall classification is not major.
l Non-major.
¢ The most severe item in sections A–G is classified as non-major and there are no other
missing data.
l At most non-major.
¢ Any missing items in sections A–G could only be classified as non-major or no disability and all
other items are classified as no disability.
TABLE 14 Infant deaths at 24 months
Baby outcome = ‘Early neonatal death’ in Guardian
OR A ‘Yes’ response to Q14 on the PBDC Form B (Baby)
OR A completed Death of a baby in the INFANT study form
MINUS Any deaths as a result of congenital anomalies recorded on the death of a baby in the INFANT study form
AND Deaths notified by the NHS Information Centre (England) and NHS Greater Glasgow & Clyde Safe Haven
(Scotland) up to 2 years after birth
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TABLE 15 Disability status at 2 years. Classified as non-major disability or major disability at 2 years if the infant
meets any one of the following criteria from the Parent Questionnaire at 24 months (criteria for major disability is
italicised)60,61
Sections A–C: cognitive function l PARCA-R composite score 2–3 SDs below mean for age
l PARCA-R composite score > 3 SDs below mean for age
Sections B–C: communication l < 10 out of 100 words from word list
l ≥ 10 out of 100 words from word list and question C6 = ‘Not yet’ to the question
‘Has your child begun to put words together yet’
l Does not use any recognisable words (including signed words)
l Does not use any sounds that can be understood
l Does not show understanding of any words or signs
Section D: physical ability Walking:
l Has an unsteady walk but does not need help
l Unable to walk without help
l Unable to walk even with help
Sitting:
l Sits unsupported but unstable
l Sits only with support
l Unable to sit
Hand use:
l Picks up by other means (right or left)
l Unable to pick up object (right or left)
l Has difficulty using one hand
l Unable to use both hands
Head control:
l Poor control but does not need support
l Can control head only with support
Section E: vision l Some difficulty but sees well enough for everyday activities
l Has considerable difficulty but can see objects if near
l Is able to see light only or has no vision
Section F: hearing l Has some hearing problems but does not need a hearing aid
l Hears well or with only a little difficulty with a hearing aid
l (Do not count if because of recurrent ear infections or glue ear and no aid)
l Has severe hearing difficulty even with a hearing aid or hearing is not helped with
an aid
Section G: growth l Height or weight 2–3 SDs below mean for age
l Height or weight > 3 SDs below mean for age
Section G: seizures l Fits, seizures or convulsions (not because of fever) but no treatment required
l On treatment now and has no seizures
l Has up to one seizure every month on treatment
l Has more than one seizure every month on treatment
Section G: feeding l Is fed with tube passed directly into the stomach (gastrostomy)
l Is fed with tube passed from nose to stomach
Section G: respiratory l Wheezing more than once a week and taking any medication for chest symptoms
when needed
l Currently on any medications for chest symptoms and taking relievers, preventers
or steroids every day
l Requires continuous oxygen therapy or mechanical ventilation
Section G: other disability l Other long-term problem that has some limitation on everyday activities but able
to function independently (review case by case)
l Needs assistance or aids for some activities
l Is completely dependent on carer
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l None.
¢ No data re missing and all items in sections A–G are classified as no disability.
l Not known.
¢ No disability reported but when some data items in sections A–G are missing.
In order to derive the classification ‘Major’ or ‘Non-major’ in the final report, all infants with ‘At least
non-major’ disability were classified as ‘Non-major’ and all infants with ‘At most non-major’ disability were
classified as ‘None’.
Protocol violation
A protocol violation is the intended failure to comply with the final study protocol as approved by the REC
and research and development departments, an example being serious non-compliance with the protocol
resulting from fraud or misconduct that affects participant rights, safety and/or the integrity of the
resultant data. Any violations were reported to the sponsor and REC as soon as possible.
Protocol deviation
A protocol deviation is an unintended failure to adhere to the final study protocol.
In this trial, the following were defined as protocol deviations.
Participants randomised in error
These include women:
l who did not receive EFM
l who had triplets or a higher-order pregnancy
l who were at < 35 weeks’ gestation
l whose infant had a known gross fetal abnormality
l who were aged < 16 years
l who were not able to give consent to participate as judged by the attending clinicians
l who received an elective caesarean section prior to the onset of labour.
Participants who do not receive the allocated intervention
These included women in the following arms:
l ‘CTG with no decision support’ arm who received partial or full decision support
l ‘CTG with decision support’ arm who did not receive decision support.
Follow-up completed outside set time window
This included infants who were aged 2 years ± 3 months when the 2-year follow-up questionnaire
was completed.
Primary analysis strategy
For the primary analysis, participants were analysed in the groups into which they were randomly allocated
(i.e. comparing the outcomes of all women and babies allocated ‘CTG with no decision support’ with
‘CTG with decision support’), regardless of the allocation received.
The two groups were compared by calculating the treatment difference adjusted for the stratification
factors used in the randomisation (centre and singleton/twin pregnancy). The adjusted analysis took
account of the correlation between treatment groups introduced by stratifying the randomisation (which
forces outcomes between treatment arms to be similar apart from any treatment effect).62 Both adjusted
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and unadjusted estimates were presented for all outcomes, but the primary inference was based on the
adjusted analysis.
The unit of randomisation was birth episode, which raises the issue of non-independence of observations.
Some women had more than one delivery over the study period and may have been randomised into the
trial more than once if they were eligible, but this was estimated to be very unlikely. Based on national
statistics and average interpregnancy intervals in the UK, we anticipated that around 10% of women in this
cohort would have a subsequent delivery within the study period, but a smaller proportion would have two
consecutive births monitored by CTG.63,64 In addition, around 1.5% of women would be expected to have
twin deliveries,65 but this proportion was likely to be lower in this cohort as some twin births will occur
before 35 weeks’ gestation and a large proportion of twin term births are by elective caesarean section.
We anticipated the proportion of non-independent observations within and between pregnancies to be
much lower than 10%; however, some outcomes can have a large intracluster correlation coefficient –
in particular the 2-year outcomes collected via the parent questionnaire – so clustering was taken into
account in the analysis.66,67
Descriptive analysis population
Baseline demographic and clinical characteristics were reported for each delivery for all women randomised
for whom we had data available, excluding protocol violations and women randomised in error who did
not give consent or who were aged < 16 years.
Comparative analysis population
l Maternal outcomes.
¢ All women randomised for whom data were available, excluding protocol violations and women
randomised in error who did not give consent or who were aged < 16 years. For women with
more than one birth episode during the study period, baseline characteristics and maternal
outcomes were reported on each occasion. For twin births the mode of delivery of the first twin
delivered was reported.
l Short-term neonatal outcomes.
¢ All babies including both twins, excluding protocol violations and women randomised in error who
did not give consent or who were aged < 16 years.
l The 24-month health and development outcomes.
¢ A sample of 7000 infants recruited during the first 2 years of the trial, excluding protocol violations,
women randomised in error who did not give consent or who were aged < 16 years and adopted
children.
Interim analysis population
Different denominators were used in the annual interim analysis.
l The total number of trial participants, excluding protocol violations and women randomised in error
who did not give consent or who were aged < 16 years.
l The number of women with post-birth data.
l The number of babies with post-birth and/or 24-month follow-up data.
DOI: 10.3310/hta22090 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 9
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brocklehurst et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
43
Representativeness of trial population and participant throughput
The flow of participants through each stage of the trial was summarised using a CONSORT diagram.68
We reported the numbers of women who:
l were randomly assigned
l received the intended intervention
l withdrew before or during CTG monitoring
l were included in the primary analysis at discharge
l were lost to follow-up
l were included in the analysis at 24 months.
Baseline comparability of randomised groups
Participants in the original two randomised groups were described separately with respect to:
l maternal age
l ethnic group
l singleton or twin pregnancy
l gestational age at trial entry
l BMI at booking visit (if recorded)
l smoking history at booking visit (if recorded)
l parity
l obstetric history
l cervical dilatation at trial entry (if recorded)
l intrauterine growth restriction (IUGR) suspected at labour onset
l labour induction.
Numbers (with percentages) for binary and categorical variables, and means (and SDs) or medians (with
lower and upper quartiles) for continuous variables were presented; no tests of statistical significance were
performed nor were CIs calculated for differences between randomised groups on any baseline variable.
Losses to follow-up
The numbers (with percentages) of losses to follow-up among women selected for the 24-month
assessment were reported and compared between the two trial arms, and the reasons recorded.
Any deaths (and their causes) were reported separately.
Description of available data
The pattern of missing data for primary and secondary outcomes, from baseline to the end of follow-up,
was summarised for the two treatment groups, with differentiation between fully and partially completed
forms/Guardian fields and those that were missing completely.
Not all data are routinely collected by all hospitals, for example BMI, smoking history, cervical dilatation,
cord artery pH and base deficit. These data were reported separately for the subset of hospitals that do
collect them routinely.
Description of compliance with intervention
A summary of the intervention received was provided, which included intermittent use of the decision
support software and/or withdrawal of consent during labour.
Unmasking of randomised treatments
In order to accurately reflect any potential impact of the decision support software in contemporary NHS
practice, such as changes in midwifery presence during labour consequent on knowledge of the allocation,
the clinicians were not masked to allocation. The local community midwives and participants may also have
been aware of the allocation. All other persons involved in the trial (except for the trial statistician and trial
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programmer), including the UCL trial co-ordinating centre, did not have access to the aggregate list of
randomisation codes. K2 Medical Systems remained masked until the data were frozen at the end of the trial.
Statistical methods used for analysis of primary outcomes
The numbers (percentages) of babies with poor neonatal outcomes were presented for each group and
the RR plus 95% CI calculated. RRs were estimated using generalised estimating equations (GEEs), or a
similar method, adjusting for the stratification factors used in the randomisation (centre and singleton/twin
pregnancy). This method of analysis accounted for the correlation in outcomes between twins and siblings
delivered in a subsequent pregnancy during the trial period. A log binomial model was planned to be used
in the first instance but, if convergence was not achieved, then a log-Poisson model would be used with a
robust variance estimator.69 The mean (SD) PARCA-R composite score was presented for each group and
the mean difference between groups plus 95% CI was calculated and compared using GEE (Gaussian
model with identity link), adjusting for stratification factors.
Significance levels
For the analysis of the primary outcomes, a p-value of 0.05 (5% significance level) was used to indicate
statistical significance. Comparisons of all other outcomes including the components of the primary
outcome were reported in full for completeness and transparency. For all other analyses, a p-value of 0.01
(1% significance level) was used to indicate statistical significance, to take into account the number of
comparisons. Two-sided statistical tests and corresponding p-values were presented throughout.
Missing data
Missing data for the short-term primary outcome were likely to be negligible, as most of the data were
collected electronically on the Guardian system before the woman left the delivery room. If any data items
were missing on the PBDC forms, completed for babies and women admitted to a higher level of care,
every effort was made to extract these data from the hospital involved.
For any partially completed PARCA-R scales in the 24-month parent questionnaires, the following
strategies for estimation of the total and subscale scores were employed when items were missing:
l Non-verbal cognition scale (PARCA-R: ‘Your child at play’ Q1–33)
¢ pro rata estimation if < 10% of (up to three) items are missing
¢ if Q6 is ‘No’, and Q6a is missing, code ‘No’ for Q6a
¢ if Q6 is ‘Don’t know’, and Q6a is missing, code ‘Don’t know’ for Q6a.
l Vocabulary subscale (PARCA-R: ‘What your child can say’)
¢ non-ticked items were coded to zero.
l Sentence complexity subscale (PARCA-R: ‘Your child’s understanding Q1–18)
¢ if Q1–6 were missing, coded to zero and analysed as ‘Not Yet’
¢ if Q6 is ‘Often’ or ‘Sometimes’ and any of Q7–18 were not completed, coded to zero.
Prespecified subgroup analysis
To examine whether or not the effect of decision support was consistent across specific subgroups of
women and babies, the following subgroup analyses were planned and carried out:
l singletons versus twins
l suspected IUGR at labour onset compared with no growth restriction
l BMI group [underweight (< 18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), obese
(≥ 30 kg/m2) or unrecorded]
l centre.
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For the trial composite primary outcome, results were presented in forest plots showing the RR plus 95% CI
for each subgroup, by treatment group, with the p-value for the statistical test of interaction.70 For the
PARCA-R composite score, the difference between the mean treatment effects was reported, within each
subgroup, with a 95% CI and the corresponding p-value.71
Using these statistical methods, we performed subgroup analyses for all prespecified neonatal outcomes
and instrumental vaginal deliveries. In addition, we analysed process outcomes by centre.
Prespecified sensitivity analysis
Following early DMC meetings, it was reported that the number of babies admitted to a neonatal unit
within 48 hours for ≥ 48 hours exceeded the number anticipated in the sample size calculation by an order
of magnitude. Following a review of cases by the masked review panel at the end of the trial, the number
still exceeded that anticipated in the sample size calculation, although to a lesser degree. Hence this
component far outweighed the other rarer components, such as stillbirth, neonatal death and moderate
or severe NNE, and strongly influenced the composite primary outcome. To explore the impact of this on
the main findings, a sensitivity analysis of the primary composite outcome was performed, including
only the most severely affected babies admitted to a neonatal unit and allocated a score of ≥ 7 points on
the Primary Outcome Review Scoring Sheet by the masked review panel.
Statistical software employed
Stata/SE version 13 for Microsoft Windows was used for this analysis.
Statistical methods used for analysis of secondary outcomes
Generalised estimating equations, or a similar method, was used for the analysis of secondary outcomes,
adjusting for the stratification factors used in the randomisation procedure (centre and singleton/twin
pregnancy). For normally distributed continuous outcomes, we presented the mean and SD for each group,
calculating the mean difference plus 99% CI using a Gaussian model with the identity link. For the length of
labour, we presented the geometric mean ratio (GMR). For binary and categorical outcomes, we presented
counts and percentages for each group and calculated the RR with corresponding 99% CI using a binomial
or Poisson model with the log-link. For the number of thumb entries per hour from trial entry to the first
yellow level of concern or full dilatation, the rate ratio plus 99% CI was calculated using a Poisson model with
the log-link. For skewed continuous outcomes, we presented the median and IQR (or entire range, whichever
was appropriate) for each group and compared the difference in medians between groups using quantile
regression. We were unable to adjust for the correlation among twins and siblings using this method.
Deviation from analysis described in protocol
For the count variables, median differences were all zero with zero CIs, although some were statistically
significant and adjusted quantile regression models were not performing well (lack of convergence), so
rate ratios were presented as the effect measure instead of median differences. Medians (IQR) were still
presented for each variable as planned. In addition, the hazard ratio was presented for the time from the
first red alert to birth instead of the median difference, in keeping with the comparison of rates for the
rest of the process outcomes. This was agreed at the INFANT project management group meeting on
23 October 2014.
The outcome time from the first red level of concern to delivery was changed to time from the last red
level of concern to delivery. This was agreed at the INFANT coinvestigator group meeting on 15 July 2015
following a review by Professor Philip Steer. It was found that the first red level of concern was frequently
an artefact and, therefore, did not accurately capture information relating to prompt action at or around
delivery following a red alert.
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Chapter 5 Trial conduct
Training
An extensive programme of training in the trial processes was delivered by the trial team at each
participating site. This included training about the use of the decision support software, how to complete
the electronic data input in preparation for download to the trial co-ordinating centre and how to
complete the necessary paper data collection forms for babies of women admitted to higher-level care
(see Appendix 4).
Recruitment
The aim was to randomise 46,000 women in the trial over 36 months. Therefore, approximately 320 women
per week needed to be recruited. A conservative estimate of the proportion of women who receive EFM in
labour, and were therefore eligible for trial entry, was 60%. The eligibility rate was expected to be higher in
some centres; for example, in one study, 80% of primigravid women who gave birth in Liverpool Women’s
Hospital were monitored continuously. In total, there were around 42,500 deliveries per annum in the
centres originally planned to participate in INFANT (the average for each centre was 4250 deliveries per
annum). This was approximately 817 deliveries per week, among which an estimated 490 women per week
(60%) would receive EFM.
Pilot work carried out in Plymouth to investigate recruitment rates found that only 2 out of 105 eligible
women declined to take part. Although this indicated that uptake was likely to be high, strategies to
promote and support recruitment were implemented in all participating centres.
During the course of the trial, recruitment graphs (e.g. Figure 11) were sent to all recruiting sites each
month. This showed the percentage of target recruitment over the years of the trial. In the example below,
this centre exceeded its recruitment target throughout the duration of the trial, achieving a very high
recruitment rate of approximately 230% of its target in 2011.
Overall, despite most centres exceeding their recruitment target, there was a delay in reaching the final
recruitment target (Figure 12). This was caused by longer than expected delays in initiating new centres
into the trial.
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FIGURE 11 Example of monthly recruitment data sent to the centres.
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Review of primary outcome
Following the TSC meeting on 2 October 2013, the INFANT project management group agreed to
undertake further work to clarify the classification of the primary outcome for the trial. This issue had
arisen because the incidence of one of the components of the composite primary outcome (admission to
the neonatal unit within 48 hours of birth for ≥ 48 hours with evidence of respiratory or feeding problems
or NNE) was substantially higher than had been anticipated, and an initial review of these cases (by PB and
DF, masked to allocation) suggested that a number of cases were included in this outcome that were
unrelated to perinatal hypoxia (Table 16). It was also recognised that, for many of these uncertain cases,
the detail provided by the INFANT data collection forms was insufficient (Figure 13). All cases were
included in this outcome if question 2 was answered ‘Yes’ and ‘Yes’ was also answered for one or more
of questions 5, 6, 8 and/or 9 (Figure 13).
It was agreed that neonatal unit discharge summaries would be collected for all babies who were admitted
to the neonatal unit within 48 hours of birth for ≥ 48 hours. A more formal process of review of a
proportion of these cases would then be undertaken by Peter Brocklehurst, David Field, Keith Greene and
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FIGURE 12 Actual vs. target recruitment.
TABLE 16 The composite primary outcome event rate overall, and the relative contribution of its four components
prior to the review
Component of primary outcome
Expected Observed
Event rate
(n/1000)
Number
(n= 29,233a)
Event rate
(n/1000)
Number
(n= 29,233a)
Intrapartum stillbirth 0.35 10 0.07 2
Neonatal death up to 28 days after birth 0.70 20 0.48 14
Moderate or severe NNE 1.30 38 0.92 27
Admission to NICU within 48 hours of birth for ≥ 48 hours
with evidence of respiratory or feeding problems or NNE
1.25 37 18.10 529
Overall (total) 3.60b 105 19.57 572
NICU, neonatal intensive care unit.
a Sample size at database lock on 6 November 2012.
b The actual sample size calculation was based on an incidence of the primary outcome in the no decision support group
of 3/1000 to err on the side of caution.
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Nikki Robertson (a neonatologist independent of the trial who is an expert on perinatal hypoxia in term
babies) to devise a more structured way of assessing the classification of these babies. This system would
then be implemented by David Field and Keith Greene for the purposes of data monitoring. There was also
agreement that this process would be repeated by an independent panel of neonatologists at the end of
the trial.
Peter Brocklehurst, David Field, Keith Greene and Nikki Robertson met on 16 January 2013 and reviewed
approximately 40 sets of discharge summaries (masked to trial allocation) and devised a data extraction
form, which included the key elements of the neonatal course which are most likely to be related to
intrapartum hypoxia. This form was not an established or validated list of criteria, but the numeric scoring
was devised to try and give some quantification of the severity of elements of the clinical course. A score
of ≥ 3 points was agreed to be evidence that the condition of the baby was likely to be associated with
intrapartum hypoxia, acknowledging that there remained uncertainty about this, as there is no absolute
measure of intrapartum hypoxia. However, having reviewed the discharge summaries with the data
extraction form, the criteria were felt to be a good reflection of the baby’s clinical condition.
Process
David Field and Keith Greene then reviewed all the discharge forms independently to score the cases.
A teleconference on 22 February 2012 resolved, by consensus with Peter Brocklehurst, the uncertain cases
so that a decision could be made as to whether or not to include each baby as having evidence of the
primary outcome (Table 17).
 
FIGURE 13 Definition of ‘Admission to neonatal intensive care unit within 48 hours of birth for ≥ 48 hours with
evidence of respiratory or feeding problems or NNE’. See Appendix 5.
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This produced a slightly revised definition of this component of the composite primary outcome:
l Admission to the neonatal unit within 48 hours of birth for ≥ 48 hours with evidence of respiratory or
feeding problems or NNE (when there is evidence of compromise at birth).
This process and revised definition were reviewed and accepted by the TSC on 18 March 2013 and by the
DMC on 21 March 2013.
Cases continued to be reviewed by David Field and Keith Greene on a monthly basis for the purposes of
data monitoring. These data were entered into the INFANT database accordingly.
Independent review panel
An independent panel of neonatologists, to review all cases of the primary outcome (all stillbirths, early
neonatal deaths, cases of NNE and babies admitted to the neonatal intensive care unit within 48 hours for
≥ 48 hours with evidence of respiratory or feeding difficulties), was assembled. An advertisement was
placed in the British Association of Perinatal Medicine newsletter for prospective panel members. In order
to ensure the independence of the panel, members could not be practising at any of the INFANT trial
recruiting centres. Brief information of what would be expected as part of the review, how often they
would be required to meet and details of payments to be made were included in the advertisement.
The role was remunerated at £500 per day. Applicants were selected by the INFANT coinvestigators group.
After an initial face-to-face meeting to establish methods of working, panel members were sent a
proportion of the cases once trial recruitment had finished. There was an overlap of cases so that every
case was reviewed by at least two reviewers. When there was lack of agreement by two members of the
panel, consensus was reached by discussion with the whole panel, at either a face-to-face meeting or
teleconference.
Follow-up of deaths to age 2 years for entire trial cohort
After the initial analysis of the results of the trial, there was an unusual finding noted with the data from
the 2-year follow-up.
TABLE 17 The composite primary outcome event rate overall, and the relative contribution of its four components
after the review
Component of primary outcome
Expected Observed
Event rate
(n/1000)
Number
(n= 29,233a)
Event rate
(n/1000)
Number
(n= 29,233a)
Intrapartum stillbirth 0.35 10 0.07 2
Neonatal death up to 28 days after birth 0.70 20 0.48 14
Moderate or severe NNE 1.30 38 0.92 27
Admission to NICU within 48 hours of birth for ≥ 48 hours
with evidence of respiratory or feeding problems or NNE
1.25 37 3.18 93
Overall (total) of those reviewed 3.60 105 4.65 136
NICU, neonatal intensive care unit.
a Sample size at database lock on 6 November 2012.
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In the original INFANT protocol, 46,000 women would be recruited and their babies would be followed up
until hospital discharge, with a sample of 7000 of these babies being followed up at 2 years to assess
longer-term outcomes, including neurodevelopmental outcomes. These 7000 babies were planned to be
selected from the early phase of trial recruitment so that follow-up would not prolong the duration of the
trial and the time to publication. We also initiated a system of ‘flagging’ with the NHS that notified the
trial team of later deaths (after initial hospital discharge) to report deaths among all of the 46,000 babies
by the time follow-up was completed. The duration of this mortality follow-up was intended to be
dependent on when the baby was born and, for babies whose mothers were recruited later in the trial,
would be < 2 years.
Once the planned follow-up was complete, the preliminary results from the INFANT trial were analysed
and presented to the coinvestigators. There was an apparent difference in the number of longer-term
deaths between groups. Given the lack of any difference in the primary outcome (early mortality and
major morbidity), this result was surprising. At a joint meeting of the TSC and DMC in December 2014,
it was suggested that the trial team should undertake a structured review of all the deaths, including
obtaining as complete information about the later deaths as possible and, masked to allocation, ascribe
cause-of-death classifications so that we could get some insight into whether this difference in deaths was
likely to be real or spurious.
The distribution of all deaths between trial entry and follow-up at this time was 20 in one arm compared
with 40 in the other arm. Masked to allocation, the cause of death was classified for babies for whom we
had known cause-of-death data, and cause-of-death data were sought from the relevant national bodies
(in England and Scotland) so that the later deaths could also be classified. Some cause-of-death data were
still missing at this time. If an infant death is a coroner’s case, there is often a delay in the cause-of-death
data becoming available.
Once the coding was undertaken, the allocations were revealed and these data were presented to the
coinvestigator group at its meeting on 4 February 2015. We compared the causes of death, including
identifying deaths for congenital anomalies and lethal genetic conditions in which the decision support
system could not be expected to make a difference. There were no differences in the numbers of deaths as
a result of lethal congenital anomalies or lethal genetic conditions between the two groups. There appeared
to be a possible difference between the two groups in terms of sudden unexplained death in infancy and
other conditions, such as sepsis, in which there might potentially be a link between condition at birth and
these later health outcomes. Although conditions might not be sufficient or severe enough to register as an
event in the primary outcome, they might predispose the child to later morbidity and mortality.
The coinvestigator group decided that they could not conclude that this was a spurious result and agreed
with the recommendations of the TSC/DMC that we should continue to follow up the remaining children
until they reached age 2 years to determine the complete number of deaths by 2 years for the entire cohort.
The last baby was born in August 2013, resulting in a continuation of follow-up until after August 2015,
allowing approximately 4 months for the majority of coroner’s case cause-of-death data to be entered into
the national systems.
During the further follow-up, it became apparent that an error had been made by the national authority in
England when searching for cases of death. Despite the denominator of the trial growing each time the
data were submitted for flagging, the search for deaths continued to be carried out for the initial submitted
cohort, which was less than half of the entire trial population.
Once this error was recognised, a greater number of deaths were identified and, by the time the final child
had reached age 2 years, the total numbers of deaths in each arm (excluding lethal congenital anomalies)
were similar, with 29 in the decision support arm and 35 in the no decision support arm, adjusted risk
ratio (aRR) 0.83 (99% CI 0.44 to 1.59).
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Chapter 6 Results
Between 6 January 2010 and 31 August 2013, 47,062 women were randomised to the INFANT trialfrom the participating centres (Table 18). A total of 1020 women (2.2%) were excluded from the
analysis of the primary outcome (Figure 14). The majority of these exclusions were because of missing or
incomplete consent forms. Data at the time of birth were available for 100% of women and babies
eligible to be analysed. Follow-up data at 2 years were available for 56% (7066/12,704) of those
contacted, although data were sufficiently complete for the analysis for 6707 children.
A total of 30 women withdrew from the trial, 23 in the decision support group and seven in the no
decision support group. The reasons given are in Table 19. A total of 1059 women were randomised in
error, and the reasons for this are given in Table 20.
Baseline characteristics were similar between the two groups in the trial (Table 21). Mean maternal age
was 29 years. The majority of women participating in the trial were of white ethnic origin and the median
BMI at booking was 25 kg/m2. Nearly 60% of women were having their first baby, and the majority of
women in both groups had a gestational age of between 38 and 41 completed weeks, although 11%
were < 38 weeks’ gestation and 6.3% were 42 weeks or later. Very few women had experienced a
previous stillbirth (1%) and approximately 6% had undergone a caesarean section in a previous birth.
In almost 60% of women, labour was induced.
TABLE 18 List of participating centres
Centre
Trial arm, n (%)
Decision support
(N= 22,987)
No decision support
(N= 23,055)
Birmingham Women’s Hospital 1131 (4.9) 1131 (4.9)
Burnley General Hospital 2058 (9.0) 2062 (8.9)
Chelsea and Westminster Hospital, London 441 (1.9) 449 (2.0)
Derriford Hospital, Plymouth 1641 (7.1) 1626 (7.1)
Homerton University Hospital, London 944 (4.1) 940 (4.1)
Liverpool Women’s Hospital 1524 (6.6) 1559 (6.8)
Northwick Park Hospital, London 926 (4.0) 936 (4.1)
Nottingham City Hospital and Queens Medical Centre 902 (3.9) 903 (3.9)
Princess Anne Hospital, Southampton 585 (2.5) 581 (2.5)
Princess Royal Hospital and Southern General Hospital, Glasgow 2041 (8.9) 2033 (8.8)
Queen Alexandra Hospital, Portsmouth 1370 (6.0) 1372 (6.0)
Rotunda Hospital, Dublin 1735 (7.6) 1728 (7.5)
Royal Bolton Hospital 499 (2.2) 510 (2.2)
Royal Derby Hospital 421 (1.8) 425 (1.8)
St Mary’s Hospital, Manchester 935 (4.1) 945 (4.1)
Stoke Mandeville Hospital 1214 (5.3) 1216 (5.3)
University College Hospital, London 196 (0.9) 192 (0.8)
University Hospital Coventry 600 (2.6) 607 (2.6)
University Hospital of North Staffordshire 1670 (7.3) 1679 (7.3)
Warrington Hospital 1730 (7.5) 1732 (7.5)
Warwick Hospital 424 (1.8) 429 (1.9)
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There was no evidence of a difference in the incidence of the primary outcome of the composite of poor
neonatal outcome between the groups, with 172 babies (0.7%) having a poor outcome in the decision
support group compared with 171 babies (0.7%) in the no decision support group (aRR 1.01, 95% CI
0.82 to 1.25) (Table 22). Similarly, there was no evidence of a difference in any individual component of
the composite primary outcome between the groups.
In a prespecified sensitivity analysis that used a different cut-off point for defining compromise at birth
(a score of ≥ 7 points indicating a more severe compromise than a score of ≥ 3 points) this made no difference
Women randomised
(n = 47,062; n = 47,648 infants)
Women included in analysis of
maternal outcomes
(n = 22,987b)
Infants included in analysis of
neonatal primary outcome
(n = 23,263)
• Women excluded from analysis as
   withdrew consent to use data (n = 16;
   n = 17 infants)
• Women excluded as full consent not
   obtained (n = 512; n = 521 infants)
Women allocated to decision support
(n = 23,515; n = 23,801 infants)
• Did not receive allocated intervention,
   n = 83
• Randomised in errora, n = 515 (2%)
Women allocated to no decision support
(n = 23,547; n = 23,847 infants)
• Did not receive allocated intervention,
   n = 16
• Withdrew from trial, n = 7
• Randomised in error, n = 544 (2%)
Women included in analysis of
maternal outcomes
(n = 23,055b)
Infants included in analysis of
neonatal primary outcome
(n = 23,351)
• Women excluded from analysis as
   withdrew consent to use data 
   (n = 6; n = 6 infants)
• Women excluded as full consent not
   obtained (n = 486; n = 490 infants)
Infants who died before 24 months
(n = 30/21,509c)
Surviving infants without primary
outcome selected for 24-month follow-up
(n = 6380)
• Not contactable, n = 87 (1%)
• No response, n = 2737 (43%)
• Questionnaire received, n = 3556 (56%)
Infants who died before 24 months
(n = 37/21,599c)
Surviving infants without primary
outcome selected for 24-month follow-up
(n = 6324)
• Not contactable, n = 72 (1%)
• No response, n = 2742 (43%)
• Questionnaire received, n = 3510 (56%)
Surviving infants without primary outcome
and questionnaire received
(n = 3556)
• Infants included in analysis of PARCA-R,
   n = 3381
• Missing data and excluded from analysis,
   n = 175
Surviving infants without primary outcome
and questionnaire received
(n = 3510)
• Infants included in analysis of PARCA-R,
   n = 3326
• Missing data and excluded from analysis,
   n = 184
Allocation
Analysis at 
discharge
Follow-up
Analysis at 
24 months
FIGURE 14 Consolidated Standards of Reporting Trials (CONSORT) flow of participants. a, One woman who withdrew
(with consent to use of data) was also randomised in error; b, the 46,042 women included in the analysis includes 448
women (1%) with two singleton birth episodes and six women with one singleton and one twin birth episode in the
study period and the allocation received for the subsequent delivery was independent of the first allocation received;
and c, data from the Republic of Ireland not included in the numerator (n= 1 decision support) or denominator
(n= 1754 in decision support and n= 1752 in no decision support) as data on deaths after discharge were not
available. Deaths in the flow chart include stillbirths (n= 1 in decision support and n= 2 in no decision support).
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TABLE 20 Reasons for being randomised in error
Reason
Trial arm, number of participants
Decision support (N= 515) No decision support (N= 544)
No labour/elective caesarean section 378 371
Date of randomisation after date of delivery 92 120
Fetal abnormality 18 19
Gestational age at entry of < 35 weeks or
not known
10 15
Not CTG monitored 9 9
Not known/other 8 10
TABLE 19 Reasons for withdrawal
Reason
Trial arm, number of participants
Decision support (N= 23) No decision support (N= 7)
No longer wishes data to be collected/used 2 2
Did not like alerts 4 0
Twin baby died 1 0
No longer wishes to be followed up 1 0
Not happy with care/approach 1 2
Too distressed 1 0
Not happy with allocation 4 0
Not known/other 9 3
TABLE 21 Maternal characteristics at trial entry
Maternal characteristic
Trial arm
Decision support (N= 22,987)a No decision support (N= 23,055)a
Maternal age at trial entry (years)
Median (IQR) 29 (25–33) 29 (25–33)
Ethnic group, n (%)b
White 17,234 (83.3) 17,213 (83.0)
Indian 743 (3.6) 724 (3.5)
Pakistani 736 (3.6) 802 (3.9)
Bangladeshi 98 (0.5) 113 (0.5)
Black Caribbean 116 (0.7) 135 (0.6)
Black African 461 (2.2) 505 (2.4)
Any other ethnic group 1296 (6.3) 1249 (6.0)
Unknown 2303 2314
continued
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TABLE 21 Maternal characteristics at trial entry (continued )
Maternal characteristic
Trial arm
Decision support (N= 22,987)a No decision support (N= 23,055)a
Twin pregnancy, n (%) 276 (1.2) 296 (1.3)
Gestational age at entry (completed weeks)
Median (IQR) 40 (39–41) 40 (39–41)
< 35+0, n (%) 4 (–d) 6 (–d)
35+0 to 37+6, n (%) 2529 (11.0) 2522 (10.9)
38+0 to 39+6, n (%) 7322 (31.9) 7266 (31.5)
40+0 to 41+6, n (%) 11,688 (50.9) 11,795 (51.2)
≥ 42+0, n (%) 1437 (6.3) 1457 (6.3)
BMI (kg/m2), at booking visit
Median (IQR) 25 (22–30) 25 (22–30)
< 18.5, n (%) 379 (2.5) 384 (2.6)
18.5 to 24.9, n (%) 6302 (42.1) 6225 (41.6)
25 to 29.9, n (%) 4531 (30.3) 4560 (30.5)
30 to 34.9, n (%) 2178 (14.5) 2237 (14.9)
35 to 39.9, n (%) 1024 (6.8) 1025 (6.8)
≥ 40, n (%) 565 (3.8) 544 (3.6)
Unknown, n 8008 8080
Smoking, at booking visit, n (%)
Yes 2448 (14.3) 2536 (14.7)
No 14,724 (85.7) 14,722 (85.3)
Unknown 5815 5797
Parity, n (%)
Nulliparous 13,736 (59.8) 13,650 (59.2)
Parous 9247 (40.2) 9390 (40.8)
Obstetric history, n (%)
Previous stillbirth 273 (1.2) 223 (1.0)
Previous elective caesarean section 208 (0.9) 253 (1.1)
Previous emergency caesarean section 1240 (5.4) 1224 (5.3)
Previous neonatal death 80 (0.4) 95 (0.4)
Cervical dilatation at time of trial entry (cm)
Median (IQR) 4 (2–6) 4 (2–5)
Unknown, n 16,184 16,339
Fetal growth restriction suspected at labour
onset, n (%)
859 (3.7) 914 (4.0)
Labour induction, n (%)
Induced 13,516 (59.2) 13,568 (59.2)
Spontaneous 8955 (39.2) 8967 (39.2)
No labour 376 (1.7) 367 (1.6)
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TABLE 22 Primary and neonatal outcomes
Outcome
Trial arm
Adjusteda RR (CI)
unless otherwise
indicated
Decision
support
(N= 23,263)
No decision
support
(N= 23,351)
Composite primary outcome (95% CI)
Composite primary outcome 1–4, n (%)b 172 (0.7) 171 (0.7) 1.01 (0.82 to 1.25)
(1) Intrapartum stillbirths, n (%)c 1 (–) 2 (–) 0.50 (0.05 to 5.53)
(2) Neonatal deaths up to 28 days after birth, n (%)d 6 (–) 4 (–) 1.51 (0.42 to 5.33)
(3) Moderate or severe NNE (requiring cooling), n (%) 18 (0.1) 21 (0.1) 0.86 (0.46 to 1.61)
(4) Admission to neonatal unit within 48 hours of
birth for ≥ 48 hours because of feeding difficulties,
respiratory illness/symptoms or NNE and evidence of
compromise at birth, n (%)
147 (0.6) 144 (0.6) 1.02 (0.81 to 1.29)
Other neonatal outcomes (99% CI)
Admission to a higher level of care, n (%) 1389 (6.0) 1429 (6.1) 0.98 (0.89 to 1.08)
An Apgar score of < 4 at 5 minutes, n (%) 43 (0.2) 65 (0.3) 0.67 (0.40 to 1.11)
Cord artery pH, n (%)
< 7.15 1625 (11.3) 1695 (11.8) 0.96 (0.88 to 1.04)
< 7.05 268 (1.9) 278 (1.9) 0.95 (0.77 to 1.19)
Mean (SD) 7.24 (0.08) 7.24 (0.08)
Unknown 8829 8981
Metabolic acidosis, n (%)e
Yes 148 (1.1) 131 (1.0) 1.12 (0.82 to 1.52)
No 13,538 (98.9) 13,533 (99.0)
Unknown 9577 9687
continued
TABLE 21 Maternal characteristics at trial entry (continued )
Maternal characteristic
Trial arm
Decision support (N= 22,987)a No decision support (N= 23,055)a
Epidural analgesia, n (%)
Yes 2682 (26.0) 2766 (26.8)
No 7628 (74.0) 7549 (73.2)
Unknowna 12,677 12,740
Presence of meconium, n (%)
Yes 449 (4.5) 454 (4.5)
No 9454 (95.5) 9535 (95.5)
Unknownc 13,084 13,066
a Women with more than one birth episode in the study period are included more than once (n = 454).
b As coded by the NHS.
c Timing of epidural and presence of meconium in relation to trial entry only collected from 2013 for most centres.
d Negligible.
Note
Missing data are < 1% unless otherwise presented; there were no apparent differences in missing data between trial arms.
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to the interpretation of the measure of effect for the primary outcome (aRR 0.97, 95% CI 0.58 to 1.63;
Table 23).
There was no evidence of any difference in any of the trial’s secondary outcomes for the baby (see Table 22),
including Apgar score, all admissions to the neonatal unit, metabolic acidosis of cord blood sample, the
need for neonatal resuscitation and duration of hospital stay.
Just over half of all births were spontaneous vaginal births and there was no statistically significant difference
between the two groups [11,823 women (50.8%) in the decision support group vs. 11,959 women (51.2%)
in the no decision support group; aRR 0.99, 99% CI 0.97 to 1.01]. Of the operative births, half were by
caesarean section and half were instrumental (Table 24). More women in the decision support group
underwent fetal blood sampling: 2366 (10.3%) in the decision support group versus 2187 (9.5%) in the no
decision support group (aRR 1.08, 99% CI 1.01 to 1.16). No other statistically significant differences were
found between the two groups from trial entry to birth in clinical outcomes (see Table 24).
TABLE 22 Primary and neonatal outcomes (continued )
Outcome
Trial arm
Adjusteda RR (CI)
unless otherwise
indicated
Decision
support
(N= 23,263)
No decision
support
(N= 23,351)
Resuscitation, n (%)
None 18,457 (87.3) 18,605 (87.6)
One intervention 2139 (10.1) 2116 (10.0) 1.03f (0.96 to 1.09)
Two or more interventions 554 (2.6) 524 (2.5)
Unknown 2113 2106
Seizures while in hospital, n (%) 39 (0.2) 41 (0.2) 0.95 (0.54 to 1.70)
Destination of baby immediately after birth, n (%)
Postnatal ward 21,571 (93.6) 21,664 (93.6)
Home 467 (2.0) 485 (2.1) 1.00
g
(0.99 to 1.00)
Transitional care unit 277 (1.2) 235 (1.0)
Neonatal unit 653 (2.8) 690 (3.0)
Transferred hospital 4 (–) 7 (–)
Stillbirth 1 (–) 2 (–)
Other 69 (0.3) 53 (0.2)
Length of hospital stay to discharge (days)
Median (IQR) 2 (1–3) 2 (1–3) Hazard ratio: 0.99
(99% CI 0.97 to 1.01)
a Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes. Minimisation factors not adjusted for in the analysis of intrapartum stillbirths, neonatal deaths
and NNE because of the small number of events. Crude effect measures not presented as identical to one decimal place
(two decimal places for most outcomes).
b The components of the primary outcome are mutually exclusive and outcomes listed higher take precedence over those
listed lower down, for example if a baby with NNE died within 28 days, the outcome would be recorded as neonatal death.
c Excluding stillbirths as a result of congenital anomalies.
d Excluding deaths as a result of congenital anomalies. Deaths after hospital discharge not reported for the Republic
of Ireland.
e A cord artery pH of < 7.05 and a base deficit of ≥ 12mmol/l.
f RR of one or more interventions vs. none.
g RR of ward or home vs. all other destinations (if known).
Note
Missing data are < 1% unless otherwise presented; there were no apparent differences in missing data between trial arms.
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TABLE 23 Sensitivity analysis of composite primary outcome (panel review score of ≥ 7 vs. ≥ 3)
Outcome
Decision
support
(N= 23,263)
No decision
support
(N= 23,351)
Adjusteda relative
risk (95% CI)
Composite primary outcome 1–4, n (%)b 28 (0.1) 29 (0.1) 0.97 (0.58 to 1.63)
Unknown 1 2
(1) Intrapartum stillbirths, n (%)c 1 (–d) 2 (–d) 0.50 (0.05 to 5.53)
(2) Neonatal deaths up to 28 days after birth, n (%)e 6 (–d) 4 (–d) 1.51 (0.42 to 5.33)
(3) NNE (requiring cooling), n (%) 18 (0.1) 21 (0.1) 0.86 (0.46 to 1.61)
(4) Admission to neonatal unit within 48 hours of birth for
≥ 48 hours as a result of feeding difficulties, respiratory illness/
symptoms or NNE and evidence of compromise at birth with panel
review score of ≥ 7, n (%)
3 (–d) 2 (–d) 1.51 (0.25 to 9.01)
a Adjusted for twin birth and clustering because of twins and multiple-birth episodes. Minimisation factors not adjusted
for because of the small number of events.
b The components of the primary outcome are mutually exclusive and outcomes listed higher take precedence over those listed
lower down, for example if a baby with NNE died within 28 days, the outcome would be recorded as neonatal death.
c Excluding stillbirths as a result of congenital anomalies.
d Negligible.
e Excluding deaths as a result of congenital anomalies. Deaths after hospital discharge not reported for the Republic
of Ireland.
TABLE 24 Delivery outcomes
Outcome
Trial arm
Adjusted RR
(99% CI)a
Decision
support
No decision
support
Number of infants in denominator 23,263 23,351
Mode of delivery, n (%)
Spontaneous cephalic vaginal 11,823 (50.8) 11,959 (51.2) 0.99 (0.97 to 1.01)
Caesarean section 5669 (24.4) 5555 (23.8)
Instrumental 5698 (24.5) 5765 (24.7)
Vaginal breech 73 (0.3) 72 (0.3)
Indications for any operative intervention (caesarean section and instrumental delivery), n (%)
Fetal distress 4278 (18.4) 4262 (18.3) 1.04b (1.00 to 1.08)
Failure to progress 5059 (21.8) 5175 (22.2) 1.01b (0.97 to 1.05)
Fetal distress and failure to progress 1774 (7.6) 1599 (6.9)
Other reason 229 (1.0) 247 (1.1)
Indication for instrumental vaginal deliveries, n (%)
Fetal distress 2608 (11.2) 2559 (11.0) 1.03b (0.97 to 1.09)
Failure to progress 2262 (9.7) 2396 (10.3) 0.97b (0.91 to 1.03)
Fetal distress and failure to progress 700 (3.0) 660 (2.8)
Other reason 117 (0.5) 134 (0.6)
continued
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TABLE 24 Delivery outcomes (continued )
Outcome
Trial arm
Adjusted RR
(99% CI)a
Decision
support
No decision
support
Caesarean section, n (%)
Grade 1 (immediate threat to life) 1138 (4.9) 1121 (4.8) 1.02c (0.92 to 1.13)
Grade 2 (some threat of compromise) 3754 (16.2) 3605 (15.5) 1.04c (0.99 to 1.09)
Grade 3 (no threat of compromise) 645 (2.8) 689 (3.0) 1.02c (0.98 to 1.07)
Grade 4 (elective – timing to suit) 12 (0.1) 12 (0.1)
Number of women in denominator 22,987 23,055
Episiotomy, n (%) 6396 (28.9) 6498 (29.3) 0.99 (0.95 to 1.03)
Unknown 826 840
Any episode of fetal blood sampling, n (%) 2366 (10.3) 2187 (9.5) 1.08 (1.01 to 1.16)
Destination of mother immediately after birth, n (%)
Ward 21,554 (94.6) 21,614 (94.5)
Home 429 (1.9) 462 (2.0) 1.00d (0.99 to 1.00)
ICU 15 (0.1) 19 (0.1)
High-dependency unit 793 (3.5) 768 (3.4)
Theatre 0 (–) 0 (–)
Other hospital 0 (–) 8 (–)
Admission to a higher level of care, n (%) 1245 (5.4) 1193 (5.2) 1.05 (0.95 to 1.16)
Length of labour from trial entry (minutes)e
Geometric mean and GMR 379 381 0.99 (0.98 to 1.01)
Median (IQR) 404 (234–638) 408 (236–640)
Unknown 871 924
Length of first stage from trial entry (minutes)e
Geometric mean and GMR 169 168 1.01 (0.98 to 1.04)
Median (IQR) 200 (100–351) 201 (96–354)
Unknown 6422 6292
Length of second stage from trial entry (minutes)e
Geometric mean and GMR 39 39 0.99 (0.96 to 1.03)
Median (IQR) 49 (15–113) 50 (16–114)
Unknown 6036 5934
a Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes. Crude effect measures not presented as identical to one decimal place (two decimal places for
most outcomes).
b RR for fetal distress and RR for failure to progress include (in the numerator) deliveries in the third category in which
both fetal distress and failure to progress were recorded.
c RRs based on cumulative totals for grade, i.e. grade 1 vs. all other deliveries, grade 1–2 vs. all other deliveries, and
grade 1–3 vs. all other deliveries.
d RR of ward or home vs. all other destinations (if known).
e Denominators exclude women with no labour (1378 in the decision support arm and 371 in the no decision support arm)
date of randomisation after date of delivery (92 in the decision support arm and 120 in the no decision support arm) and
unknown length of labour.
Note
Missing data are < 1% unless otherwise presented; there were no apparent differences in missing data between trial arms.
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Quality of care was assessed by an expert panel for all neonatal deaths and intrapartum stillbirths as well
as for all babies with an adverse outcome (trial primary outcome plus a cord artery pH of < 7.05 with a base
deficit of ≥ 12 mmol/l) (Tables 25 and 26). The addition of cord artery metabolic acidosis as a criterion for
review substantially reduced the number of babies considered by the panel. The overall proportion of cases
with poor outcome in which babies were judged to have suboptimal care likely to have affected the
outcome was 38% (27/71), which is similar to that reported previously.72 This included all instances of
suboptimal care, regardless of whether this was related to CTG interpretation or subsequent management
decisions. We could not investigate whether or not in all cases appropriate action was taken in response
to recognised abnormality, although that aspect has been examined in cases with a composite adverse
outcome and biochemical evidence of asphyxia (the analysis of suboptimal care will be reported separately).
TABLE 25 Quality-of-care outcomes
Levels of carea
Trial arm
Adjustedb RR
(99% CI)
Decision
support
No decision
support
Babies with an adverse outcomec N = 35 N = 36
Babies with an adverse outcome for whom care has been judged not
to be suboptimal (level 0), n (%)
11 (31.4) 15 (41.7)
Babies with an adverse outcome for whom care has been judged to
be suboptimal (levels 1, 2 and 3), n (%)
24 (68.6) 21 (58.3) 1.18 (0.82 to 1.68)
Level 1 7 (20.0) 2 (5.6)
Level 2 3 (8.6) 6 (16.7)
Level 3 14 (40.0) 13 (36.1)
a Level 0, no suboptimal care; level 1, suboptimal care, but different management would have made no difference to
outcome; level 2, suboptimal care, and different management might have made a difference to outcome; level 3,
suboptimal care, and different management would reasonably be expected to have made a difference to the outcome.
b Adjusted for twin birth and clustering because of twins and multiple-birth episodes. Minimisation factors not adjusted
for because of the small number of events.
c Neonatal death, stillbirth or trial primary outcome with metabolic acidosis (a cord artery pH of < 7.05 with a base deficit
of ≥ 12mmol/l).
TABLE 26 Quality-of-care outcomes (all babies in denominator)
Levels of carea
Trial arm
Adjustedb relative
risk (99% CI)
Decision
support
No decision
support
All babies N = 23,263 N = 23,351
Babies with an adverse outcomec for whom care has been judged
not to be suboptimal (level 0), n (%)
11 (0.05) 15 (0.06)
Babies with an adverse outcome for whom care has been judged to
be suboptimal (levels 1, 2 and 3), n (%)
24 (0.10) 21 (0.09) 1.15 (0.64 to 2.06)
Level 1 7 (0.03) 2 (0.01)
Level 2 3 (0.01) 6 (0.03)
Level 3 14 (0.06) 13 (0.06)
a Level 0, no suboptimal care; level 1, suboptimal care, but different management would have made no difference to
outcome; level 2, suboptimal care, and different management might have made a difference to outcome; level 3,
suboptimal care, and different management would reasonably be expected to have made a difference to the outcome.
b Adjusted for twin birth and clustering because of twins and multiple-birth episodes. Minimisation factors not adjusted
for because of the small number of events.
c Neonatal death, stillbirth or trial primary outcome with metabolic acidosis (a cord artery pH of < 7.05 with a base deficit
of ≥ 12mmol/l).
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The process outcomes collected in the trial are shown in Table 27. For women in the no decision support
group, the presence of alerts was calculated by the software during labour but not revealed to the woman
or her caregivers. Using women with any level of concern as the denominator, blue levels of concern
(the least severe alert) occurred most frequently, with a median of nine such alerts during these labours
(a rate of just below 1.4 per hour). The next more severe alert – a yellow level of concern – occurred a
median of twice per labour for both women in the decision support group and those in the no decision
support group. There was evidence of a lower rate of yellow levels of concern in the decision support group
(adjusted rate ratio 0.87, 99% CI 0.84 to 0.89; Table 27). The most severe alert, the red level of concern,
occurred infrequently (a median of once per labour, with a rate of 0.14 per hour) and there was no
evidence of a difference between the two groups (aRR 0.98, 99% CI 0.92 to 1.04).
TABLE 27 Process outcomes after trial entry
Outcome
Trial arm
Adjustedb effect
measure (99% CI)
Decision
support
(N= 22,987)
No decision
supporta
(N= 23,055)
No labour, n 378 371
Date and time of randomisation after date and time of
delivery, n
92 120
Number of remaining participants 22,517 22,564
Epidural analgesia, n (%)
Yes 2770 (27.3) 2689 (26.5) RR 1.03 (0.97 to 1.09)
No 7383 (72.7) 7453 (73.5)
Unknownc 12,364 12,422
Labour augmentation, n (%)
Yes 2705 (30.9) 2750 (31.3) RR 0.99 (0.93 to 1.04)
No 6047 (69.1) 6042 (68.7)
Unknownc 13,765 13,772
Presence of meconium, n (%)
Yes 440 (4.5) 469 (4.8) RR 0.94 (0.80 to 1.11)
No 9316 (95.5) 9346 (95.2)
Unknownc 12,761 12,749
Number of women with at least one blue, yellow or red level
of concern, n (%)
21,950 (97.5) 22,021 (97.6) RR 1.00 (1.00 to 1.00)
Number of women with at least one blue level of concern
(mild abnormality), n (%)
21,863 (97.1) 21,913 (97.1) RR 1.00 (1.00 to 1.00)
Number of women with at least one yellow level of concern
(moderate abnormality), n (%)
16,765 (74.5) 16,722 (74.1) RR 1.00 (0.99 to 1.02)
Number of women with at least one red level of concern
(severe abnormality), n (%)
2335 (10.8) 2413 (11.1) RR 0.97 (0.90 to 1.04)
Unknownd 822 833
Number of blue, yellow or red levels of concern in women with at least one level of concern
Median (IQR) 9 (5–15) 9 (5–15) Rate ratio 0.98
(0.96 to 1.00)
Rate per hour 1.37 1.40
Unknowne 765 824
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Although there was a worry within the trial term that women in the decision support group would be
left alone in labour more frequently because the decision support software was running, there was no
evidence to suggest that caregivers interacted with the Guardian system less frequently in this group.
The rate of thumbprint entries on the Guardian system was 4.22 per hour in the decision support group
and 4.21 per hour in the no decision support group (aRR 0.99, 99% CI 0.95 to 1.03; see Table 27).
TABLE 27 Process outcomes after trial entry (continued )
Outcome
Trial arm
Adjustedb effect
measure (99% CI)
Decision
support
(N= 22,987)
No decision
supporta
(N= 23,055)
Number of blue levels of concern in women with a blue level
Median (IQR) 7 (4–11) 7 (4–11) Rate ratio 1.01
(0.99 to 1.03)
Rate per hour 1.06 1.05
Unknowne 740 800
Number of yellow levels of concern in women with a yellow level
Median (IQR) 2 (1–4) 2 (1–5) Rate ratio 0.87
(0.84 to 0.89)
Rate per hour 0.35 0.40
Unknowne 354 421
Number of red levels of concern in women with a red level
Median (IQR) 1 (1–1) 1 (1–1) Rate ratio 0.98
(0.92 to 1.04)
Rate per hour 0.14 0.14
Unknownd,e 41 55
Interaction with Guardian system via number of thumbprint entries from time of trial entry to first yellow level of concern,
or until cervix fully dilated if no abnormality detected
Median (IQR) 5 (0–16) 4 (0–15) Rate ratio 0.99
(0.95 to 1.03)
Rate per hour 4.22 4.21
Unknown 1723 1603
Number of vaginal examinations
Median (IQR) 2 (1–3) 2 (1–3) Rate ratio 1.03
(1.00 to 1.05)
Rate per hour 0.28 0.27
Unknown 877 929
Time from last red level of concern to delivery (minutes)
Median (IQR) 58 (13–279) 58 (13–264) HR 0.99 (0.92 to 1.06)
Unknownd 822 823
HR, hazard ratio; RR, risk ratio.
a For the control group with CTG monitoring only, decision support software was used retrospectively to determine when
an alert would have sounded.
b Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes. Crude effect measures not presented as identical to one decimal place (two decimal places for
most outcomes).
c Timing of epidural, labour augmentation and presence of meconium only recorded and uploaded for analysis from 2013
for most centres.
d Data on timing of red levels of concern not available for two centres: Warwick Hospital (n= 823) and Derby Hospital (n= 832).
e Women with missing length of labour data not included in calculation of rates and rate ratios.
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The time from the last red level of concern to birth was similar in both groups, with a median of 58 minutes.
Although this appears lengthy, there were red levels of concern that did not prompt immediate delivery, for
example when the CTG monitor was picking up the maternal heart rate. In a subgroup of 500 traces (with
a similar number of consecutive cases from each contributing centre) containing at least one red level of
concern, the last red level of concern was judged (by an expert coinvestigator, PS) to be a valid fetal concern
for 55%. For the remainder of these traces, the maternal heart rate triggered the red level of concern in
70%, and it was triggered for other reasons in 30%.
Follow-up at 2 years
Families were contacted when the surviving child(ren) born in the INFANT trial reached age 2 years. A total
of 7066 families returned a questionnaire. There were statistically significant differences in the characteristics
of the mothers who responded and those of the entire trial cohort, as well as between mothers who did
and did not respond to an invitation to complete the questionnaire (Tables 28 and 29). Many of these
differences are very small, but, given the large number of participants in the trial, are statistically significant.
In general, the questionnaire responders, when compared with the entire trial cohort, were more likely to be
TABLE 28 Maternal characteristics at trial entry by follow-up status: responders vs. non-responders or not followed
up at 2 years (mothers of surviving infants without the trial primary outcome only)
Characteristic
Follow-up status
p-valueb
Non-responders or
not followed up at
2 years (N= 38,669)a
Responders at
2 years (N= 6986)a
Maternal age (years)
Median (IQR) 29 (24–33) 30 (26–34) < 0.001
Ethnic group, n (%)c
White 28,714 (81.9) 5461 (90.9) < 0.001
Indian 1318 (3.8) 130 (2.2)
Pakistani 1356 (3.9) 166 (2.8)
Bangladeshi 190 (0.5) 19 (0.3)
Black Caribbean 231 (0.7) 19 (0.3)
Black African 917 (2.6) 37 (0.6)
Any other ethnic group 2354 (6.7) 176 (2.9)
Unknown 3589 978
Twin pregnancy, n (%) 486 (1.3) 80 (1.2) 0.44
Gestational age at entry (completed weeks)
Median (IQR) 40 (38–41) 40 (39–41) < 0.001
< 35+0, n (%) 9 (–) 1 (–)
35+0 to 37+6, n (%) 4314 (11.2) 682 (9.8)
38+0 to 39+6, n (%) 12,467 (32.3) 2035 (29.1)
40+0 to 41+6, n (%) 19,584 (50.7) 3702 (53.0)
≥ 42+0, n (%) 2282 (5.9) 566 (8.1)
BMI (kg/m2), at booking visit
Median (IQR) 25 (22–30) 25 (22–29) 0.64
< 18.5, n (%) 644 (2.6) 110 (2.2)
18.5–24.9, n (%) 10,321 (41.8) 2125 (42.3)
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TABLE 28 Maternal characteristics at trial entry by follow-up status: responders vs. non-responders or not followed
up at 2 years (mothers of surviving infants without the trial primary outcome only) (continued )
Characteristic
Follow-up status
p-valueb
Non-responders or
not followed up at
2 years (N= 38,669)a
Responders at
2 years (N= 6986)a
25–29.9, n (%) 7467 (30.2) 1563 (31.1)
30–34.9, n (%) 3638 (14.7) 735 (14.6)
35–39.9, n (%) 1703 (6.9) 319 (6.4)
≥ 40, n (%) 936 (3.8) 169 (3.4)
Unknown 13,960 1965
Smoking (at booking visit), n (%)
Yes 4198 (15.0) 747 (11.9) < 0.001
No 23,681 (85.0) 5518 (88.1)
Unknown 10,795 721
Parity, n (%)
Nulliparous 22,792 (59.0) 4317 (61.8) < 0.001
Parous 15,858 (41.0) 2669 (38.2)
Obstetric history, n (%)
Previous stillbirth 425 (1.1) 70 (1.0) 0.47
Previous elective caesarean section 359 (0.9) 100 (1.4) < 0.001
Previous emergency caesarean section 2028 (5.2) 413 (5.9) 0.02
Previous neonatal death 153 (0.4) 19 (0.3) 0.12
Cervical dilatation at time of trial entry (cm)
Median (IQR) 4 (2–6) 4 (2–5) 0.09
Unknown 27,528 4750
Fetal growth restriction suspected at labour onset, n (%) 1506 (3.9) 247 (3.5) 0.08
Labour induction, n (%):
Induced 22,848 (59.5) 4022 (57.9) 0.01
Spontaneous 14,932 (38.9) 2829 (40.7)
No labour 632 (1.7) 101 (1.5)
Epidural analgesia, n (%)
Yes 4966 (28.0) 425 (15.9) < 0.001
No 12,798 (72.0) 2257 (84.2)
Unknownd 20,905 4304
Presence of meconium, n (%)
Yes 771 (4.5) 113 (4.1) 0.30
No 16,202 (95.5) 2642 (95.9)
Unknownd 21,696 4231
a Women with more than one birth episode in the study period are included more than once.
b p-value from chi-squared test for categorical variables and Wilcoxon rank-sum test for continuous variables.
c As coded by the NHS.
d Timing of epidural and presence of meconium in relation to trial entry only collected from 2013 for most centres.
Note
Missing data are < 1% unless otherwise presented; there were no apparent differences in missing data between trial arms.
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TABLE 29 Maternal characteristics at trial entry by follow-up status: responders vs. non-responders at 2 years
(mothers of surviving infants without the trial primary outcome only)
Characteristic
Follow-up status
p-valueb
Non-responders at
2 years (N= 5560)a
Responders at
2 years (N= 6986)a
Maternal age (years)
Median (IQR) 27 (23–31) 30 (26–34) < 0.001
Ethnic group, n (%)c
White 4094 (86.8) 5461 (90.9) < 0.001
Indian 140 (3.0) 130 (2.2)
Pakistani 230 (4.9) 166 (2.8)
Bangladeshi 18 (0.4) 19 (0.3)
Black Caribbean 15 (0.3) 19 (0.3)
Black African 54 (1.1) 37 (0.6)
Any other ethnic group 167 (3.5) 176 (2.9)
Unknown 842 978
Twin pregnancy, n (%) 78 (1.4) 80 (1.2) 0.20
Gestational age at entry (completed weeks)
Median (IQR) 40 (38–41) 40 (39–41) < 0.001
< 35+0, n (%) 2 (–) 1 (–)
35+0 to 37+6, n (%) 665 (12.0) 682 (9.8)
38+0 to 39+6, n (%) 1728 (31.1) 2035 (29.1)
40+0 to 41+6, n (%) 2787 (50.1) 3702 (53.0)
≥ 42 0, n (%) 377 (6.8) 566 (8.1)
BMI (kg/m2), at booking visit
Median (IQR) 26 (22–30) 25 (22–29) 0.01
< 18.5 130 (3.3) 110 (2.2)
18.5–24.9 1559 (39.1) 2125 (42.3)
25–29.9 1187 (29.8) 1563 (31.1)
30–34.9 607 (15.2) 735 (14.6)
35–39.9 313 (7.9) 319 (6.4)
≥ 40 192 (4.8) 169 (3.4)
Unknown 1572 1965
Smoking (at booking visit), n (%)
Yes 994 (20.7) 747 (11.9) < 0.001
No 3807 (79.3) 5518 (88.1)
Unknown 759 721
Parity, n (%)
Nulliparous 3043 (54.7) 4317 (61.8) < 0.001
Parous 2517 (45.3) 2669 (38.2)
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slightly older, to be of white ethnic origin, to have given birth at a later gestational age and to have been
having their first baby and were less likely to smoke.
Data could be analysed for 6707 of the 7066 infants for whom a questionnaire was returned (95%).
There was no evidence of a difference between the two groups in any of the 2-year outcomes, including
the long-term primary outcome of the PARCA-R, with a mean composite score of 98.0 points (SD 33.8
points) in the decision support group and 97.2 points (SD 33.4 points) in the no decision support group
(mean difference 0.63 95% CI –0.98 to 2.25) (Table 30).
Nearly 6% of children were classified as having major disability. The classification of disability used resulted in
relatively large numbers of children being assigned a major disability as a consequence of poor growth
(between 2.8% and 3% of all children) and cognitive difficulties (between 1.2 and 1.5% of all children).60,61
Other major disabilities, such as physical disability, blindness and deafness, were all very uncommon (Table 31).
TABLE 29 Maternal characteristics at trial entry by follow-up status: responders vs. non-responders at 2 years
(mothers of surviving infants without the trial primary outcome only) (continued )
Characteristic
Follow-up status
p-valueb
Non-responders at
2 years (N= 5560)a
Responders at
2 years (N= 6986)a
Obstetric history, n (%)
Previous stillbirth 77 (1.4) 70 (1.0) 0.05
Previous elective caesarean section 61 (1.1) 100 (1.4) 0.10
Previous emergency caesarean section 345 (6.2) 413 (5.9) 0.49
Previous neonatal death 22 (0.4) 19 (0.3) 0.23
Cervical dilatation at time of trial entry (cm)
Median (IQR) 4 (2–5) 4 (2–5) 0.53
Unknown 3730 4750
Fetal growth restriction suspected at labour onset, n (%) 266 (4.8) 247 (3.5) < 0.001
Labour induction, n (%)
Induced 3108 (56.2) 4022 (57.9) 0.18
Spontaneous 2336 (42.2) 2829 (40.7)
No labour 86 (1.6) 101 (1.5)
Epidural analgesia, n (%)
Yes 266 (13.8) 425 (15.9) 0.05
No 1665 (86.2) 2257 (84.2)
Unknownd 3629 4304
Presence of meconium, n (%)
Yes 66 (3.1) 113 (4.1) 0.06
No 2085 (96.9) 2642 (95.9)
Unknownd 3409 4231
a Women with more than one birth episode in the study period are included more than once.
b From the chi-squared ftest for categorical variables and the Wilcoxon rank-sum test for continuous variables.
c As coded by the NHS.
d Timing of epidural and presence of meconium in relation to trial entry only collected from 2013 for most centres.
Note
Missing data are < 1% unless otherwise presented; there were no apparent differences in missing data between trial arms.
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TABLE 30 Health and development outcomes at 2 years (in a sample of surviving infants without the primary
outcome who were selected for follow-up)
Outcome
Trial arm
Adjusteda RR (99% CI)
unless otherwise
indicatedb
Decision
support
No decision
support
Infant deaths at 2 years, n/N (%)c 29/21,508 (0.13) 35/21,597 (0.16) 0.83 (0.44 to 1.59)
Number of surviving infants without the
primary outcome 3556 3510
PARCA-R composite scoreb
Mean score (points) (SD) 98.0 (33.8) 97.2 (33.4)
Median score (points) (IQR) 98 (73–126) 97 (72–125) Mean difference (95% CI):
0.63 (–0.98 to 2.25)
Unknown 175 184
Components of the PARCA-R
Non-verbal cognition scale
l Mean score (points) (SD) 27.7 (3.7) 28.0 (3.6)
l Median score (points) (IQR) 28 (26–30) 28 (26–31) Mean difference (99% CI):
–0.22 (–0.44 to 0.01)
Vocabulary subscale
l Mean score (points) (SD) 57.4 (27.8) 56.5 (27.7)
l Median score (points) (IQR) 58 (36–81) 56 (35–80) Mean difference (99% CI):
0.82 (–0.91 to 2.54)
Sentence complexity subscale
l Mean score (points) (SD) 12.4 (5.4) 12.3 (5.3)
l Median score (points) (IQR) 12 (9–6) 12 (9–16) Mean difference (99% CI):
0.07 (–0.26 to 0.41)
Cerebral palsy, n (%) 4 (0.12) 4 (0.12) 0.99 (0.16 to 6.1)
Unknown 111 114
Non-major or major disability, n (%)d 942 (40.4) 840 (37.4) 1.08 (0.98 to 1.18)
Unknown 1225 1266
Major disability, n (%)d 134 (5.8) 135 (6.0) 0.95 (0.70 to 1.29)
Unknown 1225 1266
a Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes. Stratification factors not adjusted for in the analysis of infant deaths at 2 years and cerebral palsy
because of the small number of events. Crude effect measures are not presented as identical to one decimal place
(two decimal places for most outcomes).
b 95% CIs presented for the PARCA-R composite score (joint primary outcome).
c All deaths reported up to age 2 years excluding stillbirths (n= 3; 1 in the decision support group and 2 in the no
decision support group). Data from the Republic of Ireland not included in the numerator (n= 1, decision support) or
denominator (n= 1754 in the decision support grup and n= 1752 in no decision support group) as data on deaths after
discharge were not available.
d Disability in any of the following domains: neuromotor function, seizures, auditory function, communication, visual
function, cognitive function and other physical disability.
Note
Missing data are < 3% unless otherwise presented; there were no apparent differences in missing data between trial arms.
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TABLE 31 Components of non-major and major disability at 2 years
Disability component
Trial arm
Decision support (N= 3556) No decision support (N= 3510)
Cognition, n (%)
None 3159 (93.4) 3134 (94.2)
Non-major 180 (5.3) 143 (4.3)
Major 42 (1.2) 49 (1.5)
Unknown 175 184
Communication, n (%)
None 3132 (88.6) 3096 (88.7)
Non-major 394 (11.2) 392 (11.2)
Major 8 (0.2) 4 (0.1)
Unknown 22 18
Physical ability, n (%)
None 3161 (92.3) 3166 (93.7)
Non-major 245 (7.2) 199 (5.9)
Major 19 (0.6) 15 (0.4)
Unknown 131 130
Vision, n (%)
None 3409 (99.6) 3373 (99.7)
Non-major 14 (0.4) 8 (0.2)
Major 1 (–) 1 (–)
Unknown 132 128
Hearing, n (%)
None 3307 (99.0) 3293 (99.2)
Non-major 30 (0.9) 25 (0.8)
Major 5 (0.2) 2 (0.1)
Unknown 214 190
Growth, n (%)
None 1899 (90.5) 1882 (92.2)
Non-major 137 (6.5) 102 (5.0)
Major 63 (3.0) 58 (2.8)
Unknown 1457 1468
Seizures, n (%)
None 3302 (99.0) 3259 (98.9)
Non-major 31 (0.9) 30 (0.9)
Major 4 (0.1) 5 (0.2)
Unknown 219 216
continued
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A number of subgroup analyses were prespecified (Figures 15–40 and Tables 32–35). There was no
evidence that the decision support software produced different outcomes in any of the subgroups
(e.g. multiple pregnancy, suspected fetal growth restriction, BMI of the mother) for either the primary
outcome or a limited range of prespecified secondary outcomes. There were also no differences in the
distribution of cord blood pH measurements (Figure 41). The number of alerts in the analysis differed by
centre (Figures 33, 35–39). The reasons for this are unclear, particularly as there were no statistically
significant differences in the other outcomes by centre.
Predefined subgroup analyses of short-term outcomes
Note: results are presented on forest plots showing the RR plus 95% CI for each subgroup, by treatment
group, with the p-value for the statistical test of interaction. Subgroup analyses are not adjusted for the
stratification factors used at randomisation because of the small number of events in some subgroup
categories.
TABLE 31 Components of non-major and major disability at 2 years (continued )
Disability component
Trial arm
Decision support (N= 3556) No decision support (N= 3510)
Feeding, n (%)
None 3385 (99.9) 3326 (99.9)
Non-major 0 (0.0) 0 (0.0)
Major 3 (0.1) 5 (0.2)
Unknown 168 179
Respiratory, n (%)
None 3284 (97.0) 3266 (97.4)
Non-major 100 (3.0) 86 (2.6)
Major 0 (0.0) 0 (0.0)
Unknown 172 158
Other disability, n (%)
None 3550 (99.9) 3501 (99.8)
Non-major 0 (0.0) 0 (0.0)
Major 3 (0.1) 6 (0.2)
Unknown 3 3
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0.25 0.50 1.00 2.00 4.00
Outcome
Risk ratio
(99% CI) unless
otherwise
specified p-valueNumber of events/total number (%)
No decision supportDecision support
Favours decision
support
Favours no
decision support
Composite primary outcome (95% CI)
Singleton (0.7)(0.7)
Twin
0.51
(1.5)(1.1)
Instrumental delivery or caesarean section
Singleton (48.3)(48.9)
Twin
0.17
(53.9)(49.1)
Caesarean section
Singleton (23.6)(24.3)
Twin
0.51
(29.2)(27.5)
Admission to a higher level of care
Singleton (5.8)(5.8)
Twin
0.31
(17.1)(14.2)
An Apgar score of < 4 at 5 minutes
Singleton (0.3)(0.2)
Twin
0.22
(1.0)(0.2)
A cord artery pH of < 7.15
Singleton (11.7)(11.3)
Twin
0.02
(15.6)(8.9)
Metabolic acidosis
Singleton (0.9)(1.1)
Twin
0.15
(2.4)(1.2)
Resuscitation
Singleton (12.2)(12.6)
Twin
0.15
(21.4)(18.2)
Seizures while in hospital
Singleton (0.2)(0.2)
Twin (0.3)(0.0)
Baby destination not ward or home
Singleton (4.0)(4.1)
Twin
0.77
162/
9/
11,001/
319/
5382/
173/
1326/
101/
59/
6/
1634/
61/
122/
9/
2526/
114/
39/
2/
905/
82/ (14.0)(13.6)
Median length of hospital stay to discharge (days)a
Singleton
Twin
0.22
166/
6/
11,096/
271/
5517/
152/
1310/
78/
42/
1/
1593/
32/
144/
4/
2604/
89/
39/
0/
930/
74/
22,710
552
22,711
552
22,711
552
22,697
550
22,705
550
14,075
359
13,347
339
20,660
490
22,632
547
22,499
543
22,758
591
22,759
592
22,759
592
22,747
591
22,749
592
13,980
390
13,289
375
20,712
533
22,672
586
22,551
585
1.03 (0.83 to 1.27)
0.71 (0.26 to 1.99)
1.01 (0.99 to 1.04)
0.91 (0.75 to 1.10)
1.03 (0.98 to 1.07)
0.94 (0.67 to 1.32)
0.99 (0.90 to 1.09)
0.83 (0.54 to 1.29)
0.71 (0.42 to 1.20)
0.18 (0.01 to 3.08)
0.97 (0.89 to 1.05)
0.57 (0.32 to 1.00)
1.18 (0.86 to 1.61)
0.49 (0.11 to 2.27)
1.03 (0.97 to 1.11)
0.85 (0.60 to 1.20)
1.00 (0.56 to 1.79)
Not estimable
1.03 (0.92 to 1.16)
0.97 (0.59 to 1.60)
0.99 (0.97 to 1.01)
1.06 (0.89 to 1.26)
Trial arm
FIGURE 15 Maternal and neonatal outcomes, by twin pregnancy. a, Hazard ratios reported.
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Composite primary outcome (95% CI)
No FGR 1.01 (0.82 to 1.26)164/22,407 (0.7)166/22,384 (0.7)
FGR 0.92 (0.31 to 2.73)
0.87
7/942 (0.7)6/878 (0.7)
Instrumental delivery or caesarean section
No FGR 1.00 (0.98 to 1.03)11,051/22,409 (49.3)11,085/22,385 (49.5)
FGR 1.12 (0.93 to 1.36)
0.12
269/942 (28.6)282/878 (32.1)
Caesarean section
No FGR 1.02 (0.98 to 1.06)5432/22,409 (24.2)5530/22,385 (24.7)
FGR 1.21 (0.89 to 1.65)
0.15
123/942 (13.1)139/878 (15.8)
Admission to a higher level of care
No FGR 0.98 (0.89 to 1.09)1330/22,401 (5.9)1307/22,370 (5.8)
FGR 0.89 (0.61 to 1.31)
0.52
97/937 (10.4)81/877 (9.2)
An Apgar score of < 4 at 5 minutes
No FGR 0.68 (0.40 to 1.14)62/22,399 (0.3)42/22,377 (0.2)
FGR 0.36 (0.02 to 6.99)
0.58
3/942 (0.3)1/878 (0.1)
A cord artery pH of < 7.15
No FGR 0.96 (0.88 to 1.04)1651/13,882 (11.9)1586/13,938 (11.4)
FGR 0.87 (0.51 to 1.50)
0.66
44/488 (9.0)39/496 (7.9)
Metabolic acidosis
No FGR 1.11 (0.82 to 1.52)129/13,188 (1.0)144/13,205 (1.1)
FGR 1.98 (0.21 to 18.33)
0.51
2/476 (0.4)4/481 (0.8)
Resuscitation
No FGR 1.02 (0.96 to 1.10)2546/20,336 (12.5)2603/20,299 (12.8)
FGR 1.02 (0.71 to 1.48)
0.99
94/909 (10.3)90/851 (10.6)
Seizures while in hospital
No FGR 0.92 (0.51 to 1.67)39/22,320 (0.2)36/22,306 (0.2)
FGR 1.61 (0.15 to 16.88)
0.55
2/938 (0.2)3/873 (0.3)
Baby destination not ward or home
No FGR 1.03 (0.92 to 1.16)918/22,196 (4.1)946/22,164 (4.3)
FGR 0.90 (0.57 to 1.42)
0.46
69/940 (7.3)58/878 (6.6)
Median length of hospital stay to discharge (days)a
No FGR 0.99 (0.97 to 1.01)
FGR 0.98 (0.88 to 1.09)
0.79
0.25 0.50 1.00 2.00 4.00
Outcome
Risk ratio
(99% CI) unless
otherwise
specified p-valueNumber of events/total number (%)
No decision supportDecision support
Favours decision
support
Favours no
decision support
Trial arm
FIGURE 16 Maternal and neonatal outcomes, by suspected fetal growth restriction. a, Hazard ratios reported.
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0.25 0.50 1.00 2.00 4.00
Favours decision
support
Favours no
decision support
Composite primary outcome (95% CI)
12 to 18.4 1.36 (0.31 to 6.04)3/389 (0.8)4/381 (1.0)
18.5 to 24.9 0.93 (0.59 to 1.49)36/6319 (0.6)34/6389 (0.5)
25 to 29.9 0.77 (0.44 to 1.33)29/4622 (0.6)22/4581 (0.5)
30 to 70 1.15 (0.70 to 1.87)30/3844 (0.8)34/3803 (0.9)
Unrecorded 1.08 (0.78 to 1.48)
0.81
73/8175 (0.9)78/8108 (1.0)
Instrumental delivery or caesarean section
12 to 18.4 0.96 (0.77 to 1.21)164/389 (42.2)155/381 (40.7)
18.5 to 24.9 1.02 (0.97 to 1.07)3171/6320 (50.2)3268/6389 (51.2)
25 to 29.9 0.98 (0.93 to 1.04)2355/4623 (50.9)2293/4581 (50.1)
30 to 70 0.97 (0.91 to 1.04)1816/3844 (47.2)1750/3804 (46.0)
Unrecorded 1.03 (0.99 to 1.08)
0.20
3814/8175 (46.7)3901/8108 (48.1)
Caesarean section
12 to 18.4 0.96 (0.60 to 1.55)53/389 (13.6)50/381 (13.1)
18.5 to 24.9 1.06 (0.97 to 1.16)1347/6320 (21.3)1443/6389 (22.6)
25 to 29.9 1.03 (0.94 to 1.13)1217/4623 (26.3)1242/4581 (27.1)
30 to 70 0.99 (0.90 to 1.09)1122/3844 (29.2)1101/3804 (28.9)
Unrecorded 1.02 (0.94 to 1.10)
0.74
1816/8175 (22.2)1833/8108 (22.6)
Admission to a higher level of care
12 to 18.4 0.86 (0.41 to 1.80)26/389 (6.7)22/381 (5.8)
18.5 to 24.9 1.01 (0.83 to 1.23)338/6317 (5.4)345/6385 (5.4)
25 to 29.9 0.89 (0.71 to 1.11)284/4619 (6.1)251/4579 (5.5)
30 to 70 0.90 (0.71 to 1.14)249/3839 (6.5)222/3798 (5.8)
Unrecorded 1.04 (0.89 to 1.22)
0.48
530/8174 (6.5)548/8104 (6.8)
An Apgar score of < 4 at 5 minutes
12 to 18.4 4.08 (0.23 to 72.45)1/389 (0.3)4/381 (1.0)
18.5 to 24.9 0.64 (0.25 to 1.64)20/6319 (0.3)13/6387 (0.2)
25 to 29.9 0.61 (0.16 to 2.29)10/4623 (0.2)6/4581 (0.1)
30 to 70 0.50 (0.14 to 1.83)12/3841 (0.3)6/3804 (0.2)
Unrecorded 0.64 (0.27 to 1.55)
0.56
22/8169 (0.3)14/8102 (0.2)
A cord artery pH of < 7.15
12 to 18.4 0.69 (0.34 to 1.39)33/236 (14.0)19/197 (9.6)
18.5 to 24.9 0.91 (0.77 to 1.08)426/3697 (11.5)401/3823 (10.5)
25 to 29.9 0.95 (0.79 to 1.16)324/2810 (11.5)300/2730 (11.0)
30 to 70 0.90 (0.73 to 1.12)266/2324 (11.4)243/2358 (10.3)
Unrecorded 1.02 (0.89 to 1.17)
0.39
646/5303 (12.2)662/5326 (12.4)
Metabolic acidosis
12 to 18.4 Not estimable1/231 (0.4)0/189 (0.0)
18.5 to 24.9 1.29 (0.64 to 2.57)24/3548 (0.7)32/3676 (0.9)
25 to 29.9 0.92 (0.50 to 1.72)36/2692 (1.3)32/2593 (1.2)
30 to 70 1.17 (0.55 to 2.50)21/2207 (1.0)25/2245 (1.1)
Unrecorded 1.20 (0.73 to 1.98)
0.79
49/4986 (1.0)59/4983 (1.2)
Resuscitation
12 to 18.4 1.47 (0.89 to 2.46)38/383 (9.9)54/369 (14.6)
18.5 to 24.9 1.03 (0.90 to 1.17)695/6149 (11.3)721/6200 (11.6)
25 to 29.9 1.03 (0.89 to 1.19)552/4443 (12.4)562/4410 (12.7)
30 to 70 0.95 (0.82 to 1.10)532/3660 (14.5)501/3623 (13.8)
Unrecorded 1.05 (0.93 to 1.18)
0.26
823/6610 (12.5)855/6548 (13.1)
Seizures while in hospital
12 to 18.4 Not estimable1/386 (0.3)0/378 (0.0)
18.5 to 24.9 0.81 (0.25 to 2.58)11/6305 (0.2)9/6369 (0.1)
25 to 29.9 1.29 (0.35 to 4.74)7/4598 (0.2)9/4566 (0.2)
30 to 70 1.61 (0.37 to 7.00)5/3830 (0.1)8/3795 (0.2)
Unrecorded 0.77 (0.30 to 1.99)
0.64
17/8139 (0.2)13/8071 (0.2)
Baby destination not ward or home
12 to 18.4 1.18 (0.45 to 3.08)13/386 (3.4)15/378 (4.0)
18.5 to 24.9 1.02 (0.79 to 1.33)195/6289 (3.1)201/6343 (3.2)
25 to 29.9 0.87 (0.64 to 1.19)148/4585 (3.2)128/4542 (2.8)
30 to 70 0.93 (0.68 to 1.27)140/3801 (3.7)129/3775 (3.4)
Unrecorded 1.09 (0.93 to 1.28)
0.47
491/8075 (6.1)531/8004 (6.6)
Median length of hospital stay to discharge (days)a
12 to 18.4 1.06 (0.91 to 1.24)
18.5 to 24.9 0.98 (0.95 to 1.02)
25 to 29.9 0.99 (0.95 to 1.04)
30 to 70 1.03 (0.98 to 1.08)
Unrecorded 0.98 (0.95 to 1.02)
0.28
Outcome
Risk ratio
(99% CI) unless
otherwise
specified p-valueNumber of events/total number (%)
No decision supportDecision support
Trial arm
FIGURE 17 Maternal and neonatal outcomes, by BMI at booking visit. a, Hazard ratios reported.
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Composite primary outcome
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
1.87 (0.80 to 4.41)8/1149 (0.7)15/1148 (1.3)
0.85 (0.45 to 1.62)20/2097 (1.0)17/2091 (0.8)
1.02 (0.21 to 5.01)3/450 (0.7)3/443 (0.7)
1.01 (0.20 to 4.98)3/612 (0.5)3/606 (0.5)
2.03 (0.18 to 22.28)1/433 (0.2)2/427 (0.5)
0.96 (0.58 to 1.59)30/1650 (1.8)29/1665 (1.7)
0.99 (0.42 to 2.38)10/951 (1.1)10/957 (1.0)
1.40 (0.64 to 3.03)11/1586 (0.7)15/1549 (1.0)
1.61 (0.53 to 4.92)5/1695 (0.3)8/1682 (0.5)
0.67 (0.28 to 1.64)12/944 (1.3)8/935 (0.9)
1/920 (0.1)4/918 (0.4)
0.33 (0.09 to 1.22)9/586 (1.5)3/590 (0.5)
2.49 (0.78 to 7.93)4/2046 (0.2)10/2054 (0.5)
1.30 (0.57 to 2.96)10/1395 (0.7)13/1393 (0.9)
0.37 (0.10 to 1.41)8/1751 (0.5)3/1754 (0.2)
4.09 (0.87 to 19.19)2/514 (0.4)8/502 (1.6)
1.41 (0.45 to 4.44)5/963 (0.5)7/953 (0.7)
1.00 (0.29 to 3.46)5/1230 (0.4)5/1224 (0.4)
0.98 (0.25 to 3.88)4/194 (2.1)4/197 (2.0)
0.13 (0.03 to 0.54)16/1750 (0.9)2/1746 (0.1)
0.76 (0.17 to 3.37)4/433 (0.9)3/428 (0.7)
1.01 (0.82 to 1.25)
4.01 (0.45 to 35.80) 0.19
171/23,349 (0.7)172/23,262 (0.7)
Risk ratio
(99% CI) p-valueNumber of events/total number (%)
No decision supportDecision support
0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Trial arm
FIGURE 18 Composite primary outcome by centre.
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Risk ratio
(99% CI) p-valueNumber of events/total number (%)
No decision supportDecision support
Instrumental delivery or caesarean section
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
1.03 (0.94 to 1.14)610/1149 (53.1)630/1148 (54.9)
0.96 (0.89 to 1.04)1064/2097 (50.7)1018/2091 (48.7)
0.96 (0.84 to 1.09)292/450 (64.9)276/443 (62.3)
0.96 (0.83 to 1.10)328/612 (53.6)311/606 (51.3)
0.99 (0.82 to 1.19)206/433 (47.6)201/427 (47.1)
1.05 (0.94 to 1.17)664/1650 (40.2)703/1665 (42.2)
1.03 (0.93 to 1.15)522/951 (54.9)542/957 (56.6)
1.01 (0.91 to 1.12)703/1586 (44.3)696/1549 (44.9)
0.97 (0.87 to 1.08)688/1695 (40.6)660/1682 (39.2)
1.03 (0.93 to 1.13)569/944 (60.3)578/935 (61.8)
437/920 (47.5)419/918 (45.6)
0.98 (0.88 to 1.10)383/586 (65.4)378/590 (64.1)
1.01 (0.93 to 1.10)1001/2047 (48.9)1015/2054 (49.4)
1.05 (0.95 to 1.16)684/1395 (49.0)715/1393 (51.3)
1.04 (0.96 to 1.14)864/1752 (49.3)902/1754 (51.4)
1.06 (0.90 to 1.25)249/514 (48.4)258/502 (51.4)
1.09 (0.97 to 1.22)461/963 (47.9)496/953 (52.0)
0.97 (0.89 to 1.07)699/1230 (56.8)677/1224 (55.3)
1.10 (0.88 to 1.38)106/194 (54.6)119/198 (60.1)
1.00 (0.87 to 1.13)556/1750 (31.8)552/1746 (31.6)
0.96 (0.81 to 1.13)234/433 (54.0)221/428 (51.6)
1.01 (0.98 to 1.03)
0.96 (0.84 to 1.09) 0.69
11,320/23,351 (48.5)11,367/23,263 (48.9)
0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Trial arm
FIGURE 19 Instrumental delivery or caesarean section, by centre.
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Caesarean section
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
1.00 (0.82 to 1.22)268/1149 (23.3)269/1148 (23.4)
1.02 (0.89 to 1.16)551/2097 (26.3)558/2091 (26.7)
0.96 (0.73 to 1.26)132/450 (29.3)125/443 (28.2)
0.83 (0.66 to 1.05)200/612 (32.7)165/606 (27.2)
0.85 (0.61 to 1.17)110/433 (25.4)92/427 (21.5)
0.96 (0.79 to 1.16)311/1650 (18.8)301/1665 (18.1)
1.00 (0.84 to 1.20)290/951 (30.5)292/957 (30.5)
1.10 (0.91 to 1.33)302/1586 (19.0)324/1549 (20.9)
0.97 (0.82 to 1.16)367/1695 (21.7)355/1682 (21.1)
1.07 (0.91 to 1.26)319/944 (33.8)339/935 (36.3)
181/920 (19.7)185/918 (20.2)
0.91 (0.73 to 1.12)208/586 (35.5)190/590 (32.2)
1.06 (0.93 to 1.22)532/2047 (26.0)568/2054 (27.7)
1.10 (0.95 to 1.28)411/1395 (29.5)453/1393 (32.5)
1.15 (0.95 to 1.40)286/1752 (16.3)330/1754 (18.8)
1.01 (0.75 to 1.35)119/514 (23.2)117/502 (23.3)
1.17 (0.94 to 1.46)201/963 (20.9)233/953 (24.4)
1.01 (0.84 to 1.22)292/1230 (23.7)293/1224 (23.9)
1.36 (0.86 to 2.16)41/194 (21.1)57/198 (28.8)
0.99 (0.82 to 1.20)313/1750 (17.9)309/1746 (17.7)
0.95 (0.71 to 1.27)121/433 (27.9)114/428 (26.6)
1.02 (0.98 to 1.07)
1.02 (0.80 to 1.31) 0.26
5555/23,351 (23.8)5669/23,263 (24.4)
Risk ratio
(99% CI) p-valueNumber of events/total number (%)
No decision supportDecision support
0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Trial arm
FIGURE 20 Caesarean section by centre.
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0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Admission of infant to a higher level of care
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
1.23 (0.92 to 1.65)128/1148 (11.1)158/1148 (13.8)
0.97 (0.69 to 1.36)118/2095 (5.6)114/2086 (5.5)
0.94 (0.46 to 1.93)26/450 (5.8)24/443 (5.4)
1.00 (0.34 to 2.97)12/605 (2.0)12/602 (2.0)
0.94 (0.34 to 2.59)13/433 (3.0)12/427 (2.8)
0.87 (0.61 to 1.26)101/1650 (6.1)89/1663 (5.4)
1.15 (0.75 to 1.77)63/951 (6.6)73/956 (7.6)
0.96 (0.68 to 1.35)115/1585 (7.3)108/1548 (7.0)
0.91 (0.59 to 1.41)74/1695 (4.4)67/1682 (4.0)
0.83 (0.56 to 1.24)86/943 (9.1)71/935 (7.6)
72/920 (7.8)73/918 (8.0)
0.63 (0.36 to 1.10)51/586 (8.7)32/588 (5.4)
0.84 (0.60 to 1.18)124/2047 (6.1)105/2054 (5.1)
1.29 (0.81 to 2.06)52/1395 (3.7)67/1393 (4.8)
1.07 (0.70 to 1.64)71/1752 (4.1)76/1753 (4.3)
1.40 (0.82 to 2.40)38/514 (7.4)52/502 (10.4)
0.93 (0.54 to 1.60)48/963 (5.0)44/953 (4.6)
1.00 (0.54 to 1.87)35/1229 (2.8)35/1224 (2.9)
1.04 (0.58 to 1.86)33/194 (17.0)35/198 (17.7)
0.83 (0.60 to 1.15)133/1750 (7.6)110/1746 (6.3)
0.92 (0.49 to 1.72)34/433 (7.9)31/428 (7.2)
0.98 (0.89 to 1.07)
1.02 (0.67 to 1.54) 0.45
1427/23,338 (6.1)1388/23,247 (6.0)
Risk ratio
(99% CI) p-valueNumber of events/total number (%)
No decision supportDecision support
Trial arm
FIGURE 21 Admission of infant to a higher level of care, by centre.
D
O
I:10.3310/hta22090
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.9
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
Brocklehurst
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
77
Apgar score of < 4 at 5 minutes
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s, Hospital Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
2.00 (0.09 to 46.84)1/1147 (0.1)2/1147 (0.2)
0.33 (0.04 to 2.74)6/2097 (0.3)2/2091 (0.1)
Not estimable1/450 (0.2)0/443 (0.0)
1.01 (0.03 to 38.59)1/609 (0.2)1/602 (0.2)
Not estimable1/433 (0.2)0/427 (0.0)
0.30 (0.05 to 1.62)10/1650 (0.6)3/1665 (0.2)
Not estimable1/950 (0.1)0/957 (0.0)
1.79 (0.36 to 8.98)4/1586 (0.3)7/1549 (0.5)
1.26 (0.22 to 7.08)4/1695 (0.2)5/1682 (0.3)
0.34 (0.02 to 6.58)3/944 (0.3)1/935 (0.1)
2/920 (0.2)0/917 (0.0)
0.33 (0.02 to 6.46)3/586 (0.5)1/590 (0.2)
1.99 (0.21 to 18.53)2/2047 (0.1)4/2054 (0.2)
0.83 (0.18 to 3.96)6/1395 (0.4)5/1393 (0.4)
1.00 (0.12 to 8.17)3/1752 (0.2)3/1754 (0.2)
0.68 (0.07 to 7.14)3/514 (0.6)2/502 (0.4)
Not estimable0/959 (0.0)0/951 (0.0)
1.00 (0.08 to 13.17)2/1230 (0.2)2/1224 (0.2)
0.49 (0.02 to 11.35)2/194 (1.0)1/198 (0.5)
0.45 (0.09 to 2.20)9/1750 (0.5)4/1746 (0.2)
Not estimable1/433 (0.2)0/428 (0.0)
0.66 (0.40 to 1.10)
Not estimable 0.80
65/23,341 (0.3)43/23,255 (0.2)
Risk ratio
(99% CI) p-valueaNumber of events/total number (%)
No decision supportDecision support
0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Trial arm
FIGURE 22 Apgar score by centre. a, p-value calculated using centres with estimable RRs.
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Cord artery pH of < 7.15
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
0.80 (0.50 to 1.25)67/705 (9.5)53/701 (7.6)
1.05 (0.75 to 1.46)105/1017 (10.3)108/1001 (10.8)
0.87 (0.50 to 1.52)42/312 (13.5)34/290 (11.7)
0.59 (0.31 to 1.14)38/370 (10.3)23/379 (6.1)
0.78 (0.35 to 1.74)22/233 (9.4)17/230 (7.4)
0.97 (0.73 to 1.30)147/1479 (9.9)143/1476 (9.7)
1.07 (0.75 to 1.52)92/832 (11.1)101/853 (11.8)
0.94 (0.70 to 1.25)148/1339 (11.1)137/1322 (10.4)
1.14 (0.76 to 1.71)71/1148 (6.2)83/1174 (7.1)
0.90 (0.54 to 1.48)51/540 (9.4)46/544 (8.5)
48/491 (9.8)46/498 (9.2)
1.03 (0.54 to 1.96)30/403 (7.4)30/393 (7.6)
0.98 (0.77 to 1.24)176/719 (24.5)187/782 (23.9)
1.01 (0.68 to 1.50)75/763 (9.8)78/784 (9.9)
0.84 (0.56 to 1.26)79/801 (9.9)69/830 (8.3)
1.07 (0.70 to 1.65)57/305 (18.7)60/299 (20.1)
0.95 (0.64 to 1.42)77/625 (12.3)72/613 (11.7)
0.95 (0.73 to 1.23)159/752 (21.1)145/723 (20.1)
0.71 (0.27 to 1.87)18/131 (13.7)11/112 (9.8)
0.80 (0.59 to 1.09)136/1175 (11.6)111/1198 (9.3)
1.23 (0.83 to 1.83)57/230 (24.8)71/232 (30.6)
0.95 (0.88 to 1.04)
0.94 (0.57 to 1.57) 0.78
1695/14,370 (11.8)1625/14,434 (11.3)
Risk ratio
(99% CI) p-valueNumber of events/total number (%)
No decision supportDecision support
0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Trial arm
FIGURE 23 Cord artery pH by centre.
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Metabolic acidosis
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
1.03 (0.08 to 13.38)2/328 (0.6)2/319 (0.6)
1.66 (0.52 to 5.24)8/1003 (0.8)13/984 (1.3)
0.71 (0.07 to 7.43)3/307 (1.0)2/287 (0.7)
Not estimable0/361 (0.0)0/370 (0.0)
1.54 (0.15 to 16.02)2/232 (0.9)3/226 (1.3)
3.02 (0.37 to 24.66)2/1435 (0.1)6/1426 (0.4)
1.27 (0.43 to 3.72)10/832 (1.2)13/853 (1.5)
1.81 (0.62 to 5.27)9/1322 (0.7)16/1296 (1.2)
0.97 (0.03 to 37.00)1/1105 (0.1)1/1140 (0.1)
0.50 (0.14 to 1.78)12/513 (2.3)6/518 (1.2)
1/484 (0.2)4/489 (0.8)
1.71 (0.26 to 11.10)3/401 (0.7)5/391 (1.3)
1.00 (0.50 to 1.99)26/670 (3.9)28/719 (3.9)
1.48 (0.28 to 7.75)4/721 (0.6)6/732 (0.8)
0.48 (0.05 to 4.46)4/795 (0.5)2/827 (0.2)
1.02 (0.23 to 4.44)6/304 (2.0)6/299 (2.0)
1.03 (0.08 to 13.46)2/607 (0.3)2/591 (0.3)
0.86 (0.27 to 2.70)11/744 (1.5)9/711 (1.3)
1.17 (0.03 to 44.47)1/129 (0.8)1/110 (0.9)
0.89 (0.29 to 2.73)11/1144 (1.0)10/1170 (0.9)
1.00 (0.37 to 2.66)13/227 (5.7)13/228 (5.7)
1.13 (0.83 to 1.53)
3.96 (0.22 to 69.97) 0.94
131/13,664 (1.0)148/13,686 (1.1)
Risk ratio
(99% CI) p-valueaNumber of events/total number (%)
No decision supportDecision support
0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Trial arm
FIGURE 24 Metabolic acidosis by centre. a, p-value calculated using centres with estimable RRs.
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0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Resuscitation
Birmingham Women’s Hospitalb
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, Londonb
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
Not estimable0/00/0
0.95 (0.78 to 1.14)321/2097 (15.3)303/2091 (14.5)
1.01 (0.53 to 1.93)30/449 (6.7)30/443 (6.8)
1.06 (0.63 to 1.77)45/609 (7.4)47/602 (7.8)
0.95 (0.56 to 1.60)45/433 (10.4)42/427 (9.8)
1.04 (0.85 to 1.26)279/1650 (16.9)292/1665 (17.5)
Not estimable0/00/0
1.10 (0.88 to 1.39)208/1586 (13.1)224/1549 (14.5)
1.06 (0.85 to 1.32)229/1695 (13.5)241/1682 (14.3)
1.12 (0.73 to 1.72)63/943 (6.7)70/935 (7.5)
128/920 (13.9)107/917 (11.7)
1.20 (0.87 to 1.64)98/586 (16.7)118/590 (20.0)
1.04 (0.82 to 1.32)205/2047 (10.0)214/2054 (10.4)
1.03 (0.78 to 1.34)159/1395 (11.4)163/1393 (11.7)
1.08 (0.87 to 1.32)262/1752 (15.0)282/1754 (16.1)
0.90 (0.61 to 1.32)81/514 (15.8)71/502 (14.1)
0.92 (0.66 to 1.29)109/962 (11.3)99/951 (10.4)
1.03 (0.76 to 1.39)131/1230 (10.7)134/1224 (10.9)
0.77 (0.27 to 2.18)14/194 (7.2)11/197 (5.6)
1.06 (0.83 to 1.34)204/1750 (11.7)215/1746 (12.3)
1.05 (0.55 to 2.00)29/433 (6.7)30/428 (7.0)
1.02 (0.96 to 1.09)
0.84 (0.61 to 1.15) 0.96
2640/21,245 (12.4)2693/21,150 (12.7)
Risk ratio
(99% CI) p-valueaNumber of events/total number (%)
No decision supportDecision support
Trial arm
FIGURE 25 Resuscitation by centre. a, p-value calculated using centres with estimable RRs. b, Resuscitation data were not recorded in the Guardian system at Birmingham
Women’s Hospital and Homerton University Hospital.
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0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Seizures whilst at hospital
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
0.25 (0.01 to 4.44)4/1136 (0.4)1/1138 (0.1)
0.50 (0.02 to 11.74)2/2090 (0.1)1/2086 (0.0)
Not estimable0/448 (0.0)1/442 (0.2)
2.02 (0.09 to 47.26)1/611 (0.2)2/605 (0.3)
Not estimable1/430 (0.2)0/426 (0.0)
0.17 (0.01 to 2.67)6/1645 (0.4)1/1656 (0.1)
1.49 (0.14 to 15.60)2/949 (0.2)3/956 (0.3)
1.71 (0.26 to 11.16)3/1578 (0.2)5/1542 (0.3)
6.04 (0.37 to 97.47)1/1690 (0.1)6/1679 (0.4)
2.52 (0.29 to 21.68)2/940 (0.2)5/933 (0.5)
1/916 (0.1)2/916 (0.2)
Not estimable3/586 (0.5)0/590 (0.0)
1.66 (0.25 to 10.89)3/2038 (0.1)5/2044 (0.2)
1.00 (0.03 to 38.20)1/1391 (0.1)1/1390 (0.1)
0.40 (0.05 to 3.44)5/1748 (0.3)2/1749 (0.1)
Not estimable0/511 (0.0)0/502 (0.0)
Not estimable0/957 (0.0)2/947 (0.2)
Not estimable1/1227 (0.1)0/1223 (0.0)
0.98 (0.03 to 37.44)1/192 (0.5)1/195 (0.5)
0.25 (0.01 to 4.47)4/1743 (0.2)1/1736 (0.1)
Not estimable0/432 (0.0)0/424 (0.0)
0.95 (0.54 to 1.70)
2.00 (0.09 to 46.83) 0.43
41/23,258 (0.2)39/23,179 (0.2)
Risk ratio
(99% CI) p-valueaNumber of events/total number (%)
No decision supportDecision support
Trial arm
FIGURE 26 Seizures by centre. a, p-value calculated using centres with estimable RRs.
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Baby destination ward or home
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
0.99 (0.96 to 1.02)920/988 (93.1)908/986 (92.1)
1.00 (0.98 to 1.01)2028/2092 (96.9)2019/2089 (96.6)
0.99 (0.96 to 1.02)440/450 (97.8)426/442 (96.4)
1.00 (0.98 to 1.03)588/605 (97.2)583/599 (97.3)
0.99 (0.97 to 1.02)425/433 (98.2)417/427 (97.7)
0.98 (0.94 to 1.02)1398/1650 (84.7)1382/1664 (83.1)
1.00 (0.97 to 1.02)912/948 (96.2)913/951 (96.0)
1.01 (0.99 to 1.02)1525/1581 (96.5)1505/1548 (97.2)
1.00 (0.99 to 1.01)1662/1695 (98.1)1648/1682 (98.0)
1.02 (0.99 to 1.04)882/939 (93.9)886/929 (95.4)
895/916 (97.7)891/916 (97.3)
1.02 (0.99 to 1.06)550/586 (93.9)564/588 (95.9)
1.00 (0.99 to 1.02)1990/2040 (97.5)2007/2048 (98.0)
0.99 (0.97 to 1.00)1369/1395 (98.1)1351/1392 (97.1)
1.00 (0.99 to 1.02)1699/1747 (97.3)1700/1746 (97.4)
0.98 (0.92 to 1.04)453/513 (88.3)434/502 (86.5)
1.00 (0.98 to 1.02)932/956 (97.5)916/943 (97.1)
1.00 (0.98 to 1.02)1191/1227 (97.1)1187/1221 (97.2)
0.97 (0.93 to 1.01)192/194 (99.0)189/197 (95.9)
1.02 (1.00 to 1.03)1682/1748 (96.2)1707/1745 (97.8)
0.99 (0.95 to 1.03)416/433 (96.1)405/427 (94.8)
1.00 (0.99 to 1.00)
1.00 (0.98 to 1.01) 0.12
22,149/23,136 (95.7)22,038/23,042 (95.6)
Risk ratio
(99% CI) p-valueNumber of events/total number (%)
No decision supportDecision support
0.25 0.50 1.00 2.00 4.00
Favours no decision support Favours decision support
Trial arm
FIGURE 27 Infant destination immediately after birth, by centre.
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Hazard ratio
(99% CI) p-valueMedian time to event (days)
No decision supportDecision support
Length of hospital stay to discharge
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
0.94 (0.87 to 1.03)22
1.03 (0.96 to 1.10)22
1.03 (0.90 to 1.18)22
0.98 (0.88 to 1.10)22
1.10 (0.96 to 1.27)22
0.99 (0.92 to 1.07)11
0.98 (0.89 to 1.07)22
0.98 (0.91 to 1.05)22
1.01 (0.94 to 1.08)22
1.03 (0.93 to 1.13)22
22
1.03 (0.91 to 1.16)22
1.00 (0.94 to 1.06)22
0.99 (0.92 to 1.07)11
0.97 (0.91 to 1.04)22
0.91 (0.80 to 1.05)22
0.94 (0.85 to 1.04)22
0.98 (0.91 to 1.06)22
1.04 (0.86 to 1.27)11
1.02 (0.96 to 1.09)21
0.92 (0.80 to 1.05)22
0.99 (0.97 to 1.01)
0.99 (0.90 to 1.09) 0.50
22
0.25 0.50 1.00 2.00 4.00
Favours no decision support Favours decision support
Trial arm
FIGURE 28 Length of hospital stay to discharge, by centre.
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Epidural analgesia after trial entryb
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
1.01 (0.77 to 1.32)124/384 (32.3)126/386 (32.6)
0.95 (0.74 to 1.23)154/533 (28.9)149/541 (27.5)
0.89 (0.71 to 1.12)169/417 (40.5)151/418 (36.1)
Not estimable0/17 (0.0)1/25 (4.0)
1.04 (0.79 to 1.36)124/412 (30.1)130/417 (31.2)
0.94 (0.81 to 1.09)399/1030 (38.7)382/1048 (36.5)
0.79 (0.59 to 1.07)107/250 (42.8)82/242 (33.9)
0.99 (0.70 to 1.39)105/1000 (10.5)102/984 (10.4)
1.21 (0.82 to 1.79)61/289 (21.1)73/286 (25.5)
0.95 (0.52 to 1.72)30/130 (23.1)28/128 (21.9)
2/4 (50.0)2/3 (66.7)
0.83 (0.19 to 3.63)6/46 (13.0)5/46 (10.9)
1.14 (0.86 to 1.50)97/256 (37.9)109/253 (43.1)
1.09 (0.89 to 1.34)233/1011 (23.0)254/1010 (25.1)
1.05 (0.89 to 1.24)361/1665 (21.7)380/1674 (22.7)
1.17 (0.89 to 1.53)124/501 (24.8)142/491 (28.9)
1.11 (0.83 to 1.49)90/236 (38.1)96/226 (42.5)
1.01 (0.82 to 1.23)226/777 (29.1)228/779 (29.3)
1.22 (0.85 to 1.76)58/179 (32.4)72/182 (39.6)
1.12 (0.87 to 1.44)151/679 (22.2)172/689 (25.0)
1.27 (0.88 to 1.83)68/326 (20.9)86/325 (26.5)
1.03 (0.97 to 1.09)
1.33 (0.22 to 8.03) 0.37
2689/10,142 (26.5)2770/10,153 (27.3)
Risk ratio
(99% CI) p-valueaNumber of events/total number (%)
No decision supportDecision support
0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Trial arm
FIGURE 29 Epidural analgesia after trial entry, by centre. a, p-value calculated using centres with estimable RRs. b, Timing of epidural in relation to trial entry only collected
from 2013 onwards for each centre.
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Labour augmentation after trial entryb
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
1.01 (0.84 to 1.21)194/383 (50.7)197/385 (51.2)
0.84 (0.69 to 1.02)230/527 (43.6)196/534 (36.7)
0.99 (0.75 to 1.30)123/383 (32.1)119/375 (31.7)
1.09 (0.31 to 3.86)6/27 (22.2)7/29 (24.1)
0.99 (0.80 to 1.22)176/410 (42.9)175/413 (42.4)
1.01 (0.88 to 1.15)439/1019 (43.1)449/1036 (43.3)
1.05 (0.80 to 1.39)99/245 (40.4)103/242 (42.6)
0.94 (0.67 to 1.32)107/743 (14.4)95/702 (13.5)
0.87 (0.60 to 1.25)79/274 (28.8)68/271 (25.1)
0.82 (0.43 to 1.56)30/156 (19.2)24/152 (15.8)
0/5 (0.0)1/5 (20.0)
0.84 (0.35 to 2.00)14/47 (29.8)12/48 (25.0)
1.08 (0.85 to 1.38)114/254 (44.9)123/253 (48.6)
1.05 (0.89 to 1.23)362/1250 (29.0)378/1246 (30.3)
0.97 (0.65 to 1.46)74/804 (9.2)75/836 (9.0)
0.95 (0.78 to 1.17)201/498 (40.4)189/492 (38.4)
0.93 (0.74 to 1.18)127/236 (53.8)111/221 (50.2)
0.97 (0.65 to 1.44)73/526 (13.9)71/528 (13.4)
1.15 (0.85 to 1.55)75/180 (41.7)88/184 (47.8)
1.02 (0.77 to 1.34)128/502 (25.5)124/479 (25.9)
1.02 (0.75 to 1.38)99/323 (30.7)100/321 (31.2)
0.99 (0.93 to 1.05)
Not estimable 0.92
2750/8792 (31.3)2705/8752 (30.9)
Risk ratio
(99% CI) p-valueaNumber of events/total number (%)
No decision supportDecision support
0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Trial arm
FIGURE 30 Labour augmentation after trial entry, by centre. a, p-value calculated using centres with estimable RRs. b, Timing of labour augmentation in relation to trial entry
only collected from 2013 onwards for each centre.
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0.25 0.50 1.00 2.00 4.00
Favours decision support Favours no decision support
Presence of meconium after trial entryb
Risk ratio
(99% CI) p-valueaNumber of events/total number (%)
No decision supportDecision support
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
14/387 (3.6)26/392 (6.6)
46/533 (8.6)33/531 (6.2)
9/367 (2.5)8/363 (2.2)
0/44 (0.0)0/38 (0.0)
11/411 (2.7)20/408 (4.9)
69/998 (6.9)70/1004 (7.0)
25/246 (10.2)16/240 (6.7)
13/1403 (0.9)15/1381 (1.1)
4/320 (1.3)6/317 (1.9)
7/130 (5.4)3/116 (2.6)
0/00/0
1/47 (2.1)4/40 (10.0)
15/250 (6.0)23/242 (9.5)
60/1164 (5.2)54/1151 (4.7)
25/1409 (1.8)21/1431 (1.5)
42/482 (8.7)30/480 (6.3)
16/231 (6.9)19/229 (8.3)
14/200 (7.0)17/204 (8.3)
16/179 (8.9)10/182 (5.5)
58/689 (8.4)44/691 (6.4)
24/325 (7.4)21/316 (6.6)
469/9815 (4.8)440/9756 (4.5)
1.83 (0.80 to 4.22)
0.72 (0.41 to 1.27)
0.90 (0.26 to 3.10)
Not estimable
1.83 (0.71 to 4.74)
1.01 (0.66 to 1.54)
0.66 (0.30 to 1.45)
1.17 (0.44 to 3.10)
1.51 (0.29 to 7.90)
0.48 (0.08 to 2.76)
4.70 (0.27 to 80.64)
1.58 (0.70 to 3.61)
0.91 (0.57 to 1.46)
0.83 (0.39 to 1.76)
0.72 (0.40 to 1.30)
1.20 (0.52 to 2.78)
1.19 (0.49 to 2.91)
0.61 (0.23 to 1.68)
0.76 (0.46 to 1.24)
0.90 (0.43 to 1.89)
0.94 (0.80 to 1.12)
Not estimable 0.22
Trial arm
FIGURE 31 Presence of meconium after trial entry, by centre. a, p-value calculated using centres with estimable RRs. b, Timing of meconium in relation to trial entry only
collected from 2013 onwards for each centre.
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Number of women with at least one blue, yellow or red level of concern
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
0.99 (0.97 to 1.00)1098/1117 (98.3)1082/1114 (97.1)
1.00 (0.99 to 1.01)1985/2020 (98.3)1990/2020 (98.5)
0.99 (0.96 to 1.02)416/427 (97.4)410/426 (96.2)
1.00 (0.96 to 1.05)531/584 (90.9)519/569 (91.2)
0.99 (0.96 to 1.03)401/415 (96.6)400/417 (95.9)
1.00 (1.00 to 1.01)1599/1616 (98.9)1627/1638 (99.3)
1.00 (0.98 to 1.02)879/898 (97.9)887/905 (98.0)
1.00 (0.99 to 1.01)1541/1550 (99.4)1500/1511 (99.3)
1.01 (0.98 to 1.03)1478/1585 (93.2)1485/1579 (94.0)
0.98 (0.96 to 1.01)860/889 (96.7)848/890 (95.3)
885/901 (98.2)873/895 (97.5)
1.00 (0.98 to 1.02)560/568 (98.6)563/573 (98.3)
1.00 (0.99 to 1.01)1986/1999 (99.3)1992/2003 (99.5)
1.00 (0.98 to 1.02)1316/1363 (96.6)1321/1365 (96.8)
1.00 (0.99 to 1.02)1676/1719 (97.5)1686/1726 (97.7)
0.99 (0.97 to 1.01)496/504 (98.4)483/496 (97.4)
0.99 (0.97 to 1.00)925/938 (98.6)899/924 (97.3)
1.00 (0.98 to 1.02)1183/1212 (97.6)1180/1208 (97.7)
1.01 (0.95 to 1.08)172/184 (93.5)180/190 (94.7)
1.00 (0.99 to 1.01)1626/1657 (98.1)1633/1663 (98.2)
0.99 (0.96 to 1.02)408/418 (97.6)392/405 (96.8)
1.00 (1.00 to 1.00)
0.99 (0.98 to 1.01) 0.62
22,021/22,564 (97.6)21,950/22,517 (97.5)
Risk ratio
(99% CI) p-valueNumber of events/total number (%)
No decision supportDecision support
0.25 0.50 1.00 2.00 4.00
Fewer in decision support arm Fewer in no decision support arm
Trial arm
FIGURE 32 Number of women with at least one blue, yellow or red level of concern, by centre.
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 0.25 0.5 1 2 4
Risk ratio
(99% CI) p-valueNumber of events/total number (%)
 Number decision supportDecision support
Fewer in decision support arm Fewer in no decision support arm
Number of women with at least one blue level of concern (mild abnormality)
Birmingham Women’s Hospital 0.99 (0.97 to 1.00)1096/1117 (98.1)1079/1114 (96.9)
Burnley General Hospital 1.00 (0.99 to 1.01)1982/2020 (98.1)1987/2020 (98.4)
Chelsea and Westminster Hospital, London 0.99 (0.96 to 1.03)414/427 (97.0)410/426 (96.2)
University Hospital Coventry 1.00 (0.95 to 1.05)526/584 (90.1)510/569 (89.6)
Royal Derby Hospital 0.99 (0.95 to 1.03)395/415 (95.2)394/417 (94.5)
Derriford Hospital, Plymouth 1.01 (1.00 to 1.02)1592/1616 (98.5)1626/1638 (99.3)
Homerton University Hospital, London 1.00 (0.98 to 1.02)874/898 (97.3)882/905 (97.5)
Liverpool Women’s Hospital 1.00 (0.99 to 1.01)1541/1550 (99.4)1500/1511 (99.3)
North Staffordshire University Hospital 1.01 (0.98 to 1.04)1455/1585 (91.8)1462/1579 (92.6)
Northwick Park Hospital, London 0.99 (0.96 to 1.02)851/889 (95.7)842/890 (94.6)
Nottingham City Hospital and Queen’s 
Medical Centre 0.99 (0.98 to 1.01)885/901 (98.2)873/895 (97.5)
Princess Anne Hospital, Southampton 1.00 (0.98 to 1.02)559/568 (98.4)563/573 (98.3)
Princess Royal Hospital and Southern General 
Hospital, Glasgow 1.00 (0.99 to 1.01)1984/1999 (99.2)1988/2003 (99.3)
Queen Alexandra, Portsmouth 1.01 (0.99 to 1.03)1307/1363 (95.9)1318/1365 (96.6)
Rotunda Hospital, Dublin 1.01 (0.99 to 1.02)1658/1719 (96.5)1676/1726 (97.1)
Royal Bolton Hospital 0.99 (0.96 to 1.01)496/504 (98.4)482/496 (97.2)
St. Mary’s Hospital, Manchester 0.99 (0.97 to 1.00)922/938 (98.3)895/924 (96.9)
Stoke Mandeville Hospital 1.00 (0.98 to 1.02)1180/1212 (97.4)1178/1208 (97.5)
University College Hospital, London 1.03 (0.96 to 1.10)170/184 (92.4)180/190 (94.7)
Warrington Hospital 1.00 (0.99 to 1.01)1621/1657 (97.8)1629/1663 (98.0)
Warwick Hospital 0.99 (0.96 to 1.03)405/418 (96.9)389/405 (96.0)
Total (unadjusted) 1.00 (1.00 to 1.00)
0.39
21,913/22,564 (97.1)21,863/22,517 (97.1)
Trial arm
FIGURE 33 Number of women with at least one blue level of concern, by centre.
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Number of women with at least one yellow level of concern (moderate abnormality)
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
0.97 (0.92 to 1.02)912/1117 (81.6)880/1114 (79.0)
0.98 (0.93 to 1.03)1452/2020 (71.9)1423/2020 (70.4)
1.00 (0.90 to 1.10)326/427 (76.3)324/426 (76.1)
1.00 (0.90 to 1.11)401/584 (68.7)390/569 (68.5)
1.00 (0.89 to 1.11)302/415 (72.8)303/417 (72.7)
0.99 (0.94 to 1.04)1221/1616 (75.6)1228/1638 (75.0)
0.98 (0.93 to 1.03)761/898 (84.7)752/905 (83.1)
1.02 (0.97 to 1.07)1157/1550 (74.6)1149/1511 (76.0)
0.99 (0.92 to 1.06)1035/1585 (65.3)1018/1579 (64.5)
1.02 (0.94 to 1.10)636/889 (71.5)649/890 (72.9)
655/901 (72.7)661/895 (73.9)
1.00 (0.91 to 1.09)431/568 (75.9)433/573 (75.6)
1.04 (0.98 to 1.10)1363/1999 (68.2)1418/2003 (70.8)
1.05 (0.98 to 1.12)895/1363 (65.7)939/1365 (68.8)
1.01 (0.96 to 1.06)1277/1719 (74.3)1295/1726 (75.0)
1.03 (0.95 to 1.11)405/504 (80.4)411/496 (82.9)
0.98 (0.91 to 1.04)735/938 (78.4)706/924 (76.4)
1.02 (0.95 to 1.08)883/1212 (72.9)894/1208 (74.0)
1.03 (0.90 to 1.17)148/184 (80.4)157/190 (82.6)
1.01 (0.98 to 1.04)1425/1657 (86.0)1446/1663 (87.0)
0.99 (0.88 to 1.11)302/418 (72.2)289/405 (71.4)
1.00 (0.99 to 1.02)
1.02 (0.94 to 1.09) 0.73
16,722/22,564 (74.1)16,765/22,517 (74.5)
0.25 0.50 1.00 2.00 4.00
Risk ratio
(99% CI) p-value
No decision supportDecision support
Fewer in decision support arm Fewer in no decision support arm
Number of events/total number (%)
Trial arm
FIGURE 34 Number of women with at least one yellow level of concern, by centre.
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0.25 0.50 1.00 2.00 4.00
Risk ratio
(99% CI) p-value
No decision supportDecision support
Fewer in decision support arm Fewer in no decision support arm
Number of women with at least one red level of concern (severe abnormality)
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospitala
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospitala
Total (unadjusted)
0.78 (0.55 to 1.12)109/1117 (9.8)85/1114 (7.6)
0.77 (0.60 to 0.99)219/2020 (10.8)169/2020 (8.4)
0.81 (0.52 to 1.25)67/427 (15.7)54/426 (12.7)
1.07 (0.71 to 1.63)65/584 (11.1)68/569 (12.0)
0.87 (0.69 to 1.09)228/1616 (14.1)200/1638 (12.2)
1.13 (0.80 to 1.58)97/898 (10.8)110/905 (12.2)
0.75 (0.56 to 0.99)176/1550 (11.4)128/1511 (8.5)
1.21 (0.87 to 1.68)103/1585 (6.5)124/1579 (7.9)
0.92 (0.64 to 1.33)93/889 (10.5)86/890 (9.7)
1.19 (0.84 to 1.68)90/901 (10.0)106/895 (11.8)
0.97 (0.65 to 1.42)77/568 (13.6)75/573 (13.1)
1.03 (0.82 to 1.30)220/1999 (11.0)227/2003 (11.3)
1.11 (0.74 to 1.67)71/1363 (5.2)79/1365 (5.8)
0.93 (0.72 to 1.22)177/1719 (10.3)166/1726 (9.6)
0.99 (0.56 to 1.75)38/504 (7.5)37/496 (7.5)
1.18 (0.88 to 1.58)124/938 (13.2)144/924 (15.6)
1.28 (0.95 to 1.73)119/1212 (9.8)152/1208 (12.6)
1.25 (0.65 to 2.39)24/184 (13.0)31/190 (16.3)
0.93 (0.77 to 1.12)316/1657 (19.1)294/1663 (17.7)
0.97 (0.90 to 1.04)
0.01
2413/21,731 (11.1)2335/21,695 (10.8)
Number of events/total number (%)
Trial arm
FIGURE 35 Number of women with at least one red level of concern, by centre. a, Data on timing of red level of concern are not available for two centres: Warwick Hospital
(n= 823) and Derby Hospital (n= 832).
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Number of blue, yellow and red levels of concern
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
0.99 (0.96 to 1.02)1.411.40
0.97 (0.94 to 0.99)1.421.37
0.93 (0.88 to 0.99)1.281.20
1.03 (0.97 to 1.09)0.830.85
1.18 (1.11 to 1.26)0.861.02
0.98 (0.96 to 1.01)1.501.47
1.01 (0.98 to 1.04)1.511.52
0.94 (0.92 to 0.96)1.621.52
0.96 (0.93 to 0.99)1.151.11
0.92 (0.88 to 0.95)1.281.18
1.321.34
0.94 (0.90 to 0.99)1.221.15
0.97 (0.94 to 0.99)1.521.47
0.99 (0.96 to 1.02)1.261.25
0.95 (0.92 to 0.98)1.601.52
1.27 (1.21 to 1.34)1.181.50
0.97 (0.94 to 1.00)1.451.40
1.02 (0.98 to 1.05)1.331.35
0.93 (0.86 to 1.01)0.830.77
0.95 (0.92 to 0.97)1.551.47
1.00 (0.94 to 1.07)1.181.19
0.98 (0.97 to 0.99)
1.02 (0.98 to 1.06) <0.001
1.381.35
0.25 0.50 1.00 2.00 4.00
Rate ratio
(99% CI) p-value
No decision supportDecision support
Fewer in decision support arm Fewer in no decision support arm
Rate per hour
Trial arm
FIGURE 36 Number of blue, yellow and red levels of concern, by centre.
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0.25 0.50 1.00 2.00 4.00
Rate ratio
(99% CI) p-value
No decision supportDecision support
Fewer in decision support arm Fewer in no decision support arm
Rate per hour
Number of blue levels of concern
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
1.04 (1.00 to 1.08)0.981.02
1.00 (0.97 to 1.03)1.101.10
0.96 (0.90 to 1.03)0.960.93
1.05 (0.98 to 1.12)0.600.63
1.23 (1.14 to 1.33)0.590.73
1.02 (0.99 to 1.06)1.161.19
1.05 (1.01 to 1.09)1.031.07
0.98 (0.96 to 1.01)1.251.23
1.01 (0.98 to 1.04)0.870.87
0.97 (0.92 to 1.01)0.890.86
1.061.09
0.98 (0.92 to 1.03)0.890.87
0.99 (0.96 to 1.02)1.231.21
1.01 (0.97 to 1.05)0.970.98
0.99 (0.96 to 1.03)1.141.13
1.26 (1.19 to 1.35)0.780.99
0.99 (0.95 to 1.03)1.151.13
1.04 (1.00 to 1.08)1.031.07
0.96 (0.86 to 1.07)0.520.50
0.99 (0.96 to 1.02)1.101.09
1.04 (0.97 to 1.12)0.880.92
1.01 (1.00 to 1.02)
1.03 (0.99 to 1.08) <0.001
1.031.04
Trial arm
FIGURE 37 Number of blue levels of concern, by centre.
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0.25 0.50 1.00 2.00 4.00
Rate ratio
(99% CI) p-value
No decision supportDecision support
Fewer in decision support arm Fewer in no decision support arm
Rate per hour
Number of yellow levels of concern
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospital
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospital
Total (unadjusted)
0.89 (0.84 to 0.94)0.420.37
0.87 (0.82 to 0.92)0.300.26
0.85 (0.75 to 0.96)0.300.25
0.98 (0.88 to 1.10)0.210.21
1.08 (0.96 to 1.22)0.280.30
0.84 (0.79 to 0.89)0.320.26
0.92 (0.87 to 0.98)0.470.43
0.79 (0.75 to 0.84)0.350.28
0.80 (0.75 to 0.86)0.270.22
0.80 (0.74 to 0.86)0.370.30
0.240.22
0.85 (0.76 to 0.94)0.300.26
0.86 (0.81 to 0.91)0.280.24
0.91 (0.85 to 0.98)0.280.26
0.83 (0.78 to 0.88)0.440.37
1.31 (1.20 to 1.44)0.380.50
0.89 (0.83 to 0.97)0.280.25
0.91 (0.84 to 0.97)0.290.26
0.88 (0.76 to 1.02)0.300.26
0.82 (0.78 to 0.87)0.420.35
0.89 (0.78 to 1.01)0.300.26
0.87 (0.86 to 0.89)
0.93 (0.85 to 1.02) <0.001
0.330.29
Trial arm
FIGURE 38 Number of yellow levels of concern, by centre.
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Number of red levels of concern
Birmingham Women's Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospitala
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women's Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen's Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary's Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospitala
Total (unadjusted)
0.25 0.50 1.00 2.00 4.00
Rate ratio
(99% CI) p-value
No decision supportDecision support
Fewer in decision support arm Fewer in no decision support arm
Rate per hour
0.73 (0.51 to 1.03)0.010.01
0.78 (0.61 to 0.99)0.020.01
0.75 (0.48 to 1.16)0.030.02
1.12 (0.75 to 1.70)0.020.02
0.87 (0.69 to 1.09)0.020.02
1.13 (0.82 to 1.55)0.020.02
0.72 (0.55 to 0.94)0.020.01
1.18 (0.87 to 1.59)0.010.01
0.85 (0.59 to 1.21)0.020.01
0.020.02
0.92 (0.64 to 1.32)0.020.02
1.01 (0.81 to 1.26)0.020.02
1.02 (0.68 to 1.52)0.010.01
0.92 (0.71 to 1.21)0.020.02
0.77 (0.43 to 1.36)0.010.01
0.97 (0.73 to 1.29)0.020.02
1.54 (1.17 to 2.04)0.020.02
0.98 (0.50 to 1.96)0.010.01
0.93 (0.76 to 1.12)0.030.03
0.96 (0.89 to 1.02)
1.28 (0.94 to 1.76) 0.008
0.020.02
Trial arm
FIGURE 39 Number of red levels of concern, by centre. a, Data on timing of red level of concern are not available for two centres: Warwick Hospital (n= 823) and Derby
Hospital (n= 832).
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Time from last red level of concern to deliverya
Birmingham Women’s Hospital
Burnley General Hospital
Chelsea & Westminster Hospital, London
Coventry Hospital
Derby Hospitalb
Derriford Hospital, Plymouth
Homerton Hospital, London
Liverpool Women’s Hospital
North Staffordshire Hospital
Northwick Park Hospital, London
Nottingham City & Queen’s Medical Centre
Princess Anne Hospital, Southampton
Princess Royal & Southern General Hospital, Glasgow
Queen Alexandra Hospital, Portsmouth
Rotunda Hospital, Dublin
Royal Bolton Hospital
St. Mary’s Hospital, Manchester
Stoke Mandeville Hospital
UCLH
Warrington Hospital
Warwick Hospitalb
Total (unadjusted)
0.98 (0.68 to 1.42)5147
0.94 (0.72 to 1.22)3542
1.03 (0.65 to 1.65)4574
1.01 (0.64 to 1.58)9389
1.01 (0.79 to 1.30)4352
1.08 (0.75 to 1.54)13558.5
1.05 (0.78 to 1.42)123105.5
1.16 (0.82 to 1.63)13272.5
1.05 (0.72 to 1.54)5845
64.584.5
0.80 (0.52 to 1.24)123283
1.07 (0.84 to 1.37)11184
0.79 (0.51 to 1.21)4967
0.78 (0.59 to 1.04)2131
0.90 (0.50 to 1.62)5524
1.13 (0.83 to 1.54)74.555
1.17 (0.85 to 1.61)13497
0.87 (0.41 to 1.81)1950
0.93 (0.75 to 1.14)38.535
0.99 (0.92 to 1.07)
1.02 (0.71 to 1.48) 0.50
5858
0.25 0.50 1.00 2.00 4.00
Hazard ratio
(99% CI) p-value
No decision supportDecision support
Favours no decision support Favours decision support
Median time to event (minutes)
Trial arm
FIGURE 40 Time from last red level of concern to delivery. a, Hazard ratio of > 1 favours decision support as this implies that time to delivery (from last red level of concern)
was reached more quickly than with no decision support. b, Data on timing of red level of concern are not available for two centres: Warwick Hospital (n= 823) and Derby
Hospital (n= 832).
RESU
LTS
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
96
Predefined subgroup analyses of long-term outcomes
TABLE 34 Parent Report of Children’s Abilities-Revised composite score, by BMI
BMI (kg/m2) n (%)
Trial arm, mean score (points) (SD)
Mean difference (95% CI)Decision support No decision support
12 to 18.4 104 (2) 94.6 (37.5) 99.9 (37.9) –5.27 (–20.0 to 9.41)
18.5 to 24.9 2039 (30) 98.2 (33.7) 97.4 (32.8) 0.86 (–2.07 to 3.78)
25 to 29.9 1508 (23) 98.3 (34.8) 98.6 (33.3) –0.34 (–3.82 to 3.14)
30 to 70 1157 (17) 96.7 (34.8) 95.3 (33.1) 1.43 (–2.53 to 5.39)
Unrecorded 1899 (28) 98.3 (32.4) 97.1 (34.0) 1.27 (–1.76 to 4.30)
Total (unadjusted) 6707 (100) 98.0 (33.8) 97.2 (33.4) 0.73 (–0.88 to 2.34)
Unknown 359
Note
p-value from the test of interaction = 0.86.
TABLE 32 Parent Report of Children’s Abilities-Revised composite score, by twin pregnancy
Singleton vs. twins n (%)
Trial arm, mean score (points) (SD)
Mean difference (95% CI)Decision support No decision support
Singleton 6555 (98) 98.2 (33.7) 97.4 (33.4) 0.82 (–0.81 to 2.44)
Twin 152 (2) 85.7 (37.3) 89.7 (32.4) –3.95 (–19.4 to 11.5)
Total (unadjusted) 6707 (100) 98.0 (33.8) 97.2 (33.4) 0.73 (–0.88 to 2.34)
Unknown 359
Note
p-value from the test of interaction = 0.54.
TABLE 33 Parent Report of Children’s Abilities-Revised composite score, by suspected fetal growth restriction
FGR n (%)
Trial arm, mean score (points) (SD)
Mean difference (95% CI)Decision support No decision support
No FGR 6472 (96) 98.3 (33.7) 97.5 (33.4) 0.77 (–0.89 to 2.42)
FGR 235 (4) 89.4 (35.0) 90.9 (34.1) –1.50 (–10.5 to 7.54)
Total (unadjusted) 6707 (100) 98.0 (33.8) 97.2 (33.4) 0.73 (–0.88 to 2.34)
Unknown 359
FGR, fetal growth restriction.
Note
p-value from the test of interaction = 0.63.
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TABLE 35 Parent Report of Children’s Abilities-Revised composite score, by centre
Centrea n (%)
Trial arm, mean score
(points) (SD)
Mean difference
(95% CI)
Decision
support
No
decision
support
Birmingham Women’s Hospital 262 (4) 95.1 (32.0) 96.8 (31.0) –1.74 (–9.54 to 6.06)
Burnley General Hospital 832 (12) 94.0 (35.7) 94.0 (33.4) 0.02 (–4.73 to 4.78)
Derriford Hospital, Plymouth 814 (12) 95.6 (33.0) 94.7 (34.3) 0.84 (–3.85 to 5.53)
Liverpool Women’s Hospital 725 (11) 102.4 (33.4) 97.6 (34.6) 4.79 (–0.28 to 9.85)
Northwick Park Hospital, London 146 (2) 86.3 (34.8) 88.4 (31.4) –2.19 (–13.3 to 8.87)
Nottingham City Hospital and Queens Medical
Centre
135 (2) 98.1 (33.2) 104.4 (30.0) –6.30 (–17.1 to 4.50)
Princess Anne Hospital, Southampton 205 (3) 99.1 (32.0) 100.9 (32.0) –1.77 (–10.7 to 7.15)
Princess Royal Hospital and Southern General
Hospital, Glasgow
333 (5) 106.1 (31.9) 105.4 (32.4) 0.69 (–6.27 to 7.65)
Queen Alexandra Hospital, Portsmouth 693 (10) 98.2 (33.7) 97.7 (32.4) 0.56 (–4.44 to 5.56)
Rotunda Hospital, Dublin 161 (2) 109.8 (32.2) 110.0 (34.9) –0.19 (–10.7 to 10.3)
St Mary’s Hospital, Manchester 208 (3) 100.0 (34.8) 96.2 (32.4) 3.73 (–5.73 to 13.2)
Stoke Mandeville Hospital 462 (7) 98.3 (32.4) 96.4 (32.0) 1.86 (–4.08 to 7.80)
University Hospital of North Staffordshire 826 (12) 97.1 (34.3) 97.9 (33.3) –0.75 (–5.37 to 3.88)
Warwick Hospital 905 (14) 97.4 (33.6) 96.8 (34.4) 0.61 (–3.88 to 5.10)
Total (unadjusted) 6707 (100) 98.0 (33.8) 97.2 (33.4) 0.73 (–0.88 to 2.34)
Unknown 359
a Seven centres joining the trial at a later stage did not have infants included in the 2-year follow-up sample.
Note
p-value from the test of interaction = 0.94.
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Chapter 7 Economic evaluation
In previous chapters we showed that the use of decision support software for the management of labourdid not translate into statistically significant differences in the two primary outcomes in this trial. In
addition, we reported that other neonatal secondary outcomes at hospital discharge and at 2 years’
follow-up were similar between the two groups.
This chapter adds an additional layer of relevant information to the clinical outcomes and includes a
cost–consequences analysis conducted alongside INFANT. It was originally intended to be presented as a
cost-effectiveness analysis and a health economics analysis plan had been developed to support this
(see Appendix 10). Given the trial findings, a cost–consequences approach was deemed more appropriate
and helpful, as is discussed in detail later in this chapter.
The cost–consequences analysis was conducted from a NHS perspective and included direct costs to
mothers and their babies. A detailed overview of the analysis conducted from trial entry to hospital
discharge and up to 2 years’ follow-up is provided in this chapter. In addition to the composite primary
outcome at discharge, PARCA-R composite scores for a subset of surviving infants without the composite
primary outcome at 2 years and maternal health-related quality of life (HRQoL) at 12 and 24 months post
birth are presented.
Methods
NHS health-care resource use
A comprehensive list of health-care resource use information for mothers and their babies was collected
for the study. Data collection began when women arrived in hospital in labour and ended when postnatal
care for both mother and baby was complete. For most women, this was following hospital discharge.
A subset of women who consented to be followed up post birth were sent a questionnaire regarding
health-care resource use and maternal HRQoL information at 12 and 24 months’ follow-up.
Labour-related resource use data included procedures undertaken for mothers and infants before
discharge and were collected using the Guardian system. Additional information, such as maternal
transfers after birth, whether or not babies or mothers had been admitted to a higher level of care unit
and neonatal deaths, was collected using bespoke data collection forms. These were overseen by the trial’s
co-ordinating research midwife, who ensured that all care was documented. The forms were then posted
to the INFANT trial administrative centre for data entry.
Health-care utilisation at 12- and 24-month follow-up was identified using a postal questionnaire that
collected information about acute and community care, secondary care and maternal HRQoL. It included
outpatient appointments and inpatient stays (e.g. for operations), follow-up care and numbers of visits to
relevant health-care professionals. The questionnaires were sent to a subsample of mothers of surviving
infants who consented to follow-up and who gave birth in the first year of the trial. The 12-month follow-up
questionnaire collected resource use data between post-birth discharge and 1 year, and the 24-month
questionnaire asked about resources consumed in the previous 12 months. Two postal reminders were
sent by the trial management team for questionnaires not returned. All data collected using the postal
questionnaire were double data entered and cleaned prior to analysis. Table 36 presents categories of NHS
health-care resource use collected during the study.
To estimate whether or not the use of decision support software in INFANT would incur additional NHS
resources beyond the implementation of the Guardian system, the health economics team met with a
representative from K2 Medical Systems to identify a base-case cost for the software. All sites (and hence
all women) participating in the trial used the Guardian system, but we identified three additional aspects
to cost for the decision support tool.
DOI: 10.3310/hta22090 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 9
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brocklehurst et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
99
TABLE 36 Categories of resource use and associated unit costs used in the cost analysis (expressed in 2014–15 GBP)
Resource use item
Unit cost
(GBP) Source Notes
Maternal
Birth related
Induction 173 Schroeder et al., 201273
Episiotomy 27 Schroeder et al., 201273
Perineal tear
First- and second-degree tears 23 Schroeder et al., 201273
Third- and fourth-degree tears 649 Schroeder et al., 201273
Manual removal of the placenta 752 Schroeder et al., 201273
Blood transfusion 158 Schroeder et al., 201273 Per blood pack
Higher level of care admissions
Level of care, per day
Special care 898 NHS Reference Costs 2014
to 2015, 201574
High-dependency care 1278 NHS Reference Costs 2014
to 2015, 201574
Intensive care 1432 NHS Reference Costs 2014
to 2015, 201574
Surgery/post-birth procedures
Management of post-partum
haemorrhage using the Bakri
technique
987 NHS Reference Costs 2014
to 2015, 201574
Management of post-partum
haemorrhage using EUA
1201 NHS Reference Costs 2014
to 2015, 201574
Hysterectomy 1388 NHS Reference Costs 2014
to 2015, 201574
Perineal haematoma 987 NHS Reference Costs 2014
to 2015, 201574
Transfer to another hospital 439 Schroeder et al., 201273
Follow-up
Secondary care
Hospital inpatient (per day) 492 NHS Reference Costs 2014
to 2015, 201574
Weighted average by data
submissions of regular day or night
admissions
Postnatal ward stay (per day) 104 Schroeder et al., 201273
A&E department (per visit) 169 NHS Reference Costs 2014
to 2015, 201574
Weighted average by data
submissions of non-admitted to
emergency medicine
Outpatient clinic 111 NHS Reference Costs 2014
to 2015, 201574
Weighted average by activity of
non-paediatric outpatient
attendances
Day case 1078 NHS Reference Costs 2014
to 2015, 201574
Weighted average by data
submissions of non-paediatric day
cases
Community care
GP appointment 45 Curtis and Burns, 201575 Per patient contact lasting
11.7 minutes
Practice nurse appointment 15 Curtis and Burns, 201575 Per surgery consultation lasting
15.5 minutes
ECONOMIC EVALUATION
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TABLE 36 Categories of resource use and associated unit costs used in the cost analysis (expressed in 2014–15 GBP)
(continued )
Resource use item
Unit cost
(GBP) Source Notes
Community nurse appointment 67 Curtis and Burns, 201575 Per visit lasting 60 minutes
Physiotherapy appointment 38 Curtis and Burns, 201575 Per visit lasting 60 minutes
Hospital community counselling 51 Curtis and Burns, 201575 Per visit lasting 60 minutes
Other 43 Average of community care visits
Infant
Birth related: mode of birth
Vaginal delivery 1724 NHS Reference Costs 2014
to 2015, 201574
Normal delivery, cc = 0 (HRG data)
Breech delivery 2311 NHS Reference Costs 2014
to 2015, 201574
Normal delivery, cc = 1 (HRG data)
Assisted delivery 2046 NHS Reference Costs 2014
to 2015, 201574
Assisted delivery, cc = 0 (HRG data)
Caesarean section delivery 3895 NHS Reference Costs 2014
to 2015, 201574
Emergency C-section
Resuscitation 177 Schroeder et al., 201273
Higher level of care admissions
Level of care, per day
Special care 486 NHS Reference Costs 2014
to 2015, 201574
High-dependency care 847 NHS Reference Costs 2014
to 2015, 201574
Intensive care 1176 NHS Reference Costs 2014
to 2015, 201574
Transfer to another hospital 1101 NHS Reference Costs 2014
to 2015, 201574
Neonatal critical care,
transportation
Neonatal death 703 Schroeder et al., 201273
Consultations
General 167 NHS Reference Costs 2014
to 2015, 201574
Orthopaedic 279 NHS Reference Costs 2014
to 2015, 201574
Surgery
Paediatric cardiology 3895 NHS Reference Costs 2014
to 2015, 201574
Plastic surgery 1828 NHS Reference Costs 2014
to 2015, 201574
Gastrointestinal surgery 3706 NHS Reference Costs 2014
to 2015, 201574
Paediatric neurosurgery 1105 NHS Reference Costs 2014
to 2015, 201574
Total body cooling 6424 Regier et al., 200976
Follow-up
Secondary care
Hospital inpatient (per day) 757 NHS Reference Costs 2014
to 2015, 201574
Paediatric high-dependency ward
Postnatal ward stay (per day) 104 Schroeder et al., 201273
continued
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The first was the price to be paid by the NHS for the new software. A price for the decision support
software had not been determined at the time the study was concluded. We understand that this price
would be determined using a particular commercial strategy by K2 Medical Systems and would probably
be selected in view of the trial results. Therefore, for the base-case scenario it was initially assumed that
the software would be made available free of charge to the NHS. Scenarios to address this were identified
for a multiway sensitivity analysis, to include any cost shifting in actual practice.
Second, an annual maintenance fee would be needed for software updates and other related information
technology issues. A maintenance fee for the whole Guardian system had already been paid by the trial
sites so it was assumed that further maintenance needed for the software would be included. Although
the fee could potentially increase as a result of the installation of the decision support software, in the
base case it was assumed that the fee would not change.
Finally, training of NHS staff members to develop familiarity and technical competence with the software
was reviewed. All training received by staff during the preparation of the trial was delivered during
working hours and was fitted into regular working patterns. Therefore, staff did not have to take
additional time off work to learn how to use the decision support tool. It was assumed that a similar
model would be used across the NHS and that no separate training costs were required. Consequently,
in our base case, none of the three identified elements would incur additional NHS resource use, so no
specific costs for the use of decision support software in INFANT were assigned. Scenarios to address this
were identified for a multiway sensitivity analysis, to include any cost shifting in actual practice.
Unit costs
Sources and associated estimates of unit costs for the different categories of health-care resource use are
presented in Table 36. Information was primarily extracted from secondary national sources including
the Personal Social Services Research Unit75 and NHS Reference Costs.74 The unit costs associated with
induction, episiotomy, perineal tear, manual removal of the placenta, blood transfusion and neonatal death
TABLE 36 Categories of resource use and associated unit costs used in the cost analysis (expressed in 2014–15 GBP)
(continued )
Resource use item
Unit cost
(GBP) Source Notes
A&E department (per visit) 169 NHS Reference Costs 2014
to 2015, 201574
Weighted average by data
submissions of non-admitted to
emergency medicine
Outpatient clinic 180 NHS Reference Costs 2014
to 2015, 201574
Weighted average by activity of
paediatric outpatient attendances
Day case 661 NHS Reference Costs 2014
to 2015, 201574
Weighted average by data
submissions of paediatric day cases
Community care
GP appointment 45 Curtis and Burns, 201575 Per patient contact lasting
11.7 minutes
Practice nurse appointment 15 Curtis and Burns, 201575 Per surgery consultation lasting
15.5 minutes
Health visitor 76 Curtis and Burns, 201575 Per visit lasting 60 minutes
Community nurse appointment 67 Curtis and Burns, 201575 Per visit lasting 60 minutes
Community paediatrician 274 NHS Reference Costs 2014
to 2015, 201574
Non-admitted face-to-face
attendance
Physiotherapy appointment 80 NHS Reference Costs 2014
to 2015, 201574
Per one-to-one child session
Other 93 Average of community care visits
A&E, accident and emergency; cc, complication score; EUA, examination under anaesthetic; HRG, Healthcare Resource Group.
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were not available in any of the secondary data sources consulted. Therefore, we replicated the ‘bottom-up’
costing survey conducted in a recent cost-effectiveness analysis of the Birthplace in England programme to
estimate the unit costs for these items.73 A bottom-up costing proforma was circulated to all trial midwives to
complete. These were then followed up with face-to-face interviews. The proformas represented a detailed
approach to capturing all possible NHS resources used in the care of the mother and baby during the period
between admission and discharge. A working document was generated to capture the generalisability and
variability of the procedures. For each scenario, the trial midwife was asked to describe in detail the ‘standard
procedures’ that would be undertaken for labour and birth events and, when possible, the typical ratios of
‘staff-to-woman’ care. Scenarios were then varied between the least and the most complex, and included a
description of the associated change in activity, staffing level and related resource use. Each of the interviews
included approximately 1.5 hours of structured time. The data were then compiled into comparative resource
use spreadsheets and were cross-referenced. The original unit costs (calculated for the Birthplace in England
study) were then revised to be trial specific. The cost associated with total body cooling was not available in the
Personal Social Services Research Unit or NHS reference costs data and was extracted from a study investigating
the cost-effectiveness of total-body hypothermia plus intensive care versus intensive care alone to treat NNE.76
All costs were expressed in 2014–15 GBP inflated to this base using the most up-to-date Hospital and
Community Health Service inflation index.77 Costs incurred between 12 and 24 months’ follow-up were
discounted at an annual rate of 3.5%, as recommended by current guidance.78
Cost analysis
Categories of resource use and associated costs are presented separately for mothers and their babies.
Quantities of resource use in each category were multiplied by the corresponding unit cost to estimate the
cost in a particular category. This was then averaged across each trial arm to obtain a mean cost per mother
or baby. Costs from post-birth discharge to 12 months, and then from 12 to 24 months’ follow-up, were
combined to estimate the overall costs at 2 years post birth. The total costs for the following categories are
presented separately for the mother–baby dyad: trial entry to hospital discharge, community professional
visits and secondary care. Given that we present the economic evaluation as a cost–consequences analysis,
and that the numbers of participants used to estimate costs to hospital discharge and to 2 years’ follow-up
were different, an overall total cost over the trial period was not calculated. Analyses were by ‘intention to
treat’, indicating that the costs incurred were attributed to the original trial arm.
A conditional two-stage top-down costing approach was designed to cost prescribed medications for
mothers or their babies. In the first stage, the proportion of mothers or babies with prescribed medications
and the number of courses received were compared between trial arms. Were statistically significant
differences to be observed between the groups, a microcosting method would be followed to cost the
type of medication and the number of courses received on an individual basis. No statistically significant
differences in the medications or the number of courses prescribed were observed between the groups
and the cost of medication was excluded from the analysis.
Health outcome measures
The two primary outcomes of the trial were a composite of poor neonatal outcome and the PARCA-R
composite score at age 2 years. These were used for the cost–consequences analysis. PARCA-R information
was collected on a subset of infants selected from those without the composite primary outcome at birth. The
parents of all babies born without the primary outcome in the first and second years of the trial were sent
follow-up questionnaires. This was to maximise the effort to reach the sample size of approximately 7000 at
24 months’ follow-up by the end of the recruitment period for the larger trial. The subset of participants
completing PARCA-R questionnaires and those completing the questionnaires collecting health-care resource
use and maternal HRQoL data overlapped, with some women receiving both questionnaires.
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The maternal HRQoL information was collected using the EuroQol-5 Dimensions, three-level version
(EQ-5D-3L), at 12 and 24 months’ follow-up.79 The EQ-5D-3L is a multiattribute generic instrument
widely used in the conduct of cost–utility analysis of competing technologies and is recommended by
reimbursement organisations such as NICE.78 It has two components: a descriptive system and a ‘feeling
thermometer’ using a visual analogue scale. The descriptive system covers five dimensions (mobility,
self-care, usual activity, pain/discomfort and anxiety/depression), with each dimension including three levels
(no problem, some problems and extreme problems). The EQ-5D-3L identifies 243 different health states
that can be converted into a preference-based score using a value set obtained from a representative
sample of the UK general population.80
Statistical analysis
Health-care resource use between treatment arms was compared using RRs for binomial variables and
mean differences for continuous covariates. Costs and EQ-5D-3L scores were compared using mean
differences between treatment arms. Parametric and non-parametric methods accurately estimate the true
SEs of means when large sample sizes for continuous variables are used even when the data are highly
skewed.81 Hence, mean resource use, cost and EQ-5D-3L score differences, and their associated uncertainty
between the INFANT decision support and no decision support groups were estimated using parametric
methods. In line with the statistical analysis of the primary outcomes, differences between treatment arms
were adjusted using a random intercept binomial (for RRs) or linear (for mean differences) model adjusting
for the stratification factors at randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes. A 95% significance level was used in all the comparisons made.
In all categories except for two health-care resource categories (manual removal of the placenta and infant
resuscitation), the level of missing data was < 5%. Therefore, the cost analysis to the point of hospital
discharge was conducted using a complete case analysis. Nevertheless, the 12- and 24-month follow-ups
suffered from a larger number of missing data (specifically for resource use and EQ-5D-3L) and a multiple
imputation framework with a chained equation was implemented.82 This was developed using recent
guidance for handling missing data in cost-effectiveness analysis.83 We constructed an imputation model
that included covariates with complete data on trial entry characteristics (maternal age at trial entry, twin
pregnancy, gestational age at trial entry, whether the mother was nulliparous or multiparous, the baby’s
birth weight and mode of delivery), EQ-5D-3L scores and all individual categories of resource use variables
at 12 and 24 months’ follow-up. We used prediction mean matching, estimated 50 different imputations
and the imputation model was implemented separately by trial allocation. Mean estimates and estimates of
SEs were combined between imputed data sets using Rubin’s rule84 and were also adjusted using a random
intercept binomial (for RRs) or linear (for mean differences) model adjusting for the stratification factors at
randomisation (centre and twin birth) and clustering because of twins and multiple-birth episodes.
Results
Figure 41 presents the flow of participants and the sources of information used in each component of the
cost–consequences analysis. For completeness, the numbers of participants for the two primary outcomes
already reported in the CONSORT diagram in Figure 14 are also included in this flow chart. The totals of
46,042 women and 46,614 infants are those included in the analysis (i.e. excluding women with missing
consent forms and those who withdrew consent to use their data). Estimating the cost analysis to the
point of hospital discharge used all women and infants participating in the trial although there were more
missing data given the number of categories used for the calculation of costs up to this point. A subset of
12,704 women with surviving babies without the composite primary outcome were sent a questionnaire
that included the PARCA-R at the 24-month follow-up. A total of 7066 questionnaires (56%) were
received, resulting in 6707 infants with complete PARCA-R information. The health-care resource use and
maternal HRQoL follow-up questionnaire at 12- and 24-month follow-ups was circulated to a subset of
3875 women with surviving babies in the trial. A total of 2389 questionnaires (62%) were received and
multiple imputation was used to handle missing data and to present the cost analysis over the 24-month
follow-up period on 3798 women and 3875 babies.
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      n = 2106
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FIGURE 41 Flow of participants and data availability included in each component of the cost–consequences analysis.
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Tables 37 and 38 present the maternal and infant health-care resource use from trial entry to postnatal
hospital discharge. No statistically significant differences were detected in any category of resource
use assessed.
TABLE 37 Maternal health-care resource use from trial entry to hospital discharge
Resource
Trial arm
RR/mean difference
(95% CI)a
Decision support
(N= 22,987)
No decision support
(N= 23,055)
Induction, n (%) 13,516 (59.16) 13,568 (59.24) 1.00 (0.99 to 1.02)
Unknown 140 153
Episiotomy, n (%) 6396 (28.86) 6498 (29.25) 0.99 (0.96 to 1.02)
Unknown 826 840
Perineal tear, n (%)
First- and second-degree tear 8105 (36.26) 8226 (37.13) 0.98 (0.95 to 1.00)
Third- and fourth-degree tear 652 (2.95) 697 (3.15) 0.94 (0.84 to 1.04)
Unknown 881 902
Manual removal of the placenta, n (%) 396 (1.72) 421 (1.83) 0.93 (0.81 to 1.06)
Unknown 3703 3626
Medical and surgical management post birth, n (%)
Management of postpartum haemorrhage
using the Bakri technique
18 (< 0.1) 23 (< 0.1) 0.78 (0.42 to 1.45)
Management of postpartum haemorrhage
using EUA
44 (< 0.1) 49 (< 0.1) 0.90 (0.60 to 1.36)
Hysterectomy 8 (< 0.1) 5 (< 0.1) 1.61 (0.53 to 4.91)
Perineal haematoma 19 (< 0.1) 10 (< 0.1) 1.90 (0.88 to 4.09)
PPH with blood transfusion 1 (< 0.1) 2 (< 0.1) 0.50 (0.045 to 5.50)
Hospital length of stay, n (%)
Length of stay (days), mean (SD) 2 (8.87) 2 (8.33) –0.01 (–0.17 to 0.14)
Unknown 42 32
Higher level of care admissions (days), mean (SD)
High-dependency care 0.04 (0.32) 0.04 (0.24) 0.003 (–0.002 to 0.008)
Intensive care 0.00 (0.29) 0.00 (0.07) 0.001 (–0.002 to 0.005)
EUA, examination under anaesthetic.
a Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes with 95% CIs used.
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Tables 39 and 40 show the results of the maternal and infant cost analysis from trial entry to hospital
discharge. The total mean maternal costs from trial entry to hospital discharge were estimated to be
£431 (SE £7) and £433 (SE £6) in the decision support and no decision support groups, respectively; the
non-significant mean-adjusted cost difference was –£2 (95% CI –£28 to £24). The total mean infant costs
from trial entry to hospital discharge were estimated to be £2539 (SE £12) and £2541 (SE £15) in the
decision support and no decision support groups, respectively; the non-significant mean-adjusted cost
difference was £1 (95% CI –£37 to £39).
TABLE 38 Infant health-care resource use from trial entry to hospital discharge
Resource
Trial arm
RR/mean difference
(95% CI)a
Decision support
(N= 23,263)
No decision support
(N= 23,351)
Mode of birth, n (%)
Spontaneous vaginal birth 11,823 (50.82) 11,959 (51.21) 0.99 (0.97 to 1.01)
Breech birth 73 (0.31) 72 (0.31) 1.06 (0.78 to 1.43)
Ventouse vaginal birth 2522 (10.84) 2509 (10.74) 1.01 (0.96 to 1.06)
Forceps vaginal birth 3176 (13.65) 3256 (13.94) 0.98 (0.93 to 1.02)
Caesarean section 5669 (24.37) 5555 (23.79) 1.02 (0.99 to 1.06)
Resuscitation, n (%)
Initial 2139 (10.11) 2116 (9.96) 1.02 (0.96 to 1.07)
Intensive 554 (2.62) 524 (2.47) 1.07 (0.94 to 1.20)
Unknown 2113 2106
Higher level of care admissions (days), mean (SD)
Special care 0.21 (1.61) 0.23 (2.86) –0.029 (–0.07 to 0.013)
High-dependency care 0.04 (0.75) 0.04 (0.91) –0.006 (–0.021 to 0.009)
Intensive care 0.05 (0.85) 0.04 (0.64) 0.007 (–0.007 to 0.021)
Neonatal surgery, n (%) 23 (0.10) 26 (0.11)
Paediatric cardiology 7 (0.03) 5 (0.02) 1.41 (0.45 to 4.43)
Plastic surgery 5 (0.02) 10 (0.04) 0.50 (0.17 to 1.47)
Gastrointestinal surgery 10 (0.04) 11 (0.05) 0.85 (0.34 to 2.11)
Paediatric neurosurgery 2 (0.01) 0 –
Total body cooling 19 (0.1) 21 (0.1) 0.90 (0.48 to 1.69)
Intrapartum stillbirth, n (%) 1 (–) 2 (–) 0.46 (0.04 to 6.05)
Neonatal death, n (%) 6 (–) 4 (–) 1.51 (0.42 to 5.33)
a Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes with 95% CIs used.
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TABLE 39 Cost analysis of maternal health-care resource use from trial entry to hospital discharge (expressed in
2014–15 GBP)
Resource
Trial arm
Mean
difference
(95% CI)b
Decision support
(N= 22,987)
No decision support
(N= 23,055)
na Mean (SE) na Mean (SE)
Induction 22,847 102 (0.56) 22,902 102 (0.56)
Episiotomy 22,161 8 (0.08) 22,215 8 (0.08)
Perineal tear 22,106 27 (0.71) 22,153 28 (0.73)
Manual removal of the placenta 19,284 12 (0.65) 19,429 14 (0.66)
Medical and surgical management 22,987 4 (0.46) 23,055 4 (0.46)
Blood transfusion 22,987 2 (1.3) 23,055 3 (1.3)
Maternal transfer 22,987 0.22 (0.06) 23,055 0.13 (0.05)
Hospital length of stay 22,945 226 (6.07) 23,023 227 (5.69)
Higher level of care admissions
High-dependency care 22,987 49 (2.68) 23,055 45 (2.01)
Intensive care 22,987 4 (2.72) 23,055 2 (0.62)
Total maternal cost from trial entry to hospital discharge 18,777 431.3 (6.8) 18,956 432.6 (6.4) –2 (–28 to 24)
a The sample size used for calculation of means and SEs, which comprises the number of mothers with relevant data.
b Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes with 95% CIs used.
TABLE 40 Cost analysis of infant health-care resource use from trial entry to hospital discharge (expressed in
2014–15 GBP)
Resource
Trial arm
Mean
difference
(95% CI)b
Decision support
(N= 23,263)
No decision support
(N= 23,351)
na Mean (SE) na Mean (SE)
Mode of birth 23,263 2334 (5.88) 23,351 2322 (5.82)
Resuscitation 21,150 8 (0.19) 21,245 8 (0.19)
Neonatal surgery
Paediatric cardiology 23,263 1 (0.44) 23,351 0.83 (0.37)
Plastic surgery 23,263 0.39 (0.18) 23,351 0.78 (0.25)
Gastrointestinal surgery 23,263 1.6 (0.50) 23,351 2 (0.50)
Paediatric neurosurgery 23,263 0.09 (0.07) 23,351 0
Total body cooling 23,263 5 (1.20) 23,351 6 (1.26)
Neonatal death 23,263 0.18 (0.07) 23,351 0.12 (0.06)
Higher level of care admissions
Special care 23,263 99 (5.13) 23,351 114 (9.11)
High-dependency care 23,263 36 (4.21) 23,351 41 (5.05)
Intensive care 23,263 54 (6.61) 23,351 46 (5.00)
Total infant cost from trial entry to hospital discharge 21,150 2539.3 (12.4) 21,245 2540.9 (14.9) 1 (–37 to 39)
a The sample size used for calculation of means and SEs, which comprises the number of mothers with relevant data.
b Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes with 95% CIs used.
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Table 41 presents the results of the maternal health-care resource use and associated costs over 24 months
since hospital discharge. A significant adjusted mean cost difference of –£166 (95% CI –£319 to –£12) was
observed in secondary care admissions for mothers, favouring the decision support group. Such difference
was driven by slightly more admissions to all units in the no decision support group since hospital discharge.
However, when adding up all categories of costs (community plus secondary care), the total mean (SE)
maternal follow-up costs were estimated to be £753 (SE £35) and £904 (SE £77) in the decision support
and no decision support groups, respectively; the non-significant mean-adjusted cost difference was –£149
(95% CI –£314 to £16). Table 42 reports similar information for the infants. None of the categories of costs
or overall costs resulted in any statistically significant difference between the groups of infants.
Maternal HRQoL EQ-5D-3L scores at 12 and 24 months’ follow-up are presented in Table 43. Mothers
reported scores similar to the population norm for English females aged 25–34 years (currently a mean of
0.925 using the EuroQoL EQ-5D-3L index85) in both groups and, therefore, no statistically significant mean
differences in scores were observed at any follow-up point.
TABLE 41 Maternal health-care resource use and associated costs (expressed in 2014–15 GBP) from hospital
discharge to 2 years’ follow-up using multiple imputation
Resource
Trial arm
Mean cost difference
(95% CI)a
Decision support
(n= 1908)
No decision support
(n= 1890)
Mean
resource
use (SE)
Mean
cost (SE)
Mean
resource
use (SE)
Mean
cost (SE)
Community professional visits
General practice 5.30 (0.16) 234 (7) 5.01 (0.12) 222 (5) 12 (–6 to 30)
Practice nurse 1.48 (0.08) 21 (1) 1.23 (0.06) 18 (1) 4 (1 to 6)*
Community nurse 0.16 (0.04) 11 (2) 0.25 (0.06) 17 (4) –5 (–14 to 3)
Physiotherapy 0.61 (0.07) 23 (2) 0.67 (0.08) 25 (3) –2 (–9 to 6)
Hospital community counselling 0.12 (0.03) 6 (2) 0.12 (0.03) 6 (1) –0.09 (–5 to 4)
Other community professionals 1.09 (0.10) 46 (4) 0.90 (0.10) 38 (4) 8 (–3 to 20)
Total community professional visits 341 (11) 325 (10) 171 (–14 to 48)
Secondary care
Outpatient visits 0.98 (0.06) 107 (7) 0.88 (0.07) 96 (8) 11 (–9 to 31)
A&E visits 0.35 (0.03) 58 (5) 0.35 (0.03) 57 (5) 1 (–13 to 14)
Intensive care unit (nights) 0.00 (0.00) 0 (0) 0.04 (0.02) 59 (34) –60 (–128 to 9)
High-dependency ward/unit (nights) 0.05 (0.02) 58 (19) 0.11 (0.04) 120 (41) –61 (–147 to 25)
General ward (nights) 0.42 (0.05) 43 (5) 0.47 (0.05) 48 (5) –4 (–20 to 11)
Other admissions 0.18 (0.03) 87 (14) 0.29 (0.06) 140 (28) –52 (–114 to 10)
Day case 0.06 (0.01) 59 (8) 0.06 (0.01) 59 (8) 0 (–23 to 23)
Total secondary care 412 (30) 580 (73) –166 (–319 to –12)*
Total maternal follow-up 753 (35) 904 (77) –149 (–314 to 16)
*p < 0.05.
A&E, accident and emergency.
a Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes with 95% CIs used.
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TABLE 42 Infant health-care resource use and associated costs (expressed in 2014–15 GBP) from hospital discharge
to 2 years’ follow-up using multiple imputation
Resource use
Trial arm
Mean cost difference
(95% CI)a
Decision support
(n= 1940)
No decision support
(n= 1935)
Mean
resource
use (SE)
Mean cost
(SE)
Mean
resource
use (SE)
Mean cost
(SE)
Community professional visits
General practice 6.72 (0.16) 297 (7) 6.86 (0.16) 303 (7) –6 (–25 to 14)
Practice nurse 0.88 (0.06) 12 (0.81) 0.81 (0.04) 12 (0.63) 0.99 (–1 to 3)
Health visitor 1.44 (0.11) 107 (8) 1.48 (0.10) 110 (7) –2 (–23 to 19)
Community nurse 0.20 (0.03) 13 (2) 0.18 (0.04) 12 (2) 2 (–4 to 8)
Community paediatrician 0.31 (0.03) 84 (9) 0.31 (0.03) 84 (9) 3 (–23 to 28)
Physiotherapy 0.14 (0.03) 11 (2) 0.32 (0.07) 25 (5) –14 (–26 to –2)
Other community professionals 0.54 (0.06) 49 (5) 0.63 (0.08) 58 (7) –8 (–24 to 9)
Total community professional visits 575 (20) 603 (21) –24 (–82 to 34)
Secondary care
Outpatient visits 1.36 (0.08) 242 (15) 1.25 (0.07) 223 (12) 24 (–14 to 62)
A&E visits 1.14 (0.05) 188 (9) 1.01 (0.04) 167 (7) 21 (–2 to 44)
Intensive care unit (nights) 0.17 (0.05) 201 (58) 0.18 (0.06) 205 (69) –3 (–187 to 181)
High-dependency ward/unit
(nights)
0.20 (0.05) 131 (35) 0.12 (0.03) 78 (21) 53 (–29 to 134)
General ward (nights) 0.61 (0.06) 63 (6) 0.56 (0.05) 58 (6) 4 (–12 to 21)
Other admissions 0.12 (0.03) 88 (21) 0.07 (0.02) 51 (14) 37 (–14 to 87)
Day case 0.05 (0.01) 32 (5) 0.06 (0.01) 40 (6) –8 (–23 to 7)
Total secondary care 945 (90) 822 (80) 128 (–120 to 375)
Total infant follow-up 1520 (100) 1425 (92) 104 (–174 to 382)
A&E, accident and emergency.
a Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes with 95% CIs used.
TABLE 43 Maternal HRQoL using EQ-5D-3L scores at 12- and 24-month follow-up using multiple imputation analysis
EQ-5D-3L follow-up point
Trial arm
Mean difference
(95% CI)a
Decision support
(n= 1908)
No decision
support (n= 1890)
Mean
score SE
Mean
score SE
12 months 0.908 0.005 0.913 0.005 –0.005 (–0.020 to 0.012)
24 months 0.909 0.006 0.919 0.005 –0.008 (–0.023 to 0.007)
a Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes with 95% CIs used.
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A summary of the different components included in the cost–consequences analysis is reported in Table 44.
For each of the maternal and infant total mean cost components from trial entry to hospital discharge and
over 24 months’ follow-up since hospital discharge, no statistically significant differences were observed
between the groups. Similarly, no statistically significant mean differences were observed between the
groups in any of the consequences evaluated; the composite primary outcome, PARCA-R and maternal
quality-of-life scores.
Discussion
Presentation of the results
The findings of the clinical study in Chapter 6 showed no differences in the composite primary outcomes
at birth, or in PARCA-R composite scores at 2 years. Given these findings, we chose to present the results
of our economic evaluation (using the clinical outcomes reported previously) with a cost–consequences
analysis. Our statistical analysis plan refers to the estimation of a cost-effectiveness analysis, but with no
differences in costs or effects between the groups, there was no evidence of differences between the
groups to generate this. A cost–utility analysis could not be conducted, owing to the lack of HRQoL
data at baseline and postnatally, to derive quality-adjusted life-years. Given the overall trial results,
we considered that presenting the data in a disaggregated manner to show the costs and benefits
(consequences) for different time periods provides the most useful information to complement the
clinical findings.
The study was conducted at multiple labour ward sites across England, Scotland and the Republic of
Ireland, with differing configurations of care and economies of scale strengthening the generalisability of
our results. A useful ancillary benefit of this study is that it provides detailed costs of intrapartum care,
which contributes to the broader field of evidence available for health economic evaluations in the
perinatal research arena.
TABLE 44 Summary of the different components included in the cost–consequences analysis alongside the INFANT
study (2014–15 GBP)
Component
Trial arm, mean estimate
Mean difference
(unless otherwise
stated) (95% CI)aDecision support
No decision
support
Costs (2014–15 GBP)
Total maternal from trial entry to hospital discharge 431 432 –2 (–28 to 24)
Total infant from trial entry to hospital discharge 2539 2540 1 (–37 to 39)
Total maternal follow-up 753 904 –149 (–314 to 16)
Total infant follow-up 1520 1425 104 (–174 to 382)
Consequences: infant
Composite primary outcome, n (%) 172 (0.7) 171 (0.7) RR: 1.01 (0.82 to 1.25)
PARCA-R score 98.0 97.2 0.63 (–0.98 to 2.25)
Consequences: maternal
EQ-5D-3L 12 months 0.908 0.913 –0.005 (–0.020 to 0.012)
EQ-5D-3L 24 months 0.909 0.919 –0.008 (–0.023 to 0.007)
a Adjusted for stratification factors used in the randomisation (centre and twin birth) and clustering because of twins and
multiple-birth episodes with 95% CIs used.
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Findings
Both the clinical and cost–consequences analyses did not identify statistically significant differences between
the trial arms. There were also no differences in the direction of costs, namely a consistent pattern of cost
increase in one trial arm compared with the other. Within the cost categories there were small differences,
such as secondary care for mothers post birth, but, overall, the differences between groups did not reflect a
direction. We had anticipated that a decision support tool to prevent poor perinatal outcomes might have
lifelong effects, that these could be modelled using decision-analytic or Markov models, and that ‘obstetric
litigation costs averted’ would have been a key cost driver. Nevertheless, there were no differences in cost
or effectiveness to model between the arms of the trial to 24 months post birth and for the longer term.
Research was undertaken during the study to identify a composite ‘quality of care’ variable that would
identify substandard (and potentially negligent) clinical care during birth. The consistent and methodical
documentation of birth information captured in the Guardian system and decision support software
(INFANT) might assist an interrogation of the ‘quality-of-care’ for clinical staff and may be useful in future
studies. The software did not assist research for a longer-term cost-effectiveness study here but it has the
potential to shorten an obstetric litigation process and even potentially to alter the outcome of some cases.
This hypothesis is currently untested and may be relevant for future research.
The trial was not designed to assess the cost and benefit of the Guardian system and the value it provides
for labour ward staff. No research was undertaken to explicitly cost Guardian separately from the decision
support tool (INFANT). However, we did probe whether or not the combined information display (at the
patient’s bedside, centrally or remotely) and the interaction with the decision support tool caused a cost
shifting or change to practice for staff for efficiency purposes. We conducted informal interviews at
11 out of 23 sites, which were all sites where research midwives agreed to discuss the health economics
component including whether or not the sites had:
l installed Guardian for the study and had changed to be wholly paper-free, using it for all births since
the start of the trial
l installed Guardian for the study, but did not use it consistently in the ward
l used Guardian prior to and after the trial for all births.
In summary, feedback from the interviews was consistent across the sites. Interactions with Guardian and
the decision support (INFANT) system produced negligible changes and affected clinical staff differently.
Midwives generally reported no change to practice but stated that the alarms during the second stage of
labour sometimes distressed patients and might require additional checks or review, or even the option to
switch off the software. There were a few reports of increased visits to the ward by clinical staff, querying
yellow and red alerts. Most midwifery co-ordinators reported that the convenience and accessibility of the
display platforms increased time efficiency for staff co-ordination and allocation. Clinicians reported that,
although the duration of their staff shift did not change, they had greater flexibility around location
(with an increased freedom to be desk based, enabling work time to be more productive). Central hospital
information technology staff identified an increase in their staff time dedicated to the labour ward, providing
technical support to the midwifery and medical staff. It was difficult to separate out the impact of Guardian
and decision support (INFANT) for this particular activity, as both collect and display information. However,
there did not seem to be a striking change to the workload models for clinical staff, for cost shifting or
efficiency. Having documented the findings of this research question, we did not attribute a cost impact.
Limitations
As discussed, the economic evaluation presented here was originally intended to be a cost-effectiveness
analysis. The incremental cost-effectiveness ratio (ICER) was to be expressed as an incremental cost per poor
perinatal outcome prevented (at hospital discharge following birth). Two longer-term cost-effectiveness
analyses were planned: (1) to estimate the cost-effectiveness of the decision support software (INFANT) when
surviving children reached 2 years of age and (2) to incorporate lifetime cost and health consequences of
the decision support software (INFANT) for the mother and child within an economic modelling framework.
Given that there were no statistically significant differences between costs and outcomes at post-birth
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discharge or at 24 months, we would not add value to this research with a longer-term framework.
A cost-effectiveness analysis in the short term to include the cost of the software would only make the INFANT
software more expensive and, thus, less cost-effective. Our original plan to perform multiway sensitivity
analyses, to estimate and value the initial and annual maintenance fees for the decision support tool (INFANT),
would make the decision support arm more expensive. As stated earlier, several strategies had been developed
to estimate the additional software costs (apportioned per birth) via estimates of installation and maintenance
fees or via a commercial strategy by K2 Medical Systems, but given the findings in the trial, we did not pursue
a final cost estimate for the INFANT software.
The study is limited by different components of missing data. The trial suffered a large loss to follow-up;
46% of women contacted at 12-month follow-up and 38% of women contacted at 24-month follow-up
returned questionnaires. Although numerous methods and substantial effort was invested to increase the
response rate, it was an unsurprising outcome. Labour is a life-changing but acute event, and the majority
of the women in this study had uncomplicated pregnancies and a fairly straightforward labour (albeit
requiring EFM during the event). Most also had healthy babies so we surmise that they would not have felt
an innate need to personally ‘invest’ in the study, in a manner equivalent to suffering a severe long-term
illness. We also identified women pregnant with their second baby while completing questionnaires about
their first, reflecting a progression in their life stage from the original birth event. Our only contact with the
women was via postal address and, with limited resources, once this connection was lost as a result of
residential change, we were not able to trace them further. Finally, conversations with research midwives
revealed that, although recruitment into the trial was explicitly and clearly communicated to women and
their partners, and consent was required for participation, many would not have identified the use of the
decision support software (INFANT) separately from their overall birth experience. It was primarily used by
midwives and would have been associated with other clinical activity, such as documenting patient
information into the system.
As described throughout this chapter, we resolved the issue of missing data in different ways. We ensured
that missing data are noted in detail throughout, in the flow chart (see Figure 41), in each table of resource
use and in the final cost analyses (see Tables 37 and 38). For the 12- and 24-month follow-ups, we account
for missing data using multiple imputation techniques.
Value of this research
This cost–consequences analysis fills an evidence gap regarding the use of computerised interpretation
of the CTG in women receiving EFM during labour. It identifies and presents all the key resource use
associated with the intervention. It also adds evidence to a growing body of unit cost information collected
through primary sources for perinatal care.
Economic evaluation adds value to research by providing decision-makers with information that
systematically considers all the evidence, balances trade-offs to ensure that health care provides value for
money and explores uncertainty around key cost drivers and health outcomes. We have captured and
combined the key clinical and cost impacts of the decision support software (INFANT). Based on the results
presented in this chapter and previous chapters, there is no evidence to support the use of computerised
interpretation of the CTG in women in the UK and the Republic of Ireland.
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Chapter 8 Discussion and conclusion
In this trial of 46,000 women, there is no evidence of a difference in the risk of a poor neonatal outcomeusing CTG interpretation software to support decision-making. Another randomised trial (of 7730 women),
which evaluated the use of decision support in women who were monitored during labour using fetal ECG
monitoring, also found no evidence that CTG interpretation decision support improved the primary outcome
of cord blood metabolic acidosis.86
Using a composite primary outcome is not always helpful if different components of the outcome
respond differently to the intervention. If one component of the composite dominates the others, then
effectively the trial results reflect any differences detected within this dominant component.87 We initially
hypothesised that the indicence of components of the composite outcome (extended perinatal mortality,
NNE and prolonged admission to a neonatal unit following birth in a poor condition) would be similar,
with each component likely to contribute approximately one-third to the composite.
Estimates of the incidence of the components of the primary outcome for the eligible study population
were difficult to find before the trial commenced.1 The observed perinatal mortality in the study (stillbirth
and neonatal death, excluding lethal congenital anomalies) was lower than the prior estimate (13/46,614
births or 0.3 per 1000 births vs. 1.05 per 1000 births), and the incidence of NNE requiring cooling was
also lower (39/46,614 births or 0.8 births per 1000 births vs. 1.3 births per 1000 births see Chapter 2).
However, prolonged neonatal unit admission with evidence of compromise at birth, for which we had no
good data at the time the trial was planned, occurred more frequently than expected (291/46,614 births
or 6 per 1000 births), contributing substantially to the higher than anticipated overall primary event rate of
7 per 1000 births, compared with our estimated 3 per 1000 births. This allowed us to have the power to
detect more modest differences in the composite outcome than we had originally planned.
The very low numbers of perinatal deaths and longer-term adverse outcomes, such as cerebral palsy, mean
that this trial is unable to rule out even large differences in these individual outcomes. However, given this
very low event rate, the numbers needed to treat to prevent one perinatal death would be very substantial
even if the intervention was effective.
The strength of this study lies in its contemporaneous data collection and its size, the latter being designed
to detect differences in substantive perinatal outcomes, as well as in more frequent outcomes such as
cord metabolic acidosis and operative delivery. Potential weaknesses include the potential for staff to learn
from exposure to the decision support arm of the trial, resulting in improved outcomes in the control arm.
This potential weakness was identified when the trial was being planned. We acknowledged that passive
learning from the decision support system was possible and the only way to completely rule out this effect
would be to conduct a cluster randomised trial. Such a design was unfeasible given the limited number of
centres with the Guardian system in the UK and Republic of Ireland and the very low incidence of the
primary outcome measure. Moreover, part of our prior hypothesis was that, although some poor CTG
interpretation is as a result of a lack of training, some clinicians have a poor intrinsic pattern recognition
ability that is not susceptible to improvement by training. Such an intrinsic disability would, by definition,
not be affected by training, and the performance of such clinicians would be particularly improved by
assistance from automatic interpretation. Therefore, we collected a range of process outcomes to measure
the impact on clinician behaviour during the trial. There was some evidence that clinical behaviour was
changed in the decision support arm of the trial: the incidence of fetal blood sampling was higher in the
decision support group (10.3% vs. 9.5% in the no decision support group) and the incidence of repeated
yellow alerts was lower (0.35 per hour vs. 0.40 per hour in the no decision support group). It may be that
different action was taken in response to the alerts in the decision support arm of the trial, for example
the clinicians might have reduced the dose of an oxytocin infusion in women having their labour
augmented if this was leading to very frequent contractions, or changed maternal position if the CTG
abnormality resulted from vena caval compression. Such actions could have prevented further yellow alerts,
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leading to a decrease in this group, but we do not have any direct evidence showing that this was the
case. Even if it was, it did not result in any significant change in clinical outcomes. Another potential
weakness is that the UK and Republic of Ireland setting, where EFM is not routine,21 makes generalisability
of the findings to settings where EFM is routine more uncertain.
Detecting abnormalities in the fetal heart rate can only improve outcome if caregivers respond
appropriately to the alerts. An expert panel reviewed all severe adverse outcomes in the trial and found no
evidence that there were differences in suboptimal care between the two groups. Therefore, we conclude
that our hypothesis, that substandard care is largely related to failure to identify pathological fetal heart
rate patterns, is not supported. It appears that most adverse outcomes associated with preventable
substandard care involved a failure to take appropriate management decisions once the CTG abnormality
had been recognised. This aspect will be reported on in detail in a follow-up paper. Our hypothesis that
unnecessary intervention would be reduced was also not supported.
The decision support software used in this trial clearly identifies most fetal heart rate abnormalities.35–37
However, the alerts do not take into account other information about the labour, such as the duration of
labour, the rate of labour progress, presence of meconium, whether or not the woman has an elevated
temperature and whether or not there is suspected fetal growth restriction, all of which may modify the
way a clinician interprets the fetal heart rate and acts on this information. Further development of decision
support software to include these variables may improve the quality of the feedback the system provides
to clinicians and therefore may make a positive difference to outcomes. Given the importance of the
consequences of intrapartum hypoxia for parents, clinicians and health services, there continues to be an
urgent need to improve knowledge and training about the appropriate response to CTG abnormalities,
including timely intervention.
Currently, there is no evidence to support the use of computerised interpretation of the CTG in women
who have EFM in labour to improve clinical outcomes for mothers or babies.
DISCUSSION AND CONCLUSION
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Appendix 5 Data collection form for a baby
admitted to a neonatal unit
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Appendix 6 Data collection form for a baby with
neonatal encephalopathy
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Appendix 7 Data collection form for a
neonatal death
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Appendix 8 Data collection form for a mother
admitted to a higher level of care
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Appendix 9 Two-year follow-up questionnaire
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Appendix 10 Economic evaluation analysis plan
INFANT economic evaluation analyses plan
Liz Schroeder
February 2014
Glossary
CEA cost-effectiveness analysis
CUA cost–utility analysis
ICER incremental cost-effectiveness ratio
QALY quality-adjusted life-year
Aims of the INFANT Health Economic Evaluation
As shown above, determining whether or not the use of the decision support software is cost-effective for
the management of labour and birth is an objective of the trial. This objective will be met through
component studies that address specific research questions (aims).
Firstly to consider the incremental cost of an adverse perinatal outcome prevented at hospital discharge.
However, this outcome is likely to have longer-term consequences in terms of health status and health
service utilisation over the infant’s lifetime. Two longer-term evaluations are therefore planned.
In the first instance to estimate the cost-effectiveness of the decision support when surviving children reach
age 2 years (aim 2), estimated as the incremental cost per disability free life-years gained at 2 years. These
estimates will be informed with individual patient level data collected from parents participating in the
INFANT trial.
Secondly, to extrapolate long-term outcomes and costs over a lifetime expressed as an incremental cost
per quality-adjusted life-year (QALY) gained using decision–analytic modelling techniques (aim 3).
Finally, to explore the potential effect of the intervention on litigation claims for obstetrics (aim 4) in a
‘stand-alone’ study.
These aims are shown in the following table (Table 45).
Methods
Data collection
A prospective economic evaluation is being conducted alongside the trial, with the aim of estimating the
cost-effectiveness of the intelligent decision support software. Information on resource utilisation will be
collected through the Guardian data collection system, hospital-patient administration and maternity
information systems. Observational research methods will be used to collect additional costs in intrapartum,
postpartum or neonatal care for the first analysis (study aim 1).
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Postal questionnaires sent to parents at 1 year and 2 years post discharge collect resource use data for the
health service over that period (study aim 2).
Decision-analytic modelling methods (or Markov methods if required) synthesising primary INFANT and
secondary cost and epidemiological data will be used to estimate the cost-effectiveness of longer-term
outcomes (study aim 3).
A stand-alone study exploring litigation for obstetrics in the NHS and the potential effect that this
intervention may have, using current primary data sources provided by the NHS LA and outcomes from the
trial will also be undertaken (study aim 4).
The recruitment of study participants and data collection for the health economics can be viewed in the
following flow chart (Figure 42).
Brief overview of cost-effectiveness analysis and cost–utility analysis
Cost-effectiveness analysis (CEA) is a form of economic evaluation that compares the relative costs
and outcomes (effects) of two or more courses of action, using a common outcome measure. In
cost-effectiveness analyses, the costs are expressed in monetary units, while benefits are expressed in
natural or physical units, such as survival, physical abilities and health-related quality of life. CEA involves
calculating the difference in costs and difference in outcomes between the health-care interventions being
compared, and then expressing these as a ratio. Typically the ratio is measured as a value where the
denominator is a gain in health from a measure (years of life, premature births averted) and the numerator
is the cost associated with the health gain. The ICER represents the additional cost of one unit of outcome
gained by a healthcare intervention or strategy, when compared with the next best alternative, mutually
TABLE 45 Aims of the INFANT economic evaluation
Aim
1 2 3 4
Outcome measure Poor perinatal
outcome averted
Disability-free life-years ‘derived’ QALYs (using
clinical diagnosis of
mild, moderate or
severe outcomes at
2 years)
Predicted changes
in obstetric claims
(modelled scenarios)
Timeframe Initial hospital
discharge
2 years Long term (e.g.
lifetime/18-year time
horizon)
Long term (e.g.
lifetime/18-year time
horizon)
Data 47,112 women 5–7000+ all primary
outcome cases (for
which we have 2-year
outcome data)
As in (1) &
(2)+ secondary
information derived
from literature reviews –
mapping economic
data between health
states obtained from
literature
Use of INFANT data
for possible changes
to baby outcomes,
modelled scenarios
using litigation
information from
the NHS LA
1500 for resource use
data
Data collection Guardian system,
hospital information
system + observational
data
As in (1) + parent
questionnaires at
1 and 2 years
As in (1&2) + literature
reviews
As in 3, + NHS LA
10-year litigation data
Analysis Intention-to-treat
analysis, ICERs and
net benefit statistics
presented using non-
parametric statistical
methods with 95%
confidence ellipses
As in (1) Extrapolation model
for long-term
outcomes (+ decision-
analytic modelling +
sensitivity analysis)
Modelled scenarios of
changes to clinical
practice; baby
outcomes; modelled
longer-term outcomes
and litigation payouts
PARCA-R defined
predictors of mild,
moderate and severe
disability mapped to
disability-adjusted
life-years
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exclusive intervention or strategy. Three incremental cost-effectiveness ratios, or ICERs, will represent the
additional cost of one unit of outcome gained by the incorporation of the intelligent decision support
system for the management of women who are judged to require continuous electronic fetal monitoring
(EFM) compared with current clinical practice. These are the incremental cost of poor perinatal outcome
prevented at hospital discharge, the incremental cost per disability free life-years gained at 2 years and the
incremental cost per quality-adjusted life-year (QALY) gained at 18 years. A threshold value is often set by
policy makers, who may decide that only interventions with an ICER below the threshold are cost-effective
(and therefore should be funded). Various thresholds around £20,000/QALY and £40,000/QALY gained
will be explored in the analysis.
Economic evaluation design issues for INFANT study aims 1 and 2
(within-trial economic evaluation)
Trial design
INFANT is a multicentre individually randomised controlled trial of 47,112 women who are judged to
require continuous electronic fetal monitoring in labour. It is a two-arm parallel trial with one arm allocated
to CTG monitoring with decision support and one arm allocated to CTG monitoring only. At 2 years after
trial entry, a random sample of 5000–7000 children (2500–3500 in each group) are followed up at
Mothers (n = 46,000)
Mothers (n = 23,000)
No decision support
Mothers (n = 23,000)
Decision support
Outcomes (n = 23,000)
(data collected by Guardian +/–a)
Research midwife until
hospital discharge
Outcomes (n = 23,000)
(data collected by Guardian +/–a)
Research midwife until
hospital discharge
Mothers who did
NOT give consent for
any further contact
 (n = xc)
Mothersb who did
NOT give consent for
any further contact
 (n = xc)
Mothers who did
give consent for
further contact
 (n = xc)
Mothersb who did
give consent for
further contact
 (n = xc)
Mothers contacted to
conduct PARCA-R +
health questionnaire
at 2 years
(n = 2500–3500)
Mothers from the first
year’s recruitment
contacted to complete
health economics 
questionnaire at 12 
and 24 months
(n ≈ 750)
Mothers from the first
year’s recruitment
contacted to complete
health economics 
questionnaire at 12 
and 24 months
(n ≈ 750)
Health economics will
study all those with a
poor neonatal outcome – 
we will be unable to
do this for:
(a) those that do not
agree to any further
follow-up other than
data collection to
hospital discharge
(b) those recruited in
INFANT Trial years 2 and 3
FIGURE 42 Flow chart depicting recruitment and data collection for INFANT health. a, +/– represents with or
without additional data collected by the midwife as necessary. b, Only mothers recruited during the first year
of the trial so that follow-up of this group can be completed around the time that the trial stops recruiting.
c, x represents the actual numbers that would be collected.
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2 years. This sample is taken from within the sample recruited during the second year of the trial so that
follow-up of this group can be completed around the time that the trial stops recruiting.
For the economic evaluation, a subsample of approximately 750 infants from each trial arm randomly
selected within the second year, as well as all babies with the primary outcome who survive to hospital
discharge, are followed up at 1 and 2 years for resource use data in order to estimate the incremental cost
per disability free life-years gained at 2 years. Decision-analytic modelling techniques will be used to
extrapolate cost-effectiveness over a lifetime.
Time horizon and perspective of the INFANT economic evaluation
The economic evaluation will be conducted from a health service perspective and therefore only direct
costs to NHS hospital providers will be included. Societal costs, such as travel time and lost productivity to
families will not be captured. (Estimates of the longer-term costs of care including litigation costs are
discussed in Economic evaluation design issues for INFANT study aim 3 (modelling longer-term outcomes)
and Economic evaluation design issues for INFANT study aim 4 (modelling clinical scenarios that will impact
on obstetric litigation claims).
Sample size and power
The sample size of the INFANT economic evaluation is based on the primary clinical outcomes of the
INFANT trial, which is currently a pragmatic approach to the determination of sample size and power
calculation. Different techniques have been proposed for the estimation of statistical power and sample
size for economic evaluation in randomised trials, but current practice tends to prefer power calculations
based on primary clinical outcomes. This is partly because of the complexity of trying to predict the main
outcome of interest to economists, which is the joint distribution of the difference in costs and benefits
between treatment arms.6
Study end points
In the baseline study (study aim 1), we are using an intermediate outcome (poor perinatal outcome
prevented at hospital discharge) and hence additional resource use and unit cost data are needed to
capture longer-term costs and outcomes. This is the purpose of the study at 2 years where the outcome
measure is quantified in terms of disability free life-years gained (study aim 2) and for the extrapolation of
longer-term outcomes expressed as QALYs over a lifetime or to 18 years (study aim 3).
Database design and management
Collection and management of the economic data are fully integrated with the management of the clinical
data and, as such, there will be no distinction between the data sets for study aim 1. Ongoing data quality
monitoring occurs timeously to address missing and poor-quality data issues. Data queries are consistently
managed to maximise data completeness and quality. The data formatting procedures needed for the
economic analysis were prespecified such that the transfer of all necessary data for the economics study is
timely, and the design and piloting of the data capture system is complete. Double data entry for the
12- and 24-month parental questionnaires is in process.
Collection and measurement of trial costs
Trial costs/resource use
The economic evaluation focuses on main cost drivers (such as days spent in intensive care) as well as
resources that are expected to differ between the trial arms. All resource use including intervention related
resources will be included in the cost analysis. Table 46 documents the resource use data identified for the
health economics component.
For each resource, the level of aggregation will be prospectively determined. As an example, inpatient
hospitalizations might be considered in disaggregated units, such as staff time, or in highly aggregated
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TABLE 46 Resource use identified in the INFANT economic evaluation
Resource use variable
Trial arm, Mean resource use (SE)
Unit cost (£)Intervention group Standard care group
Inpatient stay
Intensive care (level 1)
High-dependency care (level 2)
Special care (level 3)
Ordinary care (level 4)
Cooling (additional to IC care)
Readmission after initial discharge
Associated with transfer (number of transfers)
Transfer
Community resource use in first year (visits)
General practitioner
Health visitor
Practice nurse
Community nurse
Community paediatrician
Physiotherapist
Community resource use in second year (visits)
General practitioner
Health visitor
Practice nurse
Community nurse
Community paediatrician
Physiotherapist
Resource use of mother
Inpatient stay
Inpatient stay ward
Inpatient stay IC
Additional investigations
Radiography
Ultrasound scans
Surgery
Other procedures (number of)
Associated with transfer (number of transfers)
Transfer
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units, such as numbers of hospitalizations or days in the hospital. A mixed case approach to costing will be
used, dependent on resource use patterns expected, and availability of national standardised cost data
(from Department of Health reference costs, typically used in economic evaluations). Items will be captured
in disaggregated units where relevant, and such costing is typically labelled ‘bottom up’. This will be
achieved by asking midwives/clinicians to document relevant staffing, medications and equipment. They
will then be sent a micro-costing sheet to correct with their own resource components (Table 47) which
will be very detailed, capturing all resource components that might be used. Further information will also
be captured during formal interviews to include cost of the intervention itself, including the potential
impact on staff working patterns.
Total cost will be measured by multiplying unit costs to resource use data. Unit costs are the cost per
standard unit. Unit costs will be consistent with measured resource use, the study’s perspective, and its
time horizon (for instance valued at 2012 prices). In some cases, unit costs will be estimated from trial data
collection sites, but more commonly they will be derived from national data sources (Department of Health
reference costs).
Statistical tests
The purpose of clinical trial cost analysis is to estimate costs, cost differences associated with treatment,
the variability of differences, and whether or not the differences occurred by chance.
Once resources have been identified and valued, differences between groups must be summarised.
Arithmetic mean cost differences are generally considered the most appropriate and robust measure,
however, cost data often do not conform to the assumptions for standard statistical tests for comparing
differences in arithmetic means. Nonparametric methods of estimating incremental net benefit will be used
to compute the cost-effectiveness acceptability curves and the confidence ellipses.
Missing data
Missing data are inevitable in economic analyses conducted alongside trials. Eliminating cases with missing
data is not recommended because it may introduce bias or severely reduce power to test hypotheses.
Nevertheless, ignoring small amounts of missing data is acceptable if a reasonable case can be made that
doing so is unlikely to bias treatment group comparisons. Imputation refers to replacing missing fields with
estimates. A strict quality control is currently in place for the INFANT data collection to minimise missing data.
However, it is expected that some missing data will occur and we will be using appropriate methods such as
multiple imputation if necessary to impute missing resource use and health-related quality of life data.
Uncertainty
Results of economic assessments in trials are subject to a number of sources of uncertainty, including
sampling uncertainty and uncertainty in parameters such as unit costs. The revised point estimate and
revised 95% CIs that result from the sensitivity analysis will be reported.
Reporting the methods and results
Cost-effectiveness acceptability curves and incremental net benefit statistics with 95% CIs will be
presented. The differences in resource use and costs tested using t tests and differences in effects will be
presented using relative risks. Net benefits are defined as Rc.ΔE – ΔC, (where Rc is the threshold cost ratio,
ΔE is the change in effects between the trial arms, and ΔC the change in costs for the trial arms). These
will be estimated for alternative values of Rc, together with their 95% confidence ellipses.
A series of sensitivity analyses will be undertaken to explore the implications of uncertainty on the
base-case incremental cost-effectiveness ratios. This will include varying variables found to be the key
cost-drivers in early analyses for cost.
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TABLE 47 Example of bottom up cost data collection extraction form
Staffing Medications Equipment Total Cost
Staff title and
grade
Length of contact
time/procedure Staffing cost (£) Drug Dose
Mode of
administration
No of treatments
per day Cost (£) Piece Llifespan Annuitised cost (£) ∑ of costs
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The health economist will receive a ‘cleaned’ database of resource use and effectiveness data from the
main INFANT statistical team conducting the primary analysis. All analyses will be performed with a
microcomputer using Stata version 13, and Microsoft Excel® 2010 (Microsoft Corporation, Redmond, WA,
USA) software.
Economic evaluation design issues for INFANT study aim 3 (modelling
longer-term outcomes)
Long-term cost-effectiveness of intelligent system to support decision-making in the
management of labour using cardiotocogram
An analysis of the cost-effectiveness of the intelligent decision support software during labour will take
into account the potential long-term outcomes to mother and child. Cost-effectiveness will be calculated in
terms of the incremental cost per QALY gained. The analysis will be intended to account for the expected
lifetime of the children, but depending on data availability we will consider shorter life horizons that can
be populated with good evidenced data such as 18 years. Tables 48 and 49 show the primary data inputs
that will be derived from the INFANT trial to populate the model.
TABLE 48 Estimated model parameter inputs (baseline model) using primary data collected from INFANT
Parameter
Trial arm, mean (95% CI)
Intervention group Standard care group
First 12 months: outcomes, and costs
Survival with NNE
Death of child
Composite: poor neonatal outcomes
EQ-5D of mother
Cost of ECG decision software
Hospital costs to discharge for surviving children
Hospital costs to discharge for women
Hospital costs for non-surviving children
Inpatient costs of children post discharge
Community care costs of children post discharge
12 to 24 months: outcomes and costs
Age assessed for DQ
Survival without neurological abnormality (using Development
Quotient)
Survival with neurological abnormality (using Development
Quotient)
EQ-5D child (from mapping study)
EQ-5D of mother
Death of child
Inpatient costs, children without neurological abnormality
Inpatient costs, children with neurological abnormality
Community care costs, children without neurological abnormality
Community care costs, children with neurological abnormality
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TABLE 49 Cost-effectiveness results and sensitivity analyses
Parameter
Trial arm, mean (95% CI)
Mean difference†
(95% CI)Intervention group Standard care group
Analysis 1 (incremental cost per poor neonatal event averted)
Cost
Effectiveness
ICER
λ = 20,000
λ = 30,000
Analysis 2 (incremental cost per disability free life-year gained; using the DQ obtained at 2 years)
Cost
Effectiveness
ICER
λ = 20,000
λ = 30,000
Analysis 3 (incremental cost per quality-adjusted life-year gained; long-term analysis)
Cost
Effectiveness
ICER
λ = 20,000
λ = 30,000
Sensitivity Analysis 1 (incremental cost per quality-adjusted life-year gained including medical legal claims)
Cost
Effectiveness
ICER
λ = 20,000
λ = 30,000
Sensitivity Analyses 2 to 4 will vary the inputs to each of the main analysis
Cost
Effectiveness
ICER
λ = 20,000
λ = 30,000
ICER = incremental cost-effectiveness ratio; λ =willingness to pay threshold held by decision-makers for an additional
quality of life gain. † The mean of the standard care group is subtracted from the mean of the intervention group.
The probability of cost-effectiveness at λ = £20,000 and λ = £30,000 was reported unless there was a 95% probability of
cost-effectiveness at a λ ≤ £20,000. All costs are reported in 20xx-20xx £Sterling.
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The long-term economic evaluation will require extrapolating and identifying future health-care costs and
the health status of mothers and infants from literature as well as the application of decision-analytic
methods to synthesise information from different sources.
A brief review of the NIHR HTA website (www.hta.ac.uk/project/htapubs.asp), the NHS Economic
Evaluation Database (NHS-EED, www.crd.york.ac.uk/) and PubMed (www.pubmed.gov) reveals only one
previous study of the long-term cost-effectiveness of cardiotocography methods in fetal monitoring during
labour.7 We will build on the results of this literature, but we will develop a de novo cost-effectiveness
model that will be populated based on available evidence, including the data collected during the trial.
At this stage, the proposed design is to use a Markov model described and simplified in Figure 43. A
structured review of the published literature available for cost-effectiveness and cost-utility modelled from
patient level data is currently in progress. The data, including an inventory of health state utility weights is
being searched through the Paediatric Economic Database Evaluation (PEDE) made available by the
Research Institute at The Hospital for Sick Children, Toronto.
Decisions about the model structure might be revised after systematic searches of the literature are
undertaken and expert clinical input is considered. Following decisions about model structure, a list of
parameter estimates required for the model will be developed. These are likely to include the series of
parameters reported in Table 50. Data collected in this trial will provide information to populate the model
which will be supplemented with available evidence in the literature following systematic searches.
Parameters may require additional modelling to capture the long-term and time-dependent nature of the
estimate values.
We will undertake deterministic and probabilistic sensitivity analysis. For the latter input parameters will
be assigned probability distributions to reflect their imprecision and Monte Carlo techniques will be used
to reflect this uncertainty in the results. We will construct cost-effectiveness acceptability curves and
cost-effectiveness confidence ellipses.
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FIGURE 43 Markov model for long-term cost-effectiveness model.
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TABLE 50 Parameters to populate long-term cost-effectiveness model
Transition probability parameters
Caesarean delivery Mortality first 2 years after moderate encephalopathy
Instrumental vaginal delivery Mortality first 2 years after severe encephalopathy
Spontaneous vaginal delivery Remain without disability
No encephalopathy after caesarean section From no disability to mild disability
No encephalopathy after instrumental delivery From no disability to moderate disability
No encephalopathy after spontaneous delivery From no disability to severe disability
Moderate encephalopathy after caesarean section From no disability to death
Moderate encephalopathy after instrumental delivery Remain with mild disability
Moderate encephalopathy after spontaneous delivery From mild disability to no disability
Severe encephalopathy after caesarean section From mild disability to moderate disability
Severe encephalopathy after instrumental delivery From mild disability to severe disability
Severe encephalopathy after spontaneous delivery From mild disability to death
Perinatal death after caesarean section Remain with moderate disability
Perinatal death after instrumental delivery From moderate disability to no disability
Perinatal death after spontaneous delivery From moderate disability to mild disability
No disability after no encephalopathy From moderate disability to severe disability
No disability after moderate encephalopathy From moderate disability to death
No disability after severe encephalopathy Remain with severe disability
Mild disability after no encephalopathy From severe disability to no disability
Mild disability after moderate encephalopathy From severe disability to mild disability
Mild disability after severe encephalopathy From severe disability to moderate disability
Moderate disability after no encephalopathy From severe disability to death
Moderate disability after moderate encephalopathy Litigation if mild disability
Moderate disability after severe encephalopathy Litigation if moderate disability
Severe disability after no encephalopathy Litigation if severe disability
Severe disability after moderate encephalopathy Litigation if perinatal death
Severe disability after severe encephalopathy Litigation if death within first 2 years
Mortality first 2 years after no encephalopathy Litigation if death after first 2 years
Resource cost
Cost of caesarean section in CG Cost moderate encephalopathy in first 2 years
Cost of caesarean section in IG Cost severe encephalopathy in first 2 years
Cost of instrumental delivery in CG Costs no disability
Cost of instrumental delivery in TG Costs mild disability
Cost of spontaneous delivery in CG Cost moderate disability
Cost of spontaneous delivery in TG Cost severe disability
Cost of decision support software Cost of litigation if mild disability
Cost no encephalopathy until discharge Cost of litigation if moderate disability
continued
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In addition to this analysis, we will also consider the effect on potential medico-legal claims that result
from adverse events during the intrapartum and neonatal periods. We will model the probability of these
claims and estimate the litigation costs related to them. We will explore different scenarios in our analyses
as can be seen in Economic evaluation design issues for INFANT study aims 4 (Modelling clinical scenarios
that will impact on obstetric litigation claims).
Economic evaluation design issues for INFANT study aim 4 (modelling
clinical scenarios that will impact on obstetric litigation claims)
The prevention of a modest proportion of perinatal asphyxia will improve the health and well-being of
thousands of children and their families throughout the world each year. A reduction in the number of
babies born with perinatal asphyxia will reduce the associated mortality and, among survivors, the burden
of ill health and incapacity over their lifetime. The implications of this cost burden to society is that
maternity services are associated with far higher litigation costs than other services and a single ‘successful’
litigation case may result in a settlement worth millions of pounds.
Medical negligence data is one method of estimating the longer-term costs of perinatal asphyxia because
the financial projections should be indicative of the cost implications for the value of life for the rest of life.
However, evaluations for litigation purposes are often not reached until 5–6 years after the birth event,
when neuro-paediatricians can identify patterns of brain damage reflecting birth asphyxia and when the
baby is likely to have cerebral palsy. It is possible that some claims are processed in 2–3 years and others
over 10–15 years.
The prevention of a modest proportion of perinatal asphyxia could thus result in substantial savings in
litigation costs in the UK. However, litigation claims and pay outs are only slightly associated with
negligence. All cases of litigation which are paid are likely to be associated with negligence. For various
reasons outcomes as a result of negligence may not lead to litigation, and other cases [which incur
economic (lawyers) costs] are brought where no settlement is made because there was no negligence.
Given that the NHSLA is the recipient of the Clinical Negligence Scheme for Trusts risk pooling schemes
and has a unique database of all claims for births, we have proposed a stand-alone study with the NHSLA
TABLE 50 Parameters to populate long-term cost-effectiveness model (continued )
Cost moderate encephalopathy until discharged Cost of litigation if severe disability
Cost severe encephalopathy until discharged Cost of litigation if perinatal death
Cost of perinatal death Cost of litigation if death within first 2 years
Cost no encephalopathy in first 2 years Cost of litigation if death after first 2 years
Outcomes
Utility no encephalopathy – child Utility no encephalopathy – parent
Utility moderate encephalopathy – child Utility moderate encephalopathy – parent
Utility severe encephalopathy – child Utility severe encephalopathy – parent
Utility no disability – child Utility no disability – parent
Utility mild disability – child Utility mild disability – parent
Utility moderate disability – child Utility moderate disability – parent
Utility severe disability – child Utility severe disability – parent
CG= control group; IT= intervention group
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to understand the proportion of cases of perinatal asphyxia that have resulted in both successful and
unsuccessful litigation (to generate baseline estimates of all successful litigation cases), the consequent
pay-outs in the cases of successful claims and how these estimates have been derived over the past
10 years.
This would use a database of time series data that shows the costs involved in settled claims, including the
initial capital compensation and then the ‘periodicals’ (annual payment for life), or any payments processed
for deaths would satisfy this evidence gap. We will then develop a model estimating the longer-term cost
of perinatal asphyxia. We understand that financial projections should be indicative of the cost implications
for the value of life for the rest of life. Furthermore, it may encompass health-care and family costs, though
may not include other therapies and state funded or local authority costs, so we would estimate these
separately.
Together, these estimates will also assist us to identify potential savings in litigation costs in the UK from
the decision support.
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